Patent Grant
9398933
The present disclosure relates to methods for improving drug efficacy in patients having obstructed airways of the lungs.
Pulmonary diseases are disorders that affect the lungs. Pulmonary diseases, such as asthma and chronic obstructive pulmonary disease (“COPD”), may lead to increased airflow resistance in the lungs. Mortality, health-related costs, and the size of the population having adverse effects due to pulmonary diseases are all substantial. These diseases often adversely affect quality of life. Symptoms are varied but often include coughing, breathlessness, and wheezing. In COPD, for example, breathlessness may be noticed when performing somewhat strenuous activities, such as running, jogging, brisk walking, etc. As the disease progresses, breathlessness may be noticed when performing non-strenuous activities, such as walking. Over time, symptoms of COPD may occur with less and less effort until they are present all of the time, thereby severely limiting a person's ability to accomplish normal tasks.
Many measures have been taken to treat or manage pulmonary diseases. For example, for COPD, bronchodilators, corticosteroids, and other medications may be administered to patients with COPD. In addition, supplemental oxygen, and pulmonary rehabilitation may also be used to treat or manage COPD. Furthermore, many pharmacological-based treatment options focus on the vagus nerve, which innervates the conducting airways from the trachea to the terminal bronchioles.
Treatment options that prevent or inhibit the production and/or the release of acetylcholine are also of great interest. For example, parasympathetic nerves provide the dominant autonomic innervation of the airways. Release of acetylcholine from parasympathetic nerves activates postjunctional muscarinic receptors present on airway smooth muscle, submucosal glands, and blood vessels to cause bronchoconstriction, mucus secretion, and vasodilatation, respectively. Acetylcholine also feeds back onto prejunctional muscarinic receptors to enhance or inhibit further acetylcholine release. In asthma and COPD, bronchoconstriction and mucus secretion is increased and the airways are hyperresponsive to contractile agents. These changes are not due to increased parasympathetic nerve activity, as the number and function of postjunctional muscarinic receptors in the airways are generally unchanged. Rather, it is the supply of acetylcholine to the postjunctional cells (smooth muscle and submucosal gland) that is increased. Therefore, preventing the release or production of acetylcholine to the postjunctional cells remains a promising treatment option.
Treatment options that block the binding of acetylcholine to its receptor in nerve cells are also of great interest. For example, stimulation of the vagus nerves can cause the release of acetylcholine and leads to bronchoconstriction, as described above. Although lung cholinergic pathways are highly complicated as recognized by one of ordinary skill in the art, in its simplest form, preganglion fibers release acetylcholine at the level of peribronchial ganglia, from which postganglion fibers are generated, leading to the release of acetylcholine in the bronchial wall. The muscarinic (M) receptors activated by the release of acetylcholine and involved in the airway tone regulation, as described above, include: M1 receptors, present on the cholinergic ganglia, with the role of facilitating neural transmission; M2 receptors, located on the postganglion endings of the cholinergic fibers, with the role of limiting further acetylcholine release from the postganglion endings; and M3 receptors, located on the smooth muscle cells, mucosal glands and vascular endothelium in the airway wall, then inducing bronchoconstriction, mucus hypersecretion and airway wall edema. Therefore, the release of acetylcholine leads to the stimulation of the airway smooth muscle and of the mucous bronchial glands in the airways via activation of the receptors, with subsequent bronchoconstriction and mucus secretion, both events causing an increase in airway resistance. This response can be blocked by the administration of anticholinergic agents such as atropine, ipratropium, or the like, which selectively block the binding of acetylcholine to its receptor in nerve cells.
However, currently, there is still no cure for COPD, and individual treatments have not resulted in optimal outcomes. Even combinations of various treatments have been shown to generate minimum improvements over individual treatments. For example, previous studies showed that a combination of two treatments, even if they were based on different mechanisms of action, resulted in substantially less than the additive effect of the two treatments. Matera et al. show that in patients with COPD, addition of ipratropium bromide (an anticholinergic agent) at the clinically recommended dose did not produce any further bronchodilation than that achieved with salmeterol (a beta agonist) or formoterol (a beta agonist) (see, Respir Med 90:497-9, 1996; Sichletidis et al., Int J Clin Pract 53:185-8, 1999). Even when oxitropium bromide (a muscarinic antagonist) was used at a dose higher than the clinically recommended dose, it resulted in a modest improvement in FEV1 (forced expiratory volume in 1 second). For example, Salmeterol caused a 0.25 liter (22%) improvement in FEV1, oxitropium caused a 0.27 liter (23%) improvement in FEV1, and oxitropium taken after salmeterol caused only an additional 0.15 liter (11%) improvement in FEV1 (see, Cazzola et al., Thorax 54:1083-86, 1999).
In one aspect, the present disclosure provides a method for improving efficacy of a drug in a patient having an obstructive lung disease or bronchial constriction in a lung or airway, the drug having a reference efficacy, the method including: (a) modulating nerve activity in the autonomic nervous system of the patient to reduce obstruction in at least one obstructed airway in the lung of the patient, and (b) subsequently administering the drug to the patient, wherein steps (a) and (b) have a treatment efficacy greater than the reference efficacy.
In a related aspect, the present disclosure provides a method for improving drug efficacy in a patient having an obstructive lung disease or bronchial constriction in a lung or airway, the method including administering a drug, wherein the patient has undergone, prior to the administration of the drug, a procedure that modulates or attenuates nerve activity in the autonomic nervous system of the patient to reduce airway obstruction in at least one obstructed airway in a lung of the patient, and wherein a post-treatment efficacy of the drug following said procedure is improved relative to a reference efficacy of the drug.
In another aspect, the present disclosure provides a method for treating a patient having an obstructive lung disease or bronchial constriction in an airway or a lung, the method including: (a) modulating or attenuating nerve activity in the autonomic nervous system of the patient to reduce obstruction in a distal airway in the lung of the patient; and (b) subsequently administering a drug while the obstruction is reduced in the distal airway.
In a related aspect, the present disclosure provides a method for treating a patient having an obstructive lung disease or bronchial constriction in an airway or a lung, the method including: administering a drug to a patient, wherein the patient has undergone a procedure that modulates nerve activity in the autonomic nervous system of the patient to reduce airway obstruction in at least one obstructed airway in a lung of the patient, wherein the drug is administered while the obstruction is reduced in the at least one obstructed airway.
In another aspect, the present disclosure provides a method for treating a patient having an obstructive lung disease or bronchial constriction in an airway or a lung, the method including: (a) administering an inhaled drug to a patient of obstructive pulmonary disease, wherein the patient has previously undergone a procedure comprising: (i) positioning a treatment device in a first airway of the patient, and (ii) delivering energy from the treatment device into a wall of the first airway to reduce airway obstruction in a second airway that is a higher generation airway than the first airway.
In another aspect, the present disclosure provides a method for treating a patient having an obstructive lung disease or bronchial constriction in an airway or a lung, the method including: (a) modulating or attenuating nerve activity in the autonomic nervous system of the patient to reduce obstruction in a distal airway in the lung of the patient; and (b) subsequently or simultaneously administering a drug or combination of drugs that inhibits or prevents the production and/or the release of acetylcholine from parasympathetic nerves at the neuromuscular junction and/or selectively blocks the binding of acetylcholine to its receptor in nerve cells (e.g. anticholinergics or antimuscarinics).
In another aspect, the present disclosure provides a method for treating a patient having an obstructive lung disease or bronchial constriction in an airway or a lung, the method including: inhibiting or preventing the binding of acetylcholine with receptors at a neuromuscular junction between a nerve fiber and a muscle cell in a wall of a first airway by inhibiting the release of acetylcholine from the nerve fiber. In some embodiments, inhibiting the release of acetylcholine can comprise injuring, either permanently or temporarily, the nerve fiber proximally of the neuromuscular junction, such as, for example, by ablation. The ablation can be accomplished via delivery of energy from a device positioned in the airway to the targeted nerve fiber. Any of a variety of energy delivery or ablation techniques can also be contemplated, and as used herein, the term “energy” is broadly construed to include, without limitation, thermal energy, cryogenic energy (e.g., cooling energy), electrical energy, acoustic energy (e.g., ultrasonic energy), radio frequency energy, pulsed high voltage energy, mechanical energy, ionizing radiation, optical energy (e.g., light energy), and combinations thereof, as well as other types of energy suitable for treating tissue. By way of example, thermal energy can be used to heat tissue. Mechanical energy can be used to puncture, tear, cut, crush, or otherwise physically damage tissue. In some embodiments, a distal tip of the energy delivery device is adapted to apply pressure to tissue in order to temporarily or permanently damage tissue. Electrical energy is particularly well suited for damaging cell membranes, such as the cell membranes of nerve trunk tissue or other targeted anatomical features. Acoustic energy can be emitted as continuous or pulsed waves, depending on the parameters of a particular application. Additionally, acoustic energy can be emitted in waveforms having various shapes, such as sinusoidal waves, triangle waves, square waves, or other wave forms.
Additionally or alternatively, inhibiting the release of acetylcholine can comprise administration of a drug that inhibits or prevents the production and/or the release of acetylcholine from parasympathetic nerves at the neuromuscular junction. In this embodiment, the corresponding receptors can be open to binding with acetylcholine or blocked to binding via the administration of an anticholinergic agent, for example. In one particular aspect, the method further includes binding an agent, such as an anticholinergic agent, to second receptors at a second neuromuscular junction in a wall of a second airway to inhibit or prevent acetylcholine from binding to second receptors. The second airway can be of a higher generation airway than the first airway. In yet another aspect, the method can further include inhibiting the release of acetylcholine by interrupting the nerve fiber, such as by ablation, along a third airway, such as the left and/or right main bronchi, the first airway being a higher generation than the third airway.
In the following description, any ranges provided herein include all the values in the ranges. It should also be noted that the term “or” is generally employed in its sense including “and/or” (i.e., to mean either one, both, or any combination thereof of the alternatives) unless the content clearly dictates otherwise. Also, as used in this specification and the appended claims, the singular forms “a,” “an,” and “the” include plural referents unless the content clearly dictates otherwise. Thus, for example, reference to “an obstructed airway” may refer to one or more obstructed airway.
The left and right vagus nerves 41, 42 originate in the brainstem, pass through the neck, and descend through the chest on either side of the trachea 20. The vagus nerves 41, 42 spread out into nerve trunks 45 that include the anterior and posterior pulmonary plexuses that wrap around the trachea 20, the left main bronchus 21, and the right main bronchus 22. The nerve trunks 45 also extend along and outside of the branching airways of the bronchial tree 27. Nerve trunks 45 are the main stem of a nerve, comprising a bundle of nerve fibers bound together by a tough sheath of connective tissue.
The primary function of the lungs 10 is to exchange oxygen from air into the blood and to exchange carbon dioxide from the blood to the air. The process of gas exchange begins when oxygen rich air is pulled into the lungs 10. Contraction of the diaphragm and intercostal chest wall muscles cooperate to decrease the pressure within the chest to cause the oxygen rich air to flow through the airways of the lungs 10. For example, air passes through the mouth and nose, the trachea 20, then through the bronchial tree 27. The air is ultimately delivered to the alveolar air sacs for the gas exchange process.
Oxygen poor blood is pumped from the right side of the heart through the pulmonary artery 30 and is ultimately delivered to alveolar capillaries. This oxygen poor blood is rich in carbon dioxide waste. Thin semi-permeable membranes separate the oxygen poor blood in capillaries from the oxygen rich air in the alveoli. These capillaries wrap around and extend between the alveoli. Oxygen from the air diffuses through the membranes into the blood, and carbon dioxide from the blood diffuses through the membranes to the air in the alveoli. The newly oxygen-enriched blood then flows from the alveolar capillaries through the branching blood vessels of the pulmonary venous system to the heart. The heart pumps the oxygen-rich blood throughout the body. The oxygen spent air in the lung is exhaled when the diaphragm and intercostal muscles relax and the lungs and chest wall elastically return to the normal relaxed states. In this manner, air can flow through the branching bronchioles, the bronchi 21, 22, and the trachea 20 and is ultimately expelled through the mouth and nose.
In the first aspect, the present disclosure provides a method for improving drug efficacy in a patient having an obstructive lung disease. Such a method comprises: (a) modulating or attenuating nerve activity in the autonomic nervous system of a patient to reduce obstruction in at least one obstructed airway in the lung of the patient, and (b) subsequently administering the drug to the patient, wherein steps (a) and (b) have a treatment efficacy greater than a reference efficacy of the drug.
The present inventor discovered that reducing obstruction of obstructed airways in lungs of patients having an obstructive lung disease (e.g., COPD) by modulating or attenuating nerve activity in the autonomic nervous system of the patients (e.g., by parasympathetic (vagus) nervous system disruption) followed by administration of a drug (e.g., a bronchodilator or short-acting anticholinergic agents) significantly improved pulmonary functions of the patient.
In one particular example, such an additive effect of administering ipratropium, an anticholinergic agent, after vagus nerve disruption was unexpected. First, because vagus nerve disruption reduces or eliminates acetylcholine production by vagus nerve, and because acetylcholine is required for ipratropium to function as a bronchodilator, one would not expect administration of ipratropium after vagus nerve disruption to significantly improve lung functions. Second, previous studies showed that a combination of two treatments, even if they were based on different mechanisms of action, resulted in substantially less than the additive effect of the two treatments (see, Matera et al., Respir Med 90:497-9, 1996; Sichletidis et al., Int J Clin Pract 53:185-8, 1999; Cazzola et al., Thorax 54:1083-86, 1999). For two treatments with similar mechanisms of action (e.g., vagus nerve disruption that eliminates or reduces acetylcholine production and pharmacological inhibition of acetylcholine production or release), one would expect that the combination of such treatments would result in less of an improvement than the combination of two treatments with different/complementary mechanisms of action.
For simplicity, a treatment that modulates or attenuates nerve activity in the autonomic nervous system of a patient having an obstructive lung disease to reduce obstruction in at least one obstructed airway in a lung of the patient is referred to herein as a “nerve activity-modulating treatment.”
A “reference efficacy” of a drug, as used herein, refers to an improvement in a symptom or a parameter associated with a symptom of a patient or a group of patients resulting from administration of the drug or combination of drugs relative to a baseline of the symptom or the parameter associated with the symptom of the patient(s) before the administration of the drug(s) to the patient(s), wherein the patient or the group of patients have not previously undergone a nerve activity-modulating treatment.
A “parameter associated with a symptom” refers to a parameter that may be measured or monitored to determine changes in the symptom. For example, a symptom of COPD is shortness of breath. FEV1 (the forced expiratory volume in 1 second) may be used as a parameter to determine the improvement or deterioration of the symptom of shortness of breath.
In certain embodiments, the patient from whom a reference efficacy of a drug is obtained is the same patient who is subsequently subjected to a nerve activity-modulating treatment. In certain other embodiments, the reference efficacy of a drug is obtained from a patient or a group of patients other than the patient who is subjected to a nerve activity-modulating treatment.
The term “treatment efficacy” of steps (a) and (b), as used herein, refers to a final improvement in a symptom or a parameter associated with a symptom of a patient resulting from step (a) (i.e., a nerve activity-modulating treatment) and step (b) (i.e., administration of the drug subsequent to the nerve activity-modulating treatment) relative to a baseline of the symptom or the parameter associated with the symptom before the patient has been subjected to either the nerve activity-modulating treatment or the administration of the drug.
“Improving efficacy of a drug” in a patient refers to an improvement of the treatment efficacy of steps (a) and (b) over a reference efficacy of the drug used in step (b).
In certain embodiments, similar to the nerve activity-modulating treatment in step (a), the drug administered in step (b) (e.g., bronchodilators) also reduces obstruction in obstructed airways in a lung of a patient. In such cases, the drug has a reference efficacy, that is, an improvement in a symptom or a parameter associated with a symptom of a patient resulting from administration of the drug over a baseline before the administration of the drug in the patient; step (a) has a post-modulating efficacy, that is, an improvement in the symptom or the parameter associated with the symptom resulting from step (a) alone over the baseline; and steps (a) and (b) have a treatment efficacy, that is, a final improvement in the symptom or the parameter associated with the symptom resulting from both steps (a) and (b) over the baseline. The post-modulating efficacy of step (a) may be less than, the same as, or more than the reference efficacy of the drug, but is less than the treatment efficacy of steps (a) and (b).
In certain other embodiments, unlike the nerve activity-modulating treatment in step (a), the drug administered in step (b) is effective in treating another symptom other than reducing obstruction in obstructed airways in a lung of a patient. In such cases, step (a) may have a minimum post-modulating efficacy, but the treatment efficacy of steps (a) and (b) is greater than the reference efficacy of the drug.
In certain embodiments, the treatment efficacy of steps (a) and (b) is at least 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 70%, or 75% greater than the reference efficacy of the drug.
In certain embodiments, the drug is a bronchodilator. In some embodiments, the combined effect of the drug and the nerve activity-modulating treatment is substantially additive. For example, the combined effect may be at least 80%-95% (e.g., at least 80%, 85%, 90%, 92%, 94% or 95%) of the sum of the effect of the drug treatment alone and the effect of the nerve activity-modulating treatment alone.
Any appropriate methods known in the art may be used in determining the reference efficacy of a drug, a post-modulation efficacy of a nerve activity-modulating treatment, and/or a final efficacy of both a nerve activity-modulating treatment and administration of the drug. For example, a reference efficacy of a drug useful in treating a lung disease or disorder (e.g., a bronchodilator), a post-modulation efficacy of a nerve activity-modulating treatment, and/or a final efficacy of both a nerve activity-modulating treatment and administration of the drug may be monitored by various pulmonary function tests, exercise capacity and quality of life questionnaires.
Pulmonary function tests involve objective and reproducible measures of basic physiologic lung parameters, such as total airflow, lung volume, and gas exchange. Indices of pulmonary function tests used for the assessment of obstructive pulmonary diseases include the forced expiratory volume in 1 second (FEV1), the forced vital capacity (FVC), the ratio of the FEV1 to FVC, the total lung capacity (TLC), airway resistance and the testing of arterial blood gases. The FEV1 is the volume of air a patient can exhale during the first second of a forceful exhalation which starts with the lungs completely filled with air. The FEV1 is also the average flow that occurs during the first second of a forceful exhalation. This parameter may be used to evaluate and determine the presence and impact of any airway obstruction. The FVC is the total volume of air a patient can exhale during a forceful exhalation that starts with the lungs completely filled with air. The FEV1/FVC is the fraction of all the air that can be exhaled during a forceful exhalation that is exhaled during the first second. A FEV1/FVC ratio less than 0.7 after the administration of at least one bronchodilator defines the presence of COPD. The TLC is the total amount of air within the lungs when the lungs are completely filled and may increase when air becomes trapped within the lungs of patients with obstructive lung disease. Airway resistance is defined as the pressure gradient between the alveoli and the mouth to the rate of air flow between the alveoli and the mouth. Similarly, resistance of a given airway would be defined as the ratio of the pressure gradient across the given airway to the flow through the airway. Arterial blood gases tests measure the amount of oxygen and the amount of carbon dioxide in the blood and are the most direct method for assessing the ability of the lungs and respiratory system to bring oxygen from the air into the blood and to get carbon dioxide from the blood out of the body.
Exercise capacity tests are objective and reproducible measures of a patient's ability to perform activities. A six-minute walk test (6 MWT) is an exercise capacity test in which a patient walks as far as possible over a flat surface in 6 minutes. Another exercise capacity test involves measuring the maximum exercise capacity of a patient. For example, a physician can measure the amount of power the patient can produce while on a cycle ergometer or the time that a patient can maintain a given level of power output. The patient can breathe 30 percent oxygen and the work load can increase by 5-10 watts every 3 minutes.
Quality of life questionnaires assess a patient's overall health and well-being. The St. George's Respiratory Questionnaire is a quality of life questionnaire that includes 75 questions designed to measure the impact of obstructive lung disease on overall health, daily life, and perceived well-being. The efficacy of a treatment for pulmonary diseases can be evaluated using pulmonary function tests, exercise capacity tests, and/or questionnaires. A treatment program can be modified based on the results from these tests and/or questionnaires.
The methods of the present disclosure are particularly useful for improving drug efficacy, improving drug delivery to a lung, and treating patients having an obstructive lung disease.
An “obstructive lung disease” refers to a category of respiratory disease characterized by airway obstruction. It is generally characterized by inflamed and easily collapsible airways, obstruction to airflow, problems exhaling and frequent office visits and hospitalizations. Obstructive lung diseases includes asthma, COPD (including chronic bronchitis and emphysema), bronchiectasis, and cystic fibrosis.
An airway or a portion thereof is “obstructed” if its diameter is smaller than the diameter of a normal airway or a portion thereof or is otherwise restricted. The obstruction of the airway may result from constriction due to smooth muscle contraction of the airway, obstruction from the presence or accumulation of mucous, and thickness of the airway wall due to edema, inflammation or the like.
Patients that may be treated according to the methods of the present disclosure include and are not limited to those suffering from asthma, COPD (including chronic bronchitis and emphysema), bronchiectasis, and cystic fibrosis.
Asthma can be characterized by contraction of airway smooth muscle, smooth muscle hypertrophy, excessive mucus production, mucous gland hypertrophy, and/or inflammation and swelling of airways. These abnormalities are the result of a complex interplay of local inflammatory cytokines (chemicals released locally by immune cells located in or near the airway wall), inhaled irritants (e.g., cold air, smoke, allergens, or other chemicals), systemic hormones (chemicals in the blood such as the anti-inflammatory cortisol and the stimulant epinephrine), local nervous system input (nerve cells contained completely within the airway wall that can produce local reflex stimulation of smooth muscle cells and mucous glands), and the central nervous system input (nervous system signals from the brain to smooth muscle cells and mucous glands carried through the vagus nerve). These conditions often cause widespread temporary tissue alterations and initially reversible airflow obstruction that may ultimately lead to permanent tissue alteration and permanent airflow obstruction that make it difficult for the asthma sufferer to breathe. Asthma can further include acute episodes or attacks of additional airway narrowing via contraction of hyper-responsive airway smooth muscle that significantly increases airflow resistance. Asthma symptoms include recurrent episodes of breathlessness (e.g., shortness of breath or dyspnea), wheezing, chest tightness, and cough.
Emphysema is a type of COPD often characterized by the alteration of lung tissue surrounding or adjacent to the airways in the lungs. Emphysema can involve destruction of lung tissue (e.g., alveoli tissue such as the alveolar sacs) that leads to reduced gas exchange and reduced radial traction applied to the airway wall by the surrounding lung tissue. The destruction of alveoli tissue leaves areas of emphysematous lung with overly large airspaces that are devoid of alveolar walls and alveolar capillaries and are thereby ineffective at gas exchange. Air becomes “trapped” in these larger airspaces. This “trapped” air may cause over-inflation of the lung, and in the confines of the chest restricts the in-flow of oxygen rich air and the proper function of healthier tissue. This results in significant breathlessness and may lead to low oxygen levels and high carbon dioxide levels in the blood. This type of lung tissue destruction occurs as part of the normal aging process, even in healthy individuals. Unfortunately, exposure to chemicals or other substances (e.g., tobacco smoke) may significantly accelerate the rate of tissue damage or destruction. Breathlessness may be further increased by airway obstruction. The reduction of radial traction may cause the airway walls to become “floppy” such that the airway walls partially or fully collapse during exhalation. An individual with emphysema may be unable to deliver air out of their lungs due to this airway collapse and airway obstructions during exhalation.
Chronic bronchitis is a type of COPD that can be characterized by contraction of the airway smooth muscle, smooth muscle hypertrophy, excessive mucus production, mucous gland hypertrophy, and inflammation of airway walls. Like asthma, these abnormalities are the result of a complex interplay of local inflammatory cytokines, inhaled irritants, systemic hormones, local nervous system, and the central nervous system. Unlike asthma where respiratory obstruction may be largely reversible, the airway obstruction in chronic bronchitis is primarily chronic and permanent. It is often difficult for a chronic bronchitis sufferer to breathe because of chronic symptoms of shortness of breath, wheezing, and chest tightness, as well as a mucus producing cough.
Bronchiectasis is a disease state defined by localized, irreversible dilation of part of the bronchia tree caused by destruction of the muscle and elastic tissue. Involved bronchi are dilated, inflamed, and easily collapsible, resulting in airflow obstruction and impaired clearance of secretions. Bronchiectasis is associated with a wide range of disorders, but it usually results from bacterial infections, such as infections caused by the Staphylococcus or Klebsiella species, or Bordetella pertussis.
Cystic fibrosis is an autosomal recessive genetic disorder affecting most critically the lungs, and also the pancreas, liver, intestine. It is characterized by abnormal transport of chloride and sodium across an epithelium, leading to thick, viscous secretions. Lung disorder associated with cystic fibrosis results from clogging of the airways due to mucus build-up, decreased mucociliary clearance, and resulting inflammation. Inflammation and infection cause injury and structural changes to the lungs, leading to a variety of symptoms. In the early stages, incessant coughing, copious phlegm production, and decreased ability to exercise are common. Many of these symptoms occur when bacteria that normally inhabit the thick mucus grow out of control and cause pneumonia. In later stages, changes in the architecture of the lung further exacerbate difficulties in breathing. In addition to typical bacterial infections, people with cystic fibrosis more commonly develop other types of lung disease, including allergic bronchopulmonary aspergillosis and infection with Mycobacterium avium complex.
Other patients having an obstructive lung disease may also benefit from the methods of the present disclosure. A non-inclusive list of other such diseases includes tuberculosis, non-tuberculous mycobacterial infections, sardoidosis, Churg-Strauss syndrome, and allergic bronchopulmonary aspergillosis.
The methods of the present disclosure comprise modulating nerve activity in a portion of the autonomic nervous system of a patient to reduce narrowing of an airway of a lung of the patient. Referring to
The lungs are innervated by the anterior and posterior pulmonary plexuses located anterior and posterior to the root of the lungs. They are mixed plexuses containing parasympathetic (vagal) and sympathetic fibers. The filaments from these plexuses accompany the bronchial tubes, supplying efferent fibers to the bronchial muscle and mucous glands and afferent fibers to the bronchial mucous membrane (which may also referred to as mucosa or the epithelium) and probably to the alveoli of the lung. The efferent fibers of parasympathetic fibers (vagus nerve) are motors to the smooth muscle of the bronchial tree (bronchoconstrictors) that constrict the bronchiolar diameters when the need for oxygen has diminished, inhibitors to the pulmonary vessels (vasodilators), and secretors to the glands of the bronchial tree (secretomotors). The afferent fibers are sensory to the respiratory epithelium (touch and pain) and to the branches of the bronchial tree (stretch). While efferent nerve tissue innervates smooth muscle cells all the way from the trachea 20 to the terminal bronchioles, the afferent fiber innervations is largely limited to the trachea 20 and larger bronchi. The efferent fibers of sympathetic fibers are inhibitors of the bronchial tree (bronchodilators) that dilate bronchioles of the lung and allows for greater alveolar oxygen exchange, motors to the pulmonary vessels (vasoconstrictors), and inhibitors to the glands of the bronchial tree. The function of afferent fibers of sympathetic fibers is unknown.
Any portion of the autonomic nervous system of a patient that controls, regulates, or affects airways in the lungs may be modulated to reduce narrowing in the airways. In certain embodiments, the activity of the parasympathetic nerves and/or sympathetic nerves in a pulmonary plexus is modulated. In certain other embodiments, the activity of the bronchial branch of the vagus nerve is modulated. Additional nerves that may be modulated include and are not limited to efferent parasympathetic nerves, afferent parasympathetic nerves, c-fibers, vagal a and b fibers, and other individual nerve fibers or tissues (e.g., nerve cells, dendrites, and supporting tissue such as neuroglia). Such nerve tissues may be along the right and/or left main bronchi of the lung root as well as along more distal airways within the lungs. The nerve can be within or outside of the airway wall.
In certain embodiments, modulating nerve activity has a sustained effect on reducing narrowing of an airway in a lung (e.g., by permanently damaging a portion of the parasympathetic nervous system). In certain other embodiments, modulating nerve activity has a transient effect on reducing narrowing of an airway in a lung (e.g., by temporarily blocking nervous system signals).
Preferably, the nerve activity-modulating treatment is targeted to the lungs (i.e., the treatment primarily affects nerve activities that control or regulate the lungs, and does not substantially affects nerve activities that control or regulate other organs). For example, because some of the nerve tissue in the network of nerve trunks 45 coalesces into other nerves (e.g., nerves connected to the esophagus, nerves through the chest and into the abdomen, and the like), specific sites should be selected to minimize, limit, or substantially eliminate unwanted influence on nerve activities that affect organs other than the lungs. In certain embodiments, the nerve activity near the carina is modulated. For example, tissue near the carina may be denervated, which inhibits, limits, or substantially eliminate sensory input that triggers reflex central constriction and/or local constriction caused by c-fibers.
Modulating nerve activity in a portion of the autonomic nervous system of a patient may be performed by attenuating activity in a portion of the parasympathetic nervous system of the patient. Alternatively, modulating nerve activity may be performed by enhancing activity in a portion of sympathetic nervous system of the patient.
Attenuating nerve activity includes, without limitation, hindering, limiting, blocking, and/or interrupting the transmission of signals. For example, the attenuation can include decreasing signal amplitude of nerve signals or weakening the transmission of nerve signals. Decreasing or stopping nervous system input to distal airways can alter airway smooth muscle tone, airway mucus production, airway inflammation, and the like, thereby controlling airflow into and out of the lungs 10. Decreasing or stopping sensory input from the airways and lungs to local effector cells or to the central nervous system can also decrease reflex bronchoconstriction, reflex mucous production, release of inflammatory mediators, and nervous system input to other cells in the lungs or organs in the body that may cause airway wall edema. In some embodiments, the nervous system input can be decreased to correspondingly decrease airway smooth muscle tone. In some embodiments, the airway mucus production can be decreased a sufficient amount to cause a substantial decrease in coughing and/or in airflow resistance. In some embodiments, the airway inflammation can be decreased a sufficient amount to cause a substantial decrease in airflow resistance and ongoing inflammatory injury to the airway wall. Signal attenuation may allow the smooth muscles to relax, prevent, limit, or substantially eliminate mucus production by mucous producing cells, and decrease inflammation.
Attenuating nerve activity in a portion of the parasympathetic nervous system may be performed by damaging the portion of the parasympathetic nervous system (e.g., by applying energy or chemicals). Alternatively, attenuating nerve activity in a portion of the parasympathetic nervous system may be performed by stimulating the portion of the parasympathetic nervous system with electrical impulses to block nervous system signals from traveling past the portion of the parasympathetic nervous system. Attenuating nerve activity in a portion of the parasympathetic nervous system may additionally be performed by non-blocking stimulation of a portion of the parasympathetic system (e.g., vagal A and B fibers) (see, e.g., US 2010/0228318, incorporated herein by reference in its entirety). Attenuating nerve activity in a portion of the parasympathetic nervous system may additionally be performed by preventing the release or production of a neurotransmitter at the prejunctional and/or postjunctional neurons, thereby preventing the neurotransmitters from influencing postjunctional activities.
In certain embodiments, attenuating nerve activity in a portion of the parasympathetic nervous system comprises damaging a nerve trunk extending along a wall of an airway. In some other embodiments, attenuating nerve activity in a portion of the parasympathetic nervous system comprises damaging a bronchial branch of the vagus nerve.
Damaging a portion of the parasympathetic nervous system may be performed using various techniques, such as by applying energy (e.g., from an interventional device) to nerves at a target site (e.g., a nerve trunk extending along a wall of an airway or a bronchial branch of the vagus nerve) either from within the airway or from outside the airway. In certain embodiments, a treatment system (e.g., a catheter) can be navigated through airways, such as the right and left main bronchi of the lung root, as well as more distal airways within the lungs of a patient having a narrowed airway in a lung such as intermediate bronchi, segmental bronchi and subsegmental bronchi. A collapsible ablation assembly can be conveniently passed through airways. An energy emitter assembly of the ablation assembly can treat one or more target sites without treating non-targeted sites. For example, the treatment system can destroy nerve tissue at target sites without destroying to any significant extent, or causing any permanent damage to, non-nerve tissue (e.g., interior airway walls) so that the non-nerve tissue can remain functional after performing treatment. The energy emitter assembly may be cooled to protect non-targeted tissue. Energy that can be used to damage a portion of the parasympathetic nervous system includes without limitation thermal energy, microwave, electrical energy, cryogenic energy, acoustic energy, radio frequency energy, pulsed high voltage energy, mechanical energy (e.g., surgery), ionizing radiation, optical energy (e.g., light energy), and a combination thereof.
In certain embodiments, damaging nerves (“denervating”) can include damaging all of the nerve tissue of a section of a nerve trunk along an airway to stop substantially all the signals from traveling through the damaged section of the nerve trunk to more distal locations along the bronchial tree or from the bronchial tree more proximally to the central nervous system. Additionally, signals that travel along nerve fibers that go directly from sensory receptors (e.g., cough and irritant receptors) in the airway to nearby effector cells (e.g., postganglionic nerve cells, smooth muscle cells, mucous cells, inflammatory cells, and vascular cells) will also be stopped. If multiple nerve trunks extend along the airway, each nerve trunk can be damaged. As such, the nerve supply along a section of the bronchial tree can be cut off.
In certain embodiments, a nerve activity-modulating treatment comprises modulating nerve activity along an airway (“first airway”) of the patient, so that the activity in a nerve that carries signals to or from an obstructed airway that is a higher generation airway of the first airway is modulated. For the purpose of this disclosure, airway branches are numbered in generations starting down from the main stem at generation 0, continuing to the main bronchi at generation 1, and on to the most distal branches at generation 2 and higher. For example, main bronchi 21, 22 (i.e., airway generation 1) of
In some embodiments, damaging a portion of the parasympathetic nervous system comprises damaging nerve tissue of a first main bronchus to substantially prevent nervous system signals from traveling to substantially all distal bronchial branches connected to the first main bronchus. In some embodiments, most or all of the bronchial branches distal to the first main bronchus are treated. The damaged nerve tissue, in certain embodiments, is positioned between a trachea and the lung through which the bronchial branches extend. In certain embodiments, a second main bronchus may be further substantially damaged to substantially prevent nervous system signals from traveling to substantially all distal bronchial branches connected to the second main bronchus.
In certain procedures, lesions are formed at the treatment site to attenuate the transmission of signals traveling along the vagus nerves 41, 42 that cause or mediate muscle contractions, mucus production, inflammation, edema, and the like. Lesions can include ablated tissue, scar tissue, openings (e.g., openings of hollow myelin sheaths), or the like. Such lesions can inhibit or prevent nerve tissue regrowth, thereby preventing an unwanted amount of functional recovery for a desired period of time. To inhibit reinnervation, axons, myelin, endoneurium or other structures can be targeted.
Exemplary treatment systems and methods for damaging a portion of the parasympathetic (vagus) nervous system include those described in U.S. Pat. No. 8,088,127, PCT Application Publication Nos. WO 2011/060200, WO 2011/056684, WO 2011/060201, WO 2013/052501, and U.S. Application Publication Nos. 2011/0118725, 2011/0301587, and 2013/0310822. Each of these applications is incorporated herein by reference in its entirety.
For example, in certain embodiments, nerve activity-modulating treatment comprises (i) positioning a treatment device in a first airway of the patient, and (ii) delivering energy from the treatment device into a wall of the first airway to reduce airway obstruction in a second airway that is a higher generation airway than the first airway. The first airway may be an airway between a trachea and a lung, a left or right main bronchus or a bronchus intermedius, or a first generation airway located outside the left and right lungs. In one embodiment, step (ii) may include delivering energy to damage a nerve trunk extending along the first airway, such as a nerve trunk disposed within connective tissue surrounding the wall of the first airway. The treatment device may comprise an energy emitter for delivering energy to the nerve trunk. Step (ii) may further comprise inhibiting damage to airway tissue disposed radially between the treatment device and the nerve trunk, such as by cooling the airway tissue using the treatment device, including absorbing heat from the airway tissue with a cooling element on the treatment device, by actively cooling the airway tissue by circulating a coolant through an expandable member, and by cooling the treatment device.
An exemplary treatment device is shown in
Each segmental bronchus may be treated by delivering energy to a single treatment site along each segmental bronchus. For example, the catheter system 204 can deliver energy to each segmental bronchus of the right lung. In some procedures, ten applications of energy can treat most of or substantially all of the right lung. In some procedures, most or substantially all of both lungs are treated using less than thirty-six different applications of energy. Depending on the anatomical structure of the bronchial tree, segmental bronchi can often be denervated using one or two applications of energy.
Function of other tissue or anatomical features, such as the mucous glands, cilia, smooth muscle, body vessels (e.g., blood vessels), and the like can be maintained when nerve tissue is ablated. Nerve tissue includes nerve cells, nerve fibers, dendrites, and supporting tissue, such as neuroglia. Nerve cells transmit electrical impulses, and nerve fibers are prolonged axons that conduct the impulses. The electrical impulses are converted to chemical signals to communicate with effector cells or other nerve cells. By way of example, a portion of an airway of the bronchial tree 27 can be denervated to attenuate one or more nervous system signals transmitted by nerve tissue. Denervating can include damaging all of the nerve tissue of a section of a nerve trunk along an airway to stop substantially all the signals from traveling through the damaged section of the nerve trunk to more distal locations along the bronchial tree or from the bronchial tree more proximally to the central nervous system. Additionally, signals that travel along nerve fibers that go directly from sensory receptors (e.g., cough and irritant receptors) in the airway to nearby effector cells (e.g., postganglionic nerve cells, smooth muscle cells, mucous cells, inflammatory cells, and vascular cells) will also be stopped. If a plurality of nerve trunks extends along the airway, each nerve trunk can be damaged. As such, the nerve supply along a section of the bronchial tree can be cut off. When the signals are cut off, the distal airway smooth muscle can relax leading to airway dilation, mucous cells decrease mucous production, or inflammatory cells stop producing airway wall swelling and edema. These changes reduce airflow resistance so as to increase gas exchange in the lungs 10, thereby reducing, limiting, or substantially eliminating one or more symptoms, such as breathlessness, wheezing, chest tightness, and the like. Tissue surrounding or adjacent to the targeted nerve tissue may be affected but not permanently damaged. In some embodiments, for example, the bronchial blood vessels along the treated airway can deliver a similar amount of blood to bronchial wall tissues and the pulmonary blood vessels along the treated airway can deliver a similar amount of blood to the alveolar sacs at the distal regions of the bronchial tree 27 before and after treatment. These blood vessels can continue to transport blood to maintain sufficient gas exchange. In some embodiments, airway smooth muscle is not damaged to a significant extent. For example, a relatively small section of smooth muscle in an airway wall which does not appreciably impact respiratory function may be reversibly altered. If energy is used to destroy the nerve tissue outside of the airways, a therapeutically effective amount of energy does not reach a significant portion of the non-targeted smooth muscle tissue.
In some embodiments, one of the left and right main bronchi 21, 22 is treated to treat one side of the bronchial tree 27. The other main bronchus 21, 22 can be treated based on the effectiveness of the first treatment. For example, the left main bronchus 21 can be treated to treat the left lung 11. The right main bronchus 22 can be treated to treat the right lung 12. In some embodiments, a single treatment system can damage the nerve tissue of one of the bronchi 21, 22 and can damage the nerve tissue of the other main bronchus 21, 22 without removing the treatment system from the trachea 20. Nerve tissue positioned along the main bronchi 21, 22 can thus be damaged without removing the treatment system from the trachea 20. In some embodiments, a single procedure can be performed to conveniently treat substantially all, or at least a significant portion (e.g., at least 50%, 70%, 80%, 90% of the bronchial airways), of the patient's bronchial tree. In other procedures, the treatment system can be removed from the patient after treating one of the lungs 11, 12. If needed, the other lung 11, 12 can be treated in a subsequent procedure.
More specifically,
In
By adjusting the rate of power delivery to the electrode 214, the rate at which coolant (e.g., saline solution) is passed into the balloon 212, the temperature of the saline solution, and the size of the balloon 212, and the exact contour and temperature of the individual isotherms can be modified. For example, by selecting the proper temperature and flow rate of saline and the rate of power delivery to the electrode, it is possible to achieve temperatures in which isotherm A=60° C., B=55° C., C=50° C., D=45° C., E=40° C., and F=37° C. Further adjustments make it possible to achieve temperatures where isotherm A=50° C., B=47.5° C., C=45° C., D=42.5° C., E=40° C., and F=37° C. Only those areas contained within the 50° C. isotherm will be heated enough to induce cell death. In some procedures, tissue at a depth of about 2 mm to about 8 mm in the airway wall can be ablated while other non-targeted tissues at a depth less than 2 mm in the airway wall are kept at a temperature below at temperature that would cause cell death. The coolant 218 can absorb energy to cool the tissue-contacting portion 215 of the energy emitter assembly 220 while the balloon 212 holds the energy emitter assembly 220 against the airway 100.
When the delivery apparatus 206 of
With continued reference to
The balloon 212 can be inflated to move the energy emitter assembly 220 near (e.g., proximate to or in contact with) the airway 100. The angle β can be increased between 70 degrees and about 110 degrees when the balloon 212 is fully inflated.
As the balloon 212 inflates, the electrode 214 moves (e.g., pivots, rotates, displaces, etc.) from a first orientation of
To deploy the energy emitting assembly 208, coolant from the elongate shaft 230 flows through the energy emitter assembly 220 and into the balloon 212. The electrode 214 can output a sufficient amount of energy to ablate a target region. The coolant absorbs thermal energy from electrode 214 and the airway wall 100.
The diameter DE of the electrode 214 and conduit 234 can be in a range of about 1.5 mm to about 2.5 mm when pressurized with coolant. Such embodiments are well suited to treat tissue outside the lung along the main bronchi. In certain embodiments, the diameter DE is about 2 mm. In yet other embodiments, the diameter DE can be in a range of about 0.1 mm to about 3 mm. The diameter DE of the deflated conduit 234 and electrode 214 can be about 0.1 mm to about 1 mm.
To treat a bronchial tree of a human, the diameter of the inflated balloon 212 can be in a range of about 12 mm to about 18 mm. For enhanced treatment flexibility, the inflated balloon diameter may be in a range of about 7 mm to about 25 mm. Of course, the balloon 212 can be other sizes to treat other organs or tissue of other animals.
The ablation assembly 208 provides differential cooling because the coolant in the energy emitter assembly 220 is at a lower temperature and higher velocity than the coolant in the balloon 212. Coolant, represented by arrows, flows out of the elongate shaft 230 and into the energy emitter assembly 220. The coolant proceeds through the energy emitter assembly 220 and the coolant channel 340 of the electrode 214. The coolant absorbs thermal energy from the electrode 214. The heated coolant flows into the tip 240 and proceeds proximally through a lumen 400, as shown in
The coolant flows through a port 430, a lumen 432, and a throttle 434. The throttles 420, 434 can cooperate to maintain a desired pressure. The throttle 420 is configured to maintain a first flow rate of the coolant through the energy emitting assembly 220 and a second flow rate of the coolant through the cooling section 209. The first flow rate can be significantly different from the second flow rate.
The conduit 234 can assume a preset shape when pressurized. The valves 420, 434 can cooperate to maintain the desired pressure within the balloon 212 within a range of about 5 psig to about 15 psig. Such pressures are well suited to help push the electrode 214 between cartilaginous rings. Other pressures can be selected based on the treatment to be performed. The valves 420, 434 can be throttle valves, butterfly valves, check valves, duck bill valves, one-way valves, or other suitable valves.
When RF energy is transmitted to the electrode 214, the electrode 214 outputs RF energy that travels through tissue. The RF energy can heat tissue (e.g., superficial and deep tissue) of the airway wall while the coolant cools the tissue (e.g., superficial tissues). The net effect of this superficial and deep heating by RF energy and superficial cooling by the circulating coolant is the concentration of heat in the outer layers of the airway wall. The temperature of the connective tissue can be higher than the temperatures of the epithelium, stroma, and/or smooth muscle. By example, the temperature of the connective tissue can be sufficiently high to cause damage to the nerve trunk tissue or other deep tissue while other non-targeted tissues of the airway are kept at a lower temperature to prevent or limit damage to the non-targeted tissues.
Heat can be concentrated in one or more of the internal layers (e.g., the stroma) of the airway wall or in the inner lining (e.g., the epithelium) of the airway wall. Furthermore, one or more of the vessels of the bronchial artery branches may be within the lesion. The heat generated using the electrode 214 can be controlled such that blood flowing through the bronchial artery branches protects those branches from thermal injury while nerve trunk tissue is damaged, even if the nerve tissue is next to the artery branches. The catheter 207 can produce relatively small regions of cell death. For example, a 2 mm to 3 mm section of tissue in the middle of the airway wall 100 or along the outer surface of the airway wall 100 can be destroyed. By the appropriate application of power and the appropriate cooling, lesions can be created at any desired depth.
A circumferential lesion can be formed around all or most of the circumference of the airway wall 100 by ablating tissue while slowly rotating the ablation assembly 208 or by positioning the ablation assembly 208 in a series of rotational positions at each of which energy is delivered for a desired time period. Some procedures form adjacent lesions that become contiguous and form a circumferential band all the way around the airway wall 100. In some embodiments, the entire loop 221 (
Additional techniques for damaging, either temporarily or permanently, a portion of the parasympathetic nervous system include vagotomy (cutting of the vagus nerve) and bronchial thermoplasty that ablates the airway wall in a multitude of bronchial branches within the lung thereby eliminating smooth muscle and damaging nerves in the airway walls of the lung.
In certain embodiments, a portion of the parasympathetic nervous system may be damaged or can have their function disrupted by delivering one or more chemicals or substances (e.g., radioactive seeds, radioactive materials, etc.) to or near a portion of the parasympathetic nervous system. Exemplary chemicals useful in damaging or disrupting nerves include hypertonic solutions, hypotonic solutions, phenols, alcohols, nerve blocking agents such as lidocaine or tetricaine, neurotoxins such as tetanus toxoid, botulinum toxin, or ricin.
In certain embodiments, attenuating nerve activity in a portion of the parasympathetic nervous system may be performed by stimulating the portion of the parasympathetic nervous system with electrical impulses to block nervous system signals from traveling past the portion of the parasympathetic nervous system. Additional methods include cooling the nerve or mechanically compressing the nerve axons within the nerves, both of which may be achieved with an implant to temporarily decrease nerve functions. Exemplary devices and methods are described in U.S. application Ser. No. 12/372,607, filed Feb. 17, 2009, and issued as U.S. Pat. No. 8,483,831, which is incorporated herein by reference.
Different attributes of airways can be evaluated to determine the effect of a nerve activity-modulating treatment and/or drug administration on the airways. Such airway attributes include, without limitation, physical properties of airways (e.g., airway compliance, contractile properties, etc.), airway resistance, dimensions of airway lumens (e.g., shapes of airways, diameters of airways, etc.), responsiveness of airways (e.g., responsiveness to stimulation), muscle characteristics (e.g., muscle tone, muscle tension, etc.), inflammatory cells, inflammatory cytokines, or the like.
In certain embodiments, modulating nerve activity to reduce narrowing of an airway in a lung of a patient may be performed by enhancing activity in a portion of sympathetic nervous system of the patient. Exemplary devices and methods for stimulating sympathetic nervous system include selective electrical nerve stimulation of the sympathetic nerves or electrical simulation using signals or pulse trains that selectively activate the sympathetic nerves.
“Subsequently administering a drug” to a patient according to the methods of the present disclosure refers to administering a drug to a patient after the nerve activity-modulating treatment. In certain embodiments, the patient has received administration of the drug before the nerve activity-modulating treatment, but received administration of the drug again after the nerve activity-modulating treatment. In certain other embodiments, the patient has not received any administration of the drug before the nerve activity-modulating treatment, and the drug administration after the nerve activity-modulating treatment is the first time that the drug is administered to the patient.
In certain embodiments, the nerve activity-modulating treatment has sustained effects. Following such a treatment (e.g., sustained disruption of the parasympathetic nervous system as induced by vagus nerve disruption), drug administration can be performed at any time after therapy and will lead to enhanced regional delivery of the lungs to the more obstructed portion of the trachea-bronchial tree. In certain other embodiments, the nerve activity-modulating treatment has transient effects. During and following such a treatment (e.g., transient disruption of the parasympathetic nervous system as induced by nerve blocking signals from an implanted or externally applied stimulator/signal generator), drug administration is typically performed during the application of the nerve blocking signal, immediately or after a short period of time (e.g., within 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 minutes) following the completion of the blocking signal while the transient effect of the nerve activity-modulating treatment has not substantially diminished (e.g., while more than 50% of the effect of the nerve activity-modulating treatment at the end of the treatment is still retained).
Various drugs for treating pulmonary diseases may be administered to a patient after the patient is subject to a nerve activity-modulating treatment. In certain embodiments, such drugs are effective in treating an obstructive lung disease. In certain other embodiments, the drugs may be for treating pulmonary diseases other than obstructive lung diseases. Exemplary drugs useful in the methods disclosed herein include those for treating asthma, acute bronchitis, COPD (including chronic bronchitis and emphysema), cystic fibrosis, tuberculosis, non-tuberculosis mycobacterial infections, sardoidosis, Churg-Strauss syndrome, allergic bronchopulmonary aspergillosis, bronchiectasis, influenza, lung cancer, pneumonia, pulmonary edema, pulmonary emboli, pulmonary fibrosis, pulmonary hypertension, sarcoidosis, asbestosis, aspergilloma, aspergillosis, atelectasis, bronchiectasis, pleural effusion, pneumoconiosis, pneumothorax, pulmonary actinomycosis, pulmonary alveolar proteinosis, pulmonary anthrax, pulmonary arteriovenous malformation, pulmonary nocariosis, pulmonary tuberculosis, pulmonary veno-occlusive disease, and rheumatoid lung disease.
In certain embodiments, the drugs are inhaled drugs. Exemplary inhaled drugs include and are not limited to bronchodilators, inhaled glucocorticoids (such as budesonide), inhaled steroids, inhaled anti-inflammatories, inhaled antibiotics (such as tobramycin and cholestine), mucolytics (such as n-acetyl cysteine (Mucomyst)), DNAse (dornase alfa), saline, oxygen, cromolyn, nedocromil, inhaled corticosteroids, expectorants (such as guaifenesin), and methylxanthines. Bronchodilators include anticholinergics (such as ipratropium and tiotropium) and beta agonists (such as albuterol, levalbuterol, salmetemol, formoterol, and arformoterol).
As described above, improvements in regional airflow may lead to concomitant improvements in matched regional blood flow, and consequently improve delivery of drugs to the lungs through the blood stream. Thus, in certain embodiments, the drugs are non-inhaled drugs. Such drugs are varied, including broad classes of oral and injected medications that might be more effective with improve delivery to areas of the lung. Exemplary non-inhaled drugs include but are not limited to theophylline, prednisone, methylprednisilone, epinephrine, and antibiotics such as azithromycin, amoxicillin, ceftriaxone, pipericillin, leukotriene modifiers.
Additional exemplary drugs that may be delivered to a lung of a patient after a nerve activity-modulating treatment include but are not limited to aminophylline, ampicillin, beclomethasone dipropionate, bupropion hydrochloride, cefaclor, cefadroxil, cefixime, cefprozil, cefuroxime axetil, cephalexin, ciclesonide, ciprofloxacin hydrochloride, clarithromycin, clindamycin, cloxacillin, erythromycin, ethambutol, fenoterol hydrobromide, fluconazole, flunisolide, fluticasone furoate, fluticasone propionate, indacaterol maleate, isoniazid, itraconazole, ketoconazole, ketotifen, levofloxacin, minocycline, mometasone furoate, montelukast sodium, moxifloxacin, nicotine, nystatin, ofloxacin, omalizumab, orciprenaline, oseltamivir, oxtriphylline, penicillin, pivampicillin, pyrazinamide, rifampin, roflumilast, cromoglycate, telithromycin, terbutaline sulfate, triamcinolone acetonide, varenicline, zafirlukast, and zanamivir.
The drugs may be administered to a patient via various routes. Inhaled drugs are typically administered via inhalation. Non-inhaled drugs may be administered enterally, such as orally, by gastric feeding tube, duodenal feeding tube, or gastrostomy, or rectally in suppository. Alternatively, such drugs may be administered parenterally, such as intravenously, intra-arterially, intraosseous infusion, intra-muscularly, intracerebrally, intracerebroventricularly, subcutaneously, or the like.
The drugs are administered to a patient in need at a therapeutically effective dose. A “therapeutically effective dose” of a drug refers to the amount of the drug sufficient to result in reducing the severity of, eliminating, or delaying the onset or reoccurrence of one or more symptoms of a disease or disorder at issue in a statistically significant manner. Such a dose may be determined or adjusted depending on various factors including the specific drug, the route of administration, the patient's condition, that is, stage of the disease, severity of symptoms caused by the disease, general health status, as well as age, gender, and weight, and other factors apparent to a person skilled in the medical art. Similarly, the dose of the drug for treating a disease or disorder may be determined according to parameters understood by a person skilled in the medical art. Optimal doses may generally be determined using experimental models and/or clinical trials. Design and execution of pre-clinical and clinical studies for a therapeutic agent (including when administered for prophylactic benefit) described herein are well within the skill of a person skilled in the relevant art.
In certain embodiments, the amount of a drug administered to a patient after a nerve activity-modulating treatment may be less than the amount required in a patient without the nerve activity-modulating treatment. The nerve activity-modulating treatment improves drug delivery to a lung of the patient and thus efficacy of the drug. Reducing the amount required for the drug to be effective may also reduce the potential side effects associated with an excessive amount of the drug in certain regions of the lung (e.g., regions of a lung that were minimally obstructed prior to the nerve activity-modulating treatment).
In a second aspect, the present disclosure provides a method for improving drug efficacy in a patient having an obstructive lung disease that comprises administering a drug to a patient who has undergone, prior to the administration of the drug, a procedure that modulates nerve activity in the autonomic nervous system of the patient to reduce airway obstruction in at least one obstructed airway in a lung of the patient, wherein a post-treatment efficacy of the drug following the procedure is improved relative to a reference efficacy of the drug.
This second aspect of the present disclosure is identical to the first aspect of the present disclosure except that the method according to the second aspect comprises administering a drug to a patient who has undergone a nerve activity-modulating treatment, while the method according to the first aspect comprises both steps of a nerve activity-modulating treatment and administration of a drug. The description of the first aspect of the present disclosure (e.g., the description of the drugs and their administration, nerve activity-modulating treatments, a reference efficacy of a drug) is applicable to this second aspect of the present disclosure unless otherwise indicated.
In the second aspect, a “post-treatment efficacy” of a drug following a nerve activity-modulating treatment refers to an improvement in a symptom or a parameter associated with a symptom of a patient who has undergone a nerve activity-modulating treatment relative to a baseline of the symptom or the parameter associated with the symptom before the patient has been subjected to either the nerve activity-modulating treatment or the administration of the drug.
In a third aspect, the present disclosure provides a method for treating a patient having an obstructive lung disease, comprising: (a) modulating nerve activity in the autonomic nervous system of the patient to reduce obstruction in a distal airway in the lung of the patient, and (b) subsequently administering a drug while the obstruction is reduced in the distal airway.
The description of the first aspect of the present disclosure (e.g., the description of the drugs and nerve activity-modulating treatments) is applicable to this third aspect of the present disclosure unless otherwise indicated.
As understood by a person skilled in the medical art, the terms, “treat” and “treatment,” refer to medical management of a disease, disorder, or condition of a subject (i.e., patient) (see, e.g., Stedman's Medical Dictionary). “Treating a patient having an obstructive lung disease,” as used herein, refers to treating an obstructive lung disease (e.g., COPD) in a patient and/or another disorder (e.g., lung cancer) that a patient having an obstructive lung disease may also have, such as reducing the number of symptoms of a disease at issue (e.g., an obstructive lung disease), decreasing the severity of one or more symptoms of the disease, or delaying the progression of the disease.
In certain embodiments, step (a) is performed without causing permanent damage to non-nerve tissue.
Step (a) may comprise attenuating nerve activity in a portion of the parasympathetic nervous system of the patient. Alternatively, step (a) may comprise stimulating nerve activity in a portion of sympathetic nervous system of the patient.
In some embodiments, step (a) comprises modulating nerve activity along an airway (“first airway”) of the patient, so that the activity in a nerve that carries signals to or from an obstructed airway that is a higher generation airway of the first airway is modulated.
In some embodiments, step (a) comprises modulating nerve activity of a pulmonary plexus or modulating nerve activity of a bronchial branch of the vagus nerve.
In certain embodiments, step (a) comprises damaging a portion of the parasympathetic nervous system, such as applying energy to the portion of the parasympathetic nervous system. The portion of the parasympathetic nervous system to which energy is applied may be a nerve trunk extending along a wall of an airway or a bronchial branch of the vagus nerve. The energy may be applied using an interventional device, either from within the airway or from outside the airway. The energy may be thermal energy, microwave, electrical energy, cryogenic energy, acoustic energy, radio frequency energy, pulsed high voltage energy, mechanical energy, ionizing radiation, and/or optical energy.
Preferably, applying energy to the portion of parasympathetic nervous system does not cause permanent damage to any interior airway walls of the patient. This may be accomplished by protecting an interior airway wall of the patient from permanent damage while applying the energy.
In certain embodiments, step (a) comprises stimulating the portion of the parasympathetic nervous system with electrical impulses to block nervous system signals from traveling past the portion of the parasympathetic nervous system.
The drugs that may be applied to a patient may be those described in connection with the methods according to the first aspect of the present disclosure. For example, the drug may be an inhaled drug, such as a bronchodilator (e.g., an anticholinergic or a beta antagonist), and a steroid, an anti-inflammatory, or an antibiotic. Alternatively, the drug may be a non-inhaled drug (e.g., an injected or intervenous drug), including theophylline, prednisone, methylprednisilone, epinephrine, or an antibiotic.
The obstruction in one or more airways in a patient having an obstructive lung disease may result from smooth muscle contraction, thickening of airway wall, mucous accumulation, or a combination thereof.
In certain embodiments, the patient to be treated suffers from chronic obstructive pulmonary disease (COPD), asthma, or cystic fibrosis.
In some embodiments, steps (a) and (b) have a treatment efficacy greater than a reference efficacy of the drug. The terms “treatment efficacy of steps (a) and (b)” and “reference efficacy of a drug” are the same as those terms described in connection with the methods according to the first aspect of the present disclosure. In one embodiment, the reference efficacy of a drug is the efficacy of the drug in the patient prior to step (a).
According to this third aspect of the present disclosure, step (b) is to administer a drug subsequent to a nerve activity-modulating treatment while the obstruction remains reduced in the distal airway by the nerve activity-modulating treatment. For example, if the nerve activity-modulating treatment (e.g., vagal nerve denervation) has a permanent effect on reducing obstructions in a distal airway, the drug may be administered at any time after the nerve activity-modulating treatment. However, if the nerve activity-modulating treatment (e.g., transient disruption of the parasympathetic nervous system induced by nerve blocking signals from an implanted or externally applied stimulator/signal generator) has a transient effect on reducing obstructions in a distal airway, drug administration is performed during, immediately, or after a short period of time while the obstruction in the distal airway remains reduced.
In a fourth aspect, the present disclosure provides a method for treating a patient having an obstructive lung disease that comprises administering a drug to a patient, wherein the patient has undergone a procedure that modulates nerve activity in the autonomic nervous system of the patient to reduce airway obstruction in at least one obstructed airway in a lung of the patient, wherein the drug is administered while the obstruction is reduced in the at least one obstructed airway.
This fourth aspect of the present disclosure is identical to the third aspect of the present disclosure except that the method according to the fourth aspect comprises administering a drug to a patient who has undergone a nerve activity-modulating treatment, while the method according to the third aspect comprises both steps of a nerve activity-modulating treatment and administration of a drug. The description of the third aspect of the present disclosure (e.g., the description of the drugs and their administration and nerve activity-modulating treatments) is applicable to this fourth aspect of the present disclosure unless otherwise indicated.
In certain embodiments according to the fourth aspect of the present disclosure, a post-treatment efficacy of the drug following a nerve activity-modulating treatment is improved relative to a reference efficacy of the drug. In such embodiments, a “post-treatment efficacy” of a drug following a nerve activity-modulating treatment refers to an improvement in a symptom or a parameter associated with a symptom of a patient who has undergone a nerve activity-modulating treatment relative to a baseline of the symptom or the parameter associated with the symptom before the patient has been subjected to either the nerve activity-modulating treatment or the administration of the drug.
In a fifth aspect, the present disclosure provides a method for treating an obstructive lung disease that comprises administering an inhaled drug to a patient of obstructive pulmonary disease, wherein the patient has previously undergone a procedure comprising: (i) positioning a treatment device in a first airway of the patient, and (ii) delivering energy from the treatment device into a wall of the first airway to reduce airway obstruction in a second airway that is a higher generation airway than the first airway.
“Treating an obstructive lung disease,” as used herein, refers to reducing the number of symptoms of an obstructive lung disease, decreasing the severity of one or more symptoms of the disease, or delaying the progression of the disease.
Obstructive lung disease is defined above in connection with the description of the methods according to the first aspect of the present disclosure. Exemplary obstructive lung diseases include COPD, asthma, bronchiectasis, and cystic fibrosis. Symptoms of such diseases and methods for monitoring or measuring such symptoms are known in the art, including those described in connection with the description of the methods according to the first aspect of the present disclosure.
Any inhaled drugs effective in treating obstructive pulmonary disease may be used in the methods disclosed herein. Exemplary inhaled drugs include and are not limited to bronchodilators, inhaled glucocorticoids (such as budesonide), inhaled steroids, inhaled anti-inflammatories, inhaled antibiotics (such as tobramycin and cholestine), mucolytics (such as n-acetyl cysteine (Mucomyst)), DNAse (dornase alfa), saline, oxygen, cromolyn, nedocromil, inhaled corticosteroids, expectorants (such as guaifenesin), and methylxanthines. Bronchodilators include anticholinergics (such as ipratropium and tiotropium) and beta agonists (such as albuterol, levalbuterol, salmetemol, formoterol, and arformoterol). The inhaled drugs are administered to a patient via inhalation.
The patients that may be treated by the methods according to the fifth aspect of the present disclosure suffer from an obstructive lung disease and have undergone a procedure that comprise (i) positioning a treatment device in a first airway of the patient, and (ii) delivering energy from the treatment device into a wall of the first airway to reduce airway obstruction in a second airway that is a higher generation airway than the first airway.
The first airway may be an airway between a trachea and a lung, a left or right main bronchus or a bronchus intermedius, or a first generation airway located outside the left and right lungs. In one embodiment, step (ii) may include delivering energy to damage a nerve trunk extending along the first airway, such as a nerve trunk disposed within connective tissue surrounding the wall of the first airway. The treatment device may comprise an energy emitter for delivering energy to the nerve trunk. Step (ii) may further comprise inhibiting damage to airway tissue disposed radially between the treatment device and the nerve trunk, such as by cooling the airway tissue using the treatment device, including absorbing heat from the airway tissue with a cooling element on the treatment device, by actively cooling the airway tissue by circulating a coolant through an expandable member, and by cooling the treatment device.
Exemplary treatment devices useful in the procedure that a patient is subjected to prior to administration of a drug include those described in U.S. Pat. No. 8,088,127, PCT Application Publication Nos. WO 2011/060200, WO 2011/056684, and WO 2011/060201, U.S. Application Publication Nos. 2011/0118725 and 2011/0301587, and U.S. Provisional Application Nos. 61/543,759 and 61/649,154. Each of these applications is incorporated herein by reference in its entirety. Certain exemplary treatment devices and their uses are also shown in
The obstruction in one or more airways in a patient having an obstructive lung disease may result from smooth muscle contraction, thickening of airway wall, mucous accumulation, or a combination thereof.
In some embodiments, a post-treatment efficacy of a drug following the procedure that the patient has undergone is improved relative to a reference efficacy of the drug. steps (a) and (b) have a treatment efficacy greater than a reference efficacy of the drug. A “post-treatment efficacy” of a drug following a procedure comprising steps (i) and (ii) as described above refers to an improvement in a symptom or a parameter associated with a symptom of a patient who has undergone a procedure comprising steps (i) and (ii) relative to a baseline of the symptom or the parameter associated with the symptom before the patient has been subjected to either the procedure or the administration of the drug. A “reference efficacy” of a drug, as used herein, is the same as this term is used in connection with the description of the first aspect of the present disclosure.
In a sixth aspect, the present disclosure provides a method for treating an obstructive lung disease that comprises (a) (i) positioning a treatment device in a first airway of a patient suffering from an obstructive lung disease, and (ii) delivering energy from the treatment device into a wall of the first airway to reduce airway obstruction in a second airway that is a higher generation airway than the first airway, and (b) subsequently administering an inhaled drug to the patient.
This sixth aspect of the present disclosure is identical to the fifth aspect of the present disclosure except that the method according to the fifth aspect comprises administering a drug to a patient who has undergone a procedure comprising steps (i) and (ii), while the method according to the sixth aspect comprises both a procedure comprising steps (a) and (b) and administration of a drug. The description of the fifth aspect of the present disclosure (e.g., the description of the drugs and their administration and procedures comprising steps (i) and (ii)) is applicable to this sixth aspect of the present disclosure unless otherwise indicated.
In some embodiments, steps (a) and (b) have a treatment efficacy greater than a reference efficacy of the drug. The terms “treatment efficacy of steps (a) and (b)” refers to an improvement in a symptom or a parameter associated with a symptom of a patient resulting from steps (a) and (b) relative to a baseline of the symptom or the parameter associated with the symptom before the patient has been subjected to either step (a) or step (b). A “reference efficacy” of a drug, as used herein, is the same as this term is used in connection with the description of the first aspect of the present disclosure.
In a seventh aspect, the present disclosure provides a method for treating a patient having an obstructive lung disease or bronchial constriction in an airway or a lung, the method including: (a) modulating or attenuating nerve activity in the autonomic nervous system of the patient to reduce obstruction in a distal airway in the lung of the patient; and (b) subsequently or simultaneously administering a drug or combination of drugs that inhibit(s) or prevent(s) the production and/or the release of acetylcholine from parasympathetic nerves at the neuromuscular junction and/or selectively block(s) the binding of acetylcholine to its receptor in nerve cells (e.g. anticholinergics or antimuscarinics).
In this aspect, step (a) can be performed as described in any of the previous aspects described above. In step (b), drugs for selectively blocking the binding of acetylcholine to its receptor in nerve cells can include, for example, anticholinergics (such as ipratropium and tiotropium). Drugs that inhibit the production and/or release of acetylcholine from the prejunctional and/or postjunctional neurons can include, for example, botulinum toxin, which acts to weaken skeletal and smooth muscle by preventing or inhibiting the docking of the acetylcholine vesicle on the inner surface of the presynaptic membrane of the neuron, thus causing chemical denervation and paresis of skeletal or smooth muscle. Additionally, organic mercurial compounds, such as methylmercury, have a high affinity for sulfhydryl groups, which causes dysfunction of the enzyme choline acetyltransferase. This inhibition may lead to acetylcholine deficiency.
In an eighth aspect, the present disclosure provides a method for treating a patient having an obstructive lung disease or bronchial constriction in an airway or a lung, the method including: inhibiting or preventing the binding of acetylcholine with receptors at a neuromuscular junction between a nerve fiber and a muscle cell in a wall of a first airway by inhibiting the release of acetylcholine from the nerve fiber. Inhibiting the release of acetylcholine can comprise injuring, either permanently or temporarily, the nerve fiber proximally of the neuromuscular junction, such as, for example, by any of the methods or devices as previously described, such as, for example ablation. The ablation can be accomplished via delivery of thermal energy, cryogenic energy (e.g., cooling energy), electrical energy, acoustic energy (e.g., ultrasonic energy), radio frequency energy, pulsed high voltage energy, mechanical energy, ionizing radiation, optical energy (e.g., light energy), or combinations thereof, and/or other types of energy suitable for treating tissue, from a device positioned in the airway to the targeted nerve fiber, for example, and as described above.
Additionally or alternatively to injuring the nerve fiber, inhibiting the release of acetylcholine can comprise administration of a drug that inhibits or prevents the production and/or the release of acetylcholine from parasympathetic nerves at the neuromuscular junction, such as, for example, botulinum toxin, and/or organic mercurial compounds, such as methylmercury.
In this embodiment, the corresponding receptors can be open to binding with acetylcholine or blocked to binding via the administration of an anticholinergic agent, for example. In one particular aspect, the method further includes binding an agent, such as by delivery of an anticholinergic agent, to second receptors at a second neuromuscular junction in a wall of a second airway to inhibit or prevent acetylcholine from binding to second receptors. The second airway can be of a higher generation airway than the first airway. In yet another aspect, the method can further include inhibiting the release of acetylcholine by interrupting the nerve fiber, such as by ablation, along a third airway, such as the left and/or right main bronchi, the first airway being a higher generation than the third airway.
In particular, a method of treating bronchial constriction in a lung comprises inhibiting the activation of muscarinic receptors in a postjunctional muscle cell of an airway by inhibiting the release of acetylcholine from a prejunctional and/or postjunctional neuron. Inhibiting the release of acetylcholine comprises injuring, either permanently or temporarily, the neuron, such as by ablating the nerve fiber. Ablation can be accomplished, for example, by using energy delivered from a treatment device, such as the ablation assembly described supra. Additionally or alternatively, inhibiting the release of acetylcholine comprises treating the prejunctional and/or postjuntional neuron with a compound, such as botulinum toxin, that prevents the release of acetylcholine from presynaptic vesicles of the neuron. The muscarinic receptors in this example, can be, for example, M3 receptors located on smooth muscle cells, mucosal glands, and/or vascular endothelium in the wall of an airway.
The method can further include the step of inhibiting the activation of muscarinic receptors in a second postjunctional muscle cell of a second airway, such as a higher generation airway than the first airway, by inhibiting acetylcholine released from a second prejunctional and/or postjuntional neuron from binding to the muscarinic receptors in the second postjunctional muscle cell of the second airway. Inhibiting the release of acetylcholine from the first neuron reduces bronchial constriction by a first amount, and inhibiting acetylcholine from binding to the muscarinic receptors in the second postjunctional muscle cell of the second airway reduces bronchial constriction by a second amount substantially greater than the first amount. Inhibiting the activation of muscarinic receptors can be accomplished, for example, by treatment with an anticholinergic compound. The method can further include the step of inhibiting the release of acetylcholine in a third airway, with the second airway being a higher generation than the third airway.
In this aspect, the method can further include the optional subsequent administration of any of a variety drugs as disclosed in previous embodiments.
The various embodiments described above can be combined to provide further embodiments. All of the U.S. patents, U.S. patent application publications, U.S. patent applications, foreign patents, foreign patent applications and non-patent publications referred to in this specification and/or listed in the Application Data Sheet are incorporated herein by reference, in their entirety. Aspects of the embodiments can be modified, if necessary to employ concepts of the various patents, applications and publications to provide yet further embodiments.
These and other changes can be made to the embodiments in light of the above-detailed description. In general, in the following claims, the terms used should not be construed to limit the claims to the specific embodiments disclosed in the specification and the claims, but should be construed to include all possible embodiments along with the full scope of equivalents to which such claims are entitled. Accordingly, the claims are not limited by the disclosure.
The present application claims the benefit of U.S. Provisional Application No. 61/746,460 filed Dec. 27, 2012, which is incorporated herein in its entirety by reference.
| Number | Name | Date | Kind |
|---|---|---|---|
| 612724 | Hamilton | Oct 1898 | A |
| 1155169 | Starkweather | Sep 1915 | A |
| 1207479 | Bisgaard | Dec 1916 | A |
| 1216183 | Swingle | Feb 1917 | A |
| 1695107 | Kahl | Dec 1928 | A |
| 2072346 | Smith | Mar 1937 | A |
| 2279714 | Meyerhof et al. | Apr 1942 | A |
| 3320957 | Sokolik | May 1967 | A |
| 3568659 | Karnegis | Mar 1971 | A |
| 3667476 | Muller | Jun 1972 | A |
| 3692029 | Adair | Sep 1972 | A |
| 3918449 | Pistor | Nov 1975 | A |
| 3946745 | Hsiang-Lai et al. | Mar 1976 | A |
| 3949743 | Shanbrom | Apr 1976 | A |
| 3995617 | Watkins et al. | Dec 1976 | A |
| 4078864 | Howell | Mar 1978 | A |
| 4095602 | Leveen | Jun 1978 | A |
| 4116589 | Rishton | Sep 1978 | A |
| 4129129 | Amrine | Dec 1978 | A |
| 4154246 | LeVeen | May 1979 | A |
| 4277168 | Oku | Jul 1981 | A |
| 4305402 | Katims | Dec 1981 | A |
| 4351330 | Scarberry | Sep 1982 | A |
| 4461283 | Doi | Jul 1984 | A |
| 4502490 | Evans et al. | Mar 1985 | A |
| 4503855 | Maslanka | Mar 1985 | A |
| 4503863 | Katims | Mar 1985 | A |
| 4512762 | Spears | Apr 1985 | A |
| 4522212 | Gelinas et al. | Jun 1985 | A |
| 4557272 | Carr | Dec 1985 | A |
| 4565200 | Cosman | Jan 1986 | A |
| 4567882 | Heller | Feb 1986 | A |
| 4573481 | Bullara | Mar 1986 | A |
| 4584998 | McGrail | Apr 1986 | A |
| 4612934 | Borkan | Sep 1986 | A |
| 4621642 | Chen | Nov 1986 | A |
| 4621882 | Krumme | Nov 1986 | A |
| 4625712 | Wampler | Dec 1986 | A |
| 4643186 | Rosen et al. | Feb 1987 | A |
| 4646737 | Hussein et al. | Mar 1987 | A |
| 4649924 | Taccardi | Mar 1987 | A |
| 4649935 | Charmillot et al. | Mar 1987 | A |
| 4658836 | Turner | Apr 1987 | A |
| 4674497 | Ogasawara | Jun 1987 | A |
| 4683890 | Hewson | Aug 1987 | A |
| 4704121 | Moise | Nov 1987 | A |
| 4706688 | Don Michael et al. | Nov 1987 | A |
| 4709698 | Johnston et al. | Dec 1987 | A |
| 4739759 | Rexroth et al. | Apr 1988 | A |
| 4754065 | Levenson et al. | Jun 1988 | A |
| 4754752 | Ginsburg et al. | Jul 1988 | A |
| 4765322 | Charmillot et al. | Aug 1988 | A |
| 4765959 | Fukasawa | Aug 1988 | A |
| 4767402 | Kost et al. | Aug 1988 | A |
| 4772112 | Zider et al. | Sep 1988 | A |
| 4773899 | Spears | Sep 1988 | A |
| 4779614 | Moise | Oct 1988 | A |
| 4784135 | Blum et al. | Nov 1988 | A |
| 4790305 | Zoltan et al. | Dec 1988 | A |
| 4799479 | Spears | Jan 1989 | A |
| 4802492 | Grunstein | Feb 1989 | A |
| 4808164 | Hess | Feb 1989 | A |
| 4817586 | Wampler | Apr 1989 | A |
| 4825871 | Cansell | May 1989 | A |
| 4827935 | Geddes et al. | May 1989 | A |
| 4846152 | Wampler et al. | Jul 1989 | A |
| 4862886 | Clarke et al. | Sep 1989 | A |
| 4881542 | Schmidt et al. | Nov 1989 | A |
| 4895557 | Moise et al. | Jan 1990 | A |
| 4902129 | Siegmund et al. | Feb 1990 | A |
| 4904472 | Belardinelli et al. | Feb 1990 | A |
| 4906229 | Wampler | Mar 1990 | A |
| 4907589 | Cosman | Mar 1990 | A |
| 4908012 | Moise et al. | Mar 1990 | A |
| 4920978 | Colvin | May 1990 | A |
| 4944722 | Carriker et al. | Jul 1990 | A |
| 4945910 | Budyko et al. | Aug 1990 | A |
| 4955377 | Lennox et al. | Sep 1990 | A |
| 4967765 | Turner et al. | Nov 1990 | A |
| 4969865 | Hwang et al. | Nov 1990 | A |
| 4976709 | Sand | Dec 1990 | A |
| 4985014 | Orejola | Jan 1991 | A |
| 4989604 | Fang | Feb 1991 | A |
| 4991603 | Cohen et al. | Feb 1991 | A |
| 4992474 | Skidmore et al. | Feb 1991 | A |
| 5005559 | Blanco et al. | Apr 1991 | A |
| 5007908 | Rydell | Apr 1991 | A |
| 5009636 | Wortley et al. | Apr 1991 | A |
| 5009936 | Yamanaka et al. | Apr 1991 | A |
| 5010892 | Colvin et al. | Apr 1991 | A |
| 5019075 | Spears et al. | May 1991 | A |
| 5027829 | Larsen | Jul 1991 | A |
| 5030645 | Kollonitsch | Jul 1991 | A |
| 5036848 | Hewson | Aug 1991 | A |
| 5053033 | Clarke | Oct 1991 | A |
| 5054486 | Yamada | Oct 1991 | A |
| 5056519 | Vince | Oct 1991 | A |
| 5056529 | de Groot | Oct 1991 | A |
| 5057107 | Parins et al. | Oct 1991 | A |
| 5074860 | Gregory et al. | Dec 1991 | A |
| 5078716 | Doll | Jan 1992 | A |
| 5084044 | Quint | Jan 1992 | A |
| 5096916 | Skupin | Mar 1992 | A |
| 5100388 | Behl et al. | Mar 1992 | A |
| 5100423 | Fearnot | Mar 1992 | A |
| 5103804 | Abele et al. | Apr 1992 | A |
| 5105826 | Smits et al. | Apr 1992 | A |
| 5106360 | Ishiwara et al. | Apr 1992 | A |
| 5107830 | Younes | Apr 1992 | A |
| 5107835 | Thomas | Apr 1992 | A |
| 5109846 | Thomas | May 1992 | A |
| 5114423 | Kasprzyk et al. | May 1992 | A |
| 5116864 | March et al. | May 1992 | A |
| 5117828 | Metzger et al. | Jun 1992 | A |
| 5123413 | Hasegawa et al. | Jun 1992 | A |
| 5126375 | Skidmore et al. | Jun 1992 | A |
| 5135480 | Bannon et al. | Aug 1992 | A |
| 5135517 | McCoy | Aug 1992 | A |
| 5139029 | Fishman et al. | Aug 1992 | A |
| 5151100 | Abele et al. | Sep 1992 | A |
| 5152286 | Sitko et al. | Oct 1992 | A |
| 5165420 | Strickland | Nov 1992 | A |
| 5167223 | Koros et al. | Dec 1992 | A |
| 5170802 | Mehra | Dec 1992 | A |
| 5170803 | Hewson et al. | Dec 1992 | A |
| 5174288 | Bardy et al. | Dec 1992 | A |
| 5188602 | Nichols | Feb 1993 | A |
| 5190540 | Lee | Mar 1993 | A |
| 5191883 | Lennox et al. | Mar 1993 | A |
| 5213576 | Abiuso et al. | May 1993 | A |
| 5215103 | Desai | Jun 1993 | A |
| 5224491 | Mehra | Jul 1993 | A |
| 5225445 | Skidmore et al. | Jul 1993 | A |
| 5231996 | Bardy et al. | Aug 1993 | A |
| 5232444 | Just et al. | Aug 1993 | A |
| 5234456 | Silvestrini | Aug 1993 | A |
| 5239982 | Trauthen | Aug 1993 | A |
| 5254088 | Lundquist et al. | Oct 1993 | A |
| 5255678 | Deslauriers et al. | Oct 1993 | A |
| 5255679 | Imran | Oct 1993 | A |
| 5265604 | Vince | Nov 1993 | A |
| 5269758 | Taheri | Dec 1993 | A |
| 5281218 | Imran | Jan 1994 | A |
| 5286254 | Shapland et al. | Feb 1994 | A |
| 5292331 | Boneau | Mar 1994 | A |
| 5293869 | Edwards et al. | Mar 1994 | A |
| 5309910 | Edwards et al. | May 1994 | A |
| 5311866 | Kagan et al. | May 1994 | A |
| 5313943 | Houser et al. | May 1994 | A |
| 5324255 | Passafaro et al. | Jun 1994 | A |
| 5324284 | Imran | Jun 1994 | A |
| 5336178 | Kaplan et al. | Aug 1994 | A |
| 5343936 | Beatenbough et al. | Sep 1994 | A |
| 5344398 | Hara | Sep 1994 | A |
| 5345936 | Pomeranz et al. | Sep 1994 | A |
| 5348554 | Imran et al. | Sep 1994 | A |
| 5366443 | Eggers et al. | Nov 1994 | A |
| 5368591 | Lennox et al. | Nov 1994 | A |
| 5370644 | Langberg | Dec 1994 | A |
| 5370675 | Edwards et al. | Dec 1994 | A |
| 5370679 | Atlee, III | Dec 1994 | A |
| 5372603 | Acker et al. | Dec 1994 | A |
| 5374287 | Rubin | Dec 1994 | A |
| 5379765 | Kajiwara et al. | Jan 1995 | A |
| 5383917 | Desai et al. | Jan 1995 | A |
| 5393207 | Maher et al. | Feb 1995 | A |
| 5394880 | Atlee, III | Mar 1995 | A |
| 5396887 | Imran | Mar 1995 | A |
| 5400778 | Jonson et al. | Mar 1995 | A |
| 5400783 | Pomeranz et al. | Mar 1995 | A |
| 5405362 | Kramer et al. | Apr 1995 | A |
| 5405366 | Fox et al. | Apr 1995 | A |
| 5411025 | Webster, Jr. | May 1995 | A |
| 5415166 | Imran | May 1995 | A |
| 5415656 | Tihon et al. | May 1995 | A |
| 5417687 | Nardella et al. | May 1995 | A |
| 5422362 | Vincent et al. | Jun 1995 | A |
| 5423744 | Gencheff et al. | Jun 1995 | A |
| 5423811 | Imran et al. | Jun 1995 | A |
| 5425023 | Haraguchi et al. | Jun 1995 | A |
| 5425703 | Feiring | Jun 1995 | A |
| 5425811 | Mashita | Jun 1995 | A |
| 5431696 | Atlee, III | Jul 1995 | A |
| 5433730 | Alt | Jul 1995 | A |
| 5437665 | Munro | Aug 1995 | A |
| 5443470 | Stern et al. | Aug 1995 | A |
| 5454782 | Perkins | Oct 1995 | A |
| 5454840 | Krakovsky et al. | Oct 1995 | A |
| 5456667 | Ham et al. | Oct 1995 | A |
| 5458596 | Lax et al. | Oct 1995 | A |
| 5465717 | Imran et al. | Nov 1995 | A |
| 5470352 | Rappaport | Nov 1995 | A |
| 5471982 | Edwards et al. | Dec 1995 | A |
| 5474530 | Passafaro et al. | Dec 1995 | A |
| 5478309 | Sweezer et al. | Dec 1995 | A |
| 5478578 | Arnold et al. | Dec 1995 | A |
| 5496271 | Burton et al. | Mar 1996 | A |
| 5496304 | Chasan | Mar 1996 | A |
| 5496311 | Abele et al. | Mar 1996 | A |
| 5496312 | Klicek | Mar 1996 | A |
| 5500011 | Desai | Mar 1996 | A |
| 5505728 | Ellman et al. | Apr 1996 | A |
| 5505730 | Edwards | Apr 1996 | A |
| 5507791 | Sitko | Apr 1996 | A |
| 5509419 | Edwards et al. | Apr 1996 | A |
| 5522862 | Testerman et al. | Jun 1996 | A |
| 5531779 | Dahl et al. | Jul 1996 | A |
| 5540681 | Strul et al. | Jul 1996 | A |
| 5540730 | Terry, Jr. et al. | Jul 1996 | A |
| 5545161 | Imran | Aug 1996 | A |
| 5545193 | Fleischman et al. | Aug 1996 | A |
| 5547469 | Rowland et al. | Aug 1996 | A |
| 5549559 | Eshel | Aug 1996 | A |
| 5549655 | Erickson | Aug 1996 | A |
| 5549661 | Kordis et al. | Aug 1996 | A |
| RE35330 | Malone et al. | Sep 1996 | E |
| 5553611 | Budd et al. | Sep 1996 | A |
| 5558073 | Pomeranz et al. | Sep 1996 | A |
| 5562608 | Sekins et al. | Oct 1996 | A |
| 5571074 | Buckman, Jr. et al. | Nov 1996 | A |
| 5571088 | Lennox et al. | Nov 1996 | A |
| 5574059 | Regunathan et al. | Nov 1996 | A |
| 5578072 | Barone et al. | Nov 1996 | A |
| 5582609 | Swanson et al. | Dec 1996 | A |
| 5588432 | Crowley | Dec 1996 | A |
| 5588812 | Taylor et al. | Dec 1996 | A |
| 5595183 | Swanson et al. | Jan 1997 | A |
| 5598848 | Swanson et al. | Feb 1997 | A |
| 5599345 | Edwards et al. | Feb 1997 | A |
| 5601088 | Swanson et al. | Feb 1997 | A |
| 5605157 | Panescu et al. | Feb 1997 | A |
| 5607419 | Amplatz et al. | Mar 1997 | A |
| 5607462 | Imran | Mar 1997 | A |
| 5620438 | Amplatz et al. | Apr 1997 | A |
| 5620463 | Drolet | Apr 1997 | A |
| 5623940 | Daikuzono | Apr 1997 | A |
| 5624392 | Saab | Apr 1997 | A |
| 5624439 | Edwards et al. | Apr 1997 | A |
| 5626618 | Ward et al. | May 1997 | A |
| 5630425 | Panescu et al. | May 1997 | A |
| 5630794 | Lax et al. | May 1997 | A |
| 5630813 | Kieturakis | May 1997 | A |
| 5634471 | Fairfax et al. | Jun 1997 | A |
| 5641326 | Adams | Jun 1997 | A |
| 5647870 | Kordis et al. | Jul 1997 | A |
| 5658278 | Imran et al. | Aug 1997 | A |
| 5658322 | Fleming | Aug 1997 | A |
| 5658549 | Akehurst et al. | Aug 1997 | A |
| 5660175 | Dayal | Aug 1997 | A |
| 5662108 | Budd et al. | Sep 1997 | A |
| 5669930 | Igarashi | Sep 1997 | A |
| 5669932 | Fischell et al. | Sep 1997 | A |
| 5674472 | Akehurst et al. | Oct 1997 | A |
| 5678535 | DiMarco | Oct 1997 | A |
| 5680860 | Imran | Oct 1997 | A |
| 5681280 | Rusk et al. | Oct 1997 | A |
| 5681308 | Edwards et al. | Oct 1997 | A |
| 5687723 | Avitall | Nov 1997 | A |
| 5688267 | Panescu et al. | Nov 1997 | A |
| 5690692 | Fleming | Nov 1997 | A |
| 5693078 | Desaj et al. | Dec 1997 | A |
| 5694934 | Edelman | Dec 1997 | A |
| 5695471 | Wampler | Dec 1997 | A |
| 5699799 | Xu et al. | Dec 1997 | A |
| 5702386 | Stern et al. | Dec 1997 | A |
| 5707218 | Maher et al. | Jan 1998 | A |
| 5707336 | Rubin | Jan 1998 | A |
| 5707352 | Sekins et al. | Jan 1998 | A |
| 5707400 | Terry, Jr. et al. | Jan 1998 | A |
| 5722401 | Pietroski et al. | Mar 1998 | A |
| 5722403 | McGee et al. | Mar 1998 | A |
| 5722416 | Swanson et al. | Mar 1998 | A |
| 5725525 | Kordis | Mar 1998 | A |
| 5727569 | Benetti et al. | Mar 1998 | A |
| 5728094 | Edwards | Mar 1998 | A |
| 5730128 | Pomeranz et al. | Mar 1998 | A |
| 5730704 | Avitall | Mar 1998 | A |
| 5730726 | Klingenstein | Mar 1998 | A |
| 5730741 | Horzewski et al. | Mar 1998 | A |
| 5733319 | Neilson et al. | Mar 1998 | A |
| 5735846 | Panescu et al. | Apr 1998 | A |
| 5740808 | Panescu et al. | Apr 1998 | A |
| 5741248 | Stern et al. | Apr 1998 | A |
| 5746224 | Edwards | May 1998 | A |
| 5752518 | McGee et al. | May 1998 | A |
| 5755714 | Murphy-Chutorian | May 1998 | A |
| 5755753 | Knowlton | May 1998 | A |
| 5759158 | Swanson | Jun 1998 | A |
| 5765568 | Sweezer, Jr. et al. | Jun 1998 | A |
| 5766605 | Sanders et al. | Jun 1998 | A |
| 5769846 | Edwards et al. | Jun 1998 | A |
| 5772590 | Webster, Jr. | Jun 1998 | A |
| 5779669 | Haissaguerre et al. | Jul 1998 | A |
| 5779698 | Clayman et al. | Jul 1998 | A |
| 5782239 | Webster, Jr. | Jul 1998 | A |
| 5782797 | Schweich, Jr. et al. | Jul 1998 | A |
| 5782827 | Gough et al. | Jul 1998 | A |
| 5782848 | Lennox | Jul 1998 | A |
| 5782899 | Imran | Jul 1998 | A |
| 5792064 | Panescu et al. | Aug 1998 | A |
| 5795303 | Swanson et al. | Aug 1998 | A |
| 5800375 | Sweezer et al. | Sep 1998 | A |
| 5800486 | Thome et al. | Sep 1998 | A |
| 5807306 | Shapland et al. | Sep 1998 | A |
| 5810757 | Sweezer, Jr. et al. | Sep 1998 | A |
| 5810807 | Ganz et al. | Sep 1998 | A |
| 5814078 | Zhou et al. | Sep 1998 | A |
| 5817028 | Anderson | Oct 1998 | A |
| 5817073 | Krespi | Oct 1998 | A |
| 5820554 | Davis et al. | Oct 1998 | A |
| 5820589 | Torgerson et al. | Oct 1998 | A |
| 5823189 | Kordis | Oct 1998 | A |
| 5827277 | Edwards | Oct 1998 | A |
| 5833651 | Donovan et al. | Nov 1998 | A |
| 5836874 | Swanson et al. | Nov 1998 | A |
| 5836905 | Lemelson et al. | Nov 1998 | A |
| 5836947 | Fleischman et al. | Nov 1998 | A |
| 5837001 | Mackey | Nov 1998 | A |
| 5843075 | Taylor | Dec 1998 | A |
| 5843077 | Edwards | Dec 1998 | A |
| 5843088 | Barra et al. | Dec 1998 | A |
| 5846238 | Jackson et al. | Dec 1998 | A |
| 5848969 | Panescu et al. | Dec 1998 | A |
| 5848972 | Triedman et al. | Dec 1998 | A |
| 5849026 | Zhou et al. | Dec 1998 | A |
| 5855577 | Murphy-Chutorian et al. | Jan 1999 | A |
| 5860974 | Abele | Jan 1999 | A |
| 5863291 | Schaer | Jan 1999 | A |
| 5865791 | Whayne et al. | Feb 1999 | A |
| 5868740 | LeVeen et al. | Feb 1999 | A |
| 5871443 | Edwards et al. | Feb 1999 | A |
| 5871483 | Jackson et al. | Feb 1999 | A |
| 5871523 | Fleischman et al. | Feb 1999 | A |
| 5873852 | Vigil et al. | Feb 1999 | A |
| 5873865 | Horzewski et al. | Feb 1999 | A |
| 5876340 | Tu et al. | Mar 1999 | A |
| 5876399 | Chia et al. | Mar 1999 | A |
| 5881727 | Edwards | Mar 1999 | A |
| 5882346 | Pomeranz et al. | Mar 1999 | A |
| 5891027 | Tu et al. | Apr 1999 | A |
| 5891135 | Jackson et al. | Apr 1999 | A |
| 5891136 | McGee et al. | Apr 1999 | A |
| 5891138 | Tu et al. | Apr 1999 | A |
| 5891182 | Fleming | Apr 1999 | A |
| 5893847 | Kordis | Apr 1999 | A |
| 5893887 | Jayaraman | Apr 1999 | A |
| 5897554 | Chia et al. | Apr 1999 | A |
| 5899882 | Waksman et al. | May 1999 | A |
| 5902268 | Saab | May 1999 | A |
| 5904651 | Swanson et al. | May 1999 | A |
| 5904711 | Flom et al. | May 1999 | A |
| 5906636 | Casscells, III et al. | May 1999 | A |
| 5908445 | Whayne et al. | Jun 1999 | A |
| 5908446 | Imran | Jun 1999 | A |
| 5908839 | Levitt et al. | Jun 1999 | A |
| 5911218 | DiMarco | Jun 1999 | A |
| 5916235 | Guglielmi | Jun 1999 | A |
| 5919147 | Jain | Jul 1999 | A |
| 5919172 | Golba, Jr. | Jul 1999 | A |
| 5924424 | Stevens et al. | Jul 1999 | A |
| 5928228 | Kordis et al. | Jul 1999 | A |
| 5931806 | Shimada | Aug 1999 | A |
| 5931835 | Mackey | Aug 1999 | A |
| 5935079 | Swanson et al. | Aug 1999 | A |
| 5941869 | Patterson et al. | Aug 1999 | A |
| 5951494 | Wang et al. | Sep 1999 | A |
| 5951546 | Lorentzen | Sep 1999 | A |
| 5954661 | Greenspon et al. | Sep 1999 | A |
| 5954662 | Swanson et al. | Sep 1999 | A |
| 5954717 | Behl et al. | Sep 1999 | A |
| 5956501 | Brown | Sep 1999 | A |
| 5957919 | Laufer | Sep 1999 | A |
| 5957961 | Maguire et al. | Sep 1999 | A |
| 5964223 | Baran | Oct 1999 | A |
| 5964753 | Edwards | Oct 1999 | A |
| 5964796 | Imran | Oct 1999 | A |
| 5971983 | Lesh | Oct 1999 | A |
| 5972026 | Laufer et al. | Oct 1999 | A |
| 5976175 | Hirano et al. | Nov 1999 | A |
| 5976709 | Kageyama et al. | Nov 1999 | A |
| 5979456 | Magovern | Nov 1999 | A |
| 5980563 | Tu et al. | Nov 1999 | A |
| 5984917 | Fleischman et al. | Nov 1999 | A |
| 5984971 | Faccioli et al. | Nov 1999 | A |
| 5989545 | Foster et al. | Nov 1999 | A |
| 5991650 | Swanson et al. | Nov 1999 | A |
| 5992419 | Sterzer et al. | Nov 1999 | A |
| 5993462 | Pomeranz et al. | Nov 1999 | A |
| 5995873 | Rhodes | Nov 1999 | A |
| 5997534 | Tu et al. | Dec 1999 | A |
| 5999855 | DiMarco | Dec 1999 | A |
| 6001054 | Regulla et al. | Dec 1999 | A |
| 6003517 | Sheffield et al. | Dec 1999 | A |
| 6004269 | Crowley et al. | Dec 1999 | A |
| 6006134 | Hill et al. | Dec 1999 | A |
| 6006755 | Edwards | Dec 1999 | A |
| 6008211 | Robinson et al. | Dec 1999 | A |
| 6009877 | Edwards | Jan 2000 | A |
| 6010500 | Sherman et al. | Jan 2000 | A |
| 6014579 | Pomeranz et al. | Jan 2000 | A |
| 6016437 | Tu et al. | Jan 2000 | A |
| 6023638 | Swanson | Feb 2000 | A |
| 6024740 | Lesh et al. | Feb 2000 | A |
| 6029091 | de la Rama et al. | Feb 2000 | A |
| 6033397 | Laufer et al. | Mar 2000 | A |
| 6036687 | Laufer et al. | Mar 2000 | A |
| 6036689 | Tu et al. | Mar 2000 | A |
| 6039731 | Taylor et al. | Mar 2000 | A |
| 6043273 | Duhaylongsod | Mar 2000 | A |
| 6045549 | Smethers et al. | Apr 2000 | A |
| 6045550 | Simpson et al. | Apr 2000 | A |
| 6050992 | Nichols | Apr 2000 | A |
| 6052607 | Edwards et al. | Apr 2000 | A |
| 6053172 | Hovda et al. | Apr 2000 | A |
| 6053909 | Shadduck | Apr 2000 | A |
| 6056744 | Edwards | May 2000 | A |
| 6056745 | Panescu et al. | May 2000 | A |
| 6056769 | Epstein et al. | May 2000 | A |
| 6060454 | Duhaylongsod | May 2000 | A |
| 6063078 | Wittkampf | May 2000 | A |
| 6063768 | First | May 2000 | A |
| 6071280 | Edwards et al. | Jun 2000 | A |
| 6071281 | Burnside et al. | Jun 2000 | A |
| 6071282 | Fleischman | Jun 2000 | A |
| 6081749 | Ingle et al. | Jun 2000 | A |
| 6083249 | Familoni | Jul 2000 | A |
| 6083255 | Laufer et al. | Jul 2000 | A |
| 6087394 | Duhaylongsod | Jul 2000 | A |
| 6090104 | Webster, Jr. | Jul 2000 | A |
| 6091995 | Ingle et al. | Jul 2000 | A |
| 6092528 | Edwards | Jul 2000 | A |
| 6097985 | Kasevich et al. | Aug 2000 | A |
| 6101412 | Duhaylongsod | Aug 2000 | A |
| 6102886 | Lundquist et al. | Aug 2000 | A |
| 6106524 | Eggers et al. | Aug 2000 | A |
| 6117101 | Diederich et al. | Sep 2000 | A |
| 6123702 | Swanson et al. | Sep 2000 | A |
| 6123703 | Tu et al. | Sep 2000 | A |
| 6123718 | Tu et al. | Sep 2000 | A |
| 6125301 | Capel | Sep 2000 | A |
| 6127410 | Duhaylongsod | Oct 2000 | A |
| 6129726 | Edwards et al. | Oct 2000 | A |
| 6135997 | Laufer et al. | Oct 2000 | A |
| 6139527 | Laufer et al. | Oct 2000 | A |
| 6139571 | Fuller et al. | Oct 2000 | A |
| 6139845 | Donovan | Oct 2000 | A |
| 6141589 | Duhaylongsod | Oct 2000 | A |
| 6142993 | Whayne et al. | Nov 2000 | A |
| 6143013 | Samson et al. | Nov 2000 | A |
| 6143277 | Ashurst et al. | Nov 2000 | A |
| 6149647 | Tu et al. | Nov 2000 | A |
| 6152143 | Edwards | Nov 2000 | A |
| 6152899 | Farley et al. | Nov 2000 | A |
| 6152953 | Hipskind | Nov 2000 | A |
| 6159194 | Eggers et al. | Dec 2000 | A |
| 6163716 | Edwards et al. | Dec 2000 | A |
| 6174323 | Biggs et al. | Jan 2001 | B1 |
| 6179833 | Taylor | Jan 2001 | B1 |
| 6183468 | Swanson et al. | Feb 2001 | B1 |
| 6197013 | Reed et al. | Mar 2001 | B1 |
| 6198970 | Freed et al. | Mar 2001 | B1 |
| 6200311 | Danek et al. | Mar 2001 | B1 |
| 6200332 | Del Giglio | Mar 2001 | B1 |
| 6200333 | Laufer | Mar 2001 | B1 |
| 6203562 | Ohkubo | Mar 2001 | B1 |
| 6210367 | Carr | Apr 2001 | B1 |
| 6212432 | Matsuura | Apr 2001 | B1 |
| 6212433 | Behl | Apr 2001 | B1 |
| 6214002 | Fleischman et al. | Apr 2001 | B1 |
| 6216043 | Swanson et al. | Apr 2001 | B1 |
| 6216044 | Kordis | Apr 2001 | B1 |
| 6216704 | Ingle et al. | Apr 2001 | B1 |
| 6217576 | Tu et al. | Apr 2001 | B1 |
| 6226543 | Gilboa et al. | May 2001 | B1 |
| 6230052 | Wolff et al. | May 2001 | B1 |
| 6231595 | Dobak, III | May 2001 | B1 |
| 6235024 | Tu | May 2001 | B1 |
| 6240307 | Beatty et al. | May 2001 | B1 |
| 6241727 | Tu et al. | Jun 2001 | B1 |
| 6245065 | Panescu et al. | Jun 2001 | B1 |
| 6251368 | Akehurst et al. | Jun 2001 | B1 |
| 6253762 | Britto | Jul 2001 | B1 |
| 6254598 | Edwards et al. | Jul 2001 | B1 |
| 6254599 | Lesh et al. | Jul 2001 | B1 |
| 6258083 | Daniel et al. | Jul 2001 | B1 |
| 6258087 | Edwards et al. | Jul 2001 | B1 |
| 6264653 | Falwell | Jul 2001 | B1 |
| 6265379 | Donovan | Jul 2001 | B1 |
| 6269813 | Fitzgerald et al. | Aug 2001 | B1 |
| 6270476 | Santoianni et al. | Aug 2001 | B1 |
| 6273886 | Edwards et al. | Aug 2001 | B1 |
| 6273907 | Laufer | Aug 2001 | B1 |
| 6283987 | Laird et al. | Sep 2001 | B1 |
| 6283988 | Laufer et al. | Sep 2001 | B1 |
| 6283989 | Laufer et al. | Sep 2001 | B1 |
| 6287304 | Eggers et al. | Sep 2001 | B1 |
| 6296639 | Truckai et al. | Oct 2001 | B1 |
| 6299633 | Laufer | Oct 2001 | B1 |
| 6302870 | Jacobsen et al. | Oct 2001 | B1 |
| 6303509 | Chen et al. | Oct 2001 | B1 |
| 6306423 | Donovan et al. | Oct 2001 | B1 |
| 6315173 | Di Giovanni et al. | Nov 2001 | B1 |
| 6315778 | Gambale et al. | Nov 2001 | B1 |
| 6317615 | KenKnight et al. | Nov 2001 | B1 |
| 6322559 | Daulton et al. | Nov 2001 | B1 |
| 6322584 | Ingle et al. | Nov 2001 | B2 |
| 6325798 | Edwards et al. | Dec 2001 | B1 |
| 6327503 | Familoni | Dec 2001 | B1 |
| 6338727 | Noda et al. | Jan 2002 | B1 |
| 6338836 | Kuth et al. | Jan 2002 | B1 |
| 6341236 | Osorio et al. | Jan 2002 | B1 |
| 6346104 | Daly et al. | Feb 2002 | B2 |
| 6355031 | Edwards et al. | Mar 2002 | B1 |
| 6356786 | Rezai et al. | Mar 2002 | B1 |
| 6356787 | Rezai et al. | Mar 2002 | B1 |
| 6357447 | Swanson et al. | Mar 2002 | B1 |
| 6358245 | Edwards et al. | Mar 2002 | B1 |
| 6358926 | Donovan | Mar 2002 | B2 |
| 6361554 | Brisken | Mar 2002 | B1 |
| 6363937 | Hovda et al. | Apr 2002 | B1 |
| 6366814 | Boveja et al. | Apr 2002 | B1 |
| 6379352 | Reynolds et al. | Apr 2002 | B1 |
| 6383509 | Donovan et al. | May 2002 | B1 |
| 6394956 | Chandrasekaran et al. | May 2002 | B1 |
| 6402744 | Edwards et al. | Jun 2002 | B2 |
| 6405732 | Edwards et al. | Jun 2002 | B1 |
| 6409723 | Edwards | Jun 2002 | B1 |
| 6411852 | Danek et al. | Jun 2002 | B1 |
| 6414018 | Duhaylongsod | Jul 2002 | B1 |
| 6416511 | Lesh et al. | Jul 2002 | B1 |
| 6416740 | Unger | Jul 2002 | B1 |
| 6423058 | Edwards et al. | Jul 2002 | B1 |
| 6423105 | Iijima et al. | Jul 2002 | B1 |
| 6424864 | Matsuura | Jul 2002 | B1 |
| 6425877 | Edwards | Jul 2002 | B1 |
| 6425887 | McGuckin et al. | Jul 2002 | B1 |
| 6425895 | Swanson et al. | Jul 2002 | B1 |
| 6432092 | Miller | Aug 2002 | B2 |
| 6436130 | Philips et al. | Aug 2002 | B1 |
| 6438423 | Rezai et al. | Aug 2002 | B1 |
| 6440128 | Edwards et al. | Aug 2002 | B1 |
| 6440129 | Simpson | Aug 2002 | B1 |
| 6442435 | King et al. | Aug 2002 | B2 |
| 6447505 | McGovern et al. | Sep 2002 | B2 |
| 6447785 | Donovan | Sep 2002 | B1 |
| 6448231 | Graham | Sep 2002 | B2 |
| 6456932 | Yagyu | Sep 2002 | B2 |
| 6458121 | Rosenstock et al. | Oct 2002 | B1 |
| 6460545 | Kordis | Oct 2002 | B2 |
| 6464680 | Brisken et al. | Oct 2002 | B1 |
| 6464697 | Edwards et al. | Oct 2002 | B1 |
| 6475160 | Sher | Nov 2002 | B1 |
| 6480746 | Ingle et al. | Nov 2002 | B1 |
| 6485416 | Platt et al. | Nov 2002 | B1 |
| 6488673 | Laufer et al. | Dec 2002 | B1 |
| 6488679 | Swanson et al. | Dec 2002 | B1 |
| 6491710 | Satake | Dec 2002 | B2 |
| 6493589 | Medhkour et al. | Dec 2002 | B1 |
| 6494880 | Swanson et al. | Dec 2002 | B1 |
| 6496737 | Rudie et al. | Dec 2002 | B2 |
| 6496738 | Carr | Dec 2002 | B2 |
| 6506399 | Donovan | Jan 2003 | B2 |
| 6510969 | Di Giovanni et al. | Jan 2003 | B2 |
| 6514246 | Swanson et al. | Feb 2003 | B1 |
| 6514290 | Loomas | Feb 2003 | B1 |
| 6519488 | KenKnight et al. | Feb 2003 | B2 |
| 6522913 | Swanson et al. | Feb 2003 | B2 |
| 6524555 | Ashurst et al. | Feb 2003 | B1 |
| 6526320 | Mitchell | Feb 2003 | B2 |
| 6526976 | Baran | Mar 2003 | B1 |
| 6529756 | Phan et al. | Mar 2003 | B1 |
| 6532388 | Hill et al. | Mar 2003 | B1 |
| 6533780 | Laird et al. | Mar 2003 | B1 |
| 6536427 | Davies et al. | Mar 2003 | B2 |
| 6544226 | Gaiser et al. | Apr 2003 | B1 |
| 6544262 | Fleischman | Apr 2003 | B2 |
| 6546928 | Ashurst et al. | Apr 2003 | B1 |
| 6546932 | Nahon et al. | Apr 2003 | B1 |
| 6546934 | Ingle et al. | Apr 2003 | B1 |
| 6547776 | Gaiser et al. | Apr 2003 | B1 |
| 6547788 | Maguire et al. | Apr 2003 | B1 |
| 6549808 | Gisel et al. | Apr 2003 | B1 |
| 6551274 | Heiner | Apr 2003 | B2 |
| 6551310 | Ganz et al. | Apr 2003 | B1 |
| 6558333 | Gilboa et al. | May 2003 | B2 |
| 6558378 | Sherman et al. | May 2003 | B2 |
| 6558381 | Ingle et al. | May 2003 | B2 |
| 6562034 | Edwards et al. | May 2003 | B2 |
| 6572612 | Stewart et al. | Jun 2003 | B2 |
| 6575623 | Werneth | Jun 2003 | B2 |
| 6575969 | Rittman, III et al. | Jun 2003 | B1 |
| 6582427 | Goble et al. | Jun 2003 | B1 |
| 6582430 | Hall | Jun 2003 | B2 |
| 6587718 | Talpade | Jul 2003 | B2 |
| 6587719 | Barrett et al. | Jul 2003 | B1 |
| 6587731 | Ingle et al. | Jul 2003 | B1 |
| 6589235 | Wong et al. | Jul 2003 | B2 |
| 6589238 | Edwards et al. | Jul 2003 | B2 |
| 6593130 | Sen et al. | Jul 2003 | B1 |
| 6599311 | Biggs et al. | Jul 2003 | B1 |
| 6601581 | Babaev | Aug 2003 | B1 |
| 6603996 | Beatty et al. | Aug 2003 | B1 |
| 6610054 | Edwards et al. | Aug 2003 | B1 |
| 6610083 | Keller et al. | Aug 2003 | B2 |
| 6610713 | Tracey | Aug 2003 | B2 |
| 6613002 | Clark et al. | Sep 2003 | B1 |
| 6613045 | Laufer et al. | Sep 2003 | B1 |
| 6620159 | Hegde | Sep 2003 | B2 |
| 6620415 | Donovan | Sep 2003 | B2 |
| 6622047 | Barrett et al. | Sep 2003 | B2 |
| 6623742 | Voet | Sep 2003 | B2 |
| 6626855 | Weng et al. | Sep 2003 | B1 |
| 6626903 | McGuckin, Jr. et al. | Sep 2003 | B2 |
| 6629535 | Ingle et al. | Oct 2003 | B2 |
| 6629951 | Laufer et al. | Oct 2003 | B2 |
| 6632440 | Quinn et al. | Oct 2003 | B1 |
| 6633779 | Schuler et al. | Oct 2003 | B1 |
| 6634363 | Danek et al. | Oct 2003 | B1 |
| 6635054 | Fjield et al. | Oct 2003 | B2 |
| 6635056 | Kadhiresan et al. | Oct 2003 | B2 |
| 6638273 | Farley et al. | Oct 2003 | B1 |
| 6640119 | Budd et al. | Oct 2003 | B1 |
| 6640120 | Swanson et al. | Oct 2003 | B1 |
| 6645200 | Koblish et al. | Nov 2003 | B1 |
| 6645496 | Aoki et al. | Nov 2003 | B2 |
| 6647617 | Beatty et al. | Nov 2003 | B1 |
| 6648881 | KenKnight et al. | Nov 2003 | B2 |
| 6649161 | Donovan | Nov 2003 | B1 |
| 6652517 | Hall et al. | Nov 2003 | B1 |
| 6652548 | Evans et al. | Nov 2003 | B2 |
| 6656960 | Puskas | Dec 2003 | B2 |
| 6658279 | Swanson et al. | Dec 2003 | B2 |
| 6663622 | Foley et al. | Dec 2003 | B1 |
| 6666858 | Lafontaine | Dec 2003 | B2 |
| 6669693 | Friedman | Dec 2003 | B2 |
| 6673068 | Berube | Jan 2004 | B1 |
| 6673070 | Edwards et al. | Jan 2004 | B2 |
| 6675047 | Konoplev et al. | Jan 2004 | B1 |
| 6676686 | Naganuma | Jan 2004 | B2 |
| 6681136 | Schuler et al. | Jan 2004 | B2 |
| 6692492 | Simpson et al. | Feb 2004 | B2 |
| 6692494 | Cooper et al. | Feb 2004 | B1 |
| 6699180 | Kobayashi | Mar 2004 | B2 |
| 6699243 | West et al. | Mar 2004 | B2 |
| 6708064 | Rezai | Mar 2004 | B2 |
| 6711436 | Duhaylongsod | Mar 2004 | B1 |
| 6712074 | Edwards et al. | Mar 2004 | B2 |
| 6712812 | Roschak et al. | Mar 2004 | B2 |
| 6712814 | Edwards et al. | Mar 2004 | B2 |
| 6714822 | King et al. | Mar 2004 | B2 |
| 6719685 | Fujikura et al. | Apr 2004 | B2 |
| 6719694 | Weng et al. | Apr 2004 | B2 |
| 6723053 | Ackerman et al. | Apr 2004 | B2 |
| 6723091 | Goble et al. | Apr 2004 | B2 |
| 6728562 | Budd et al. | Apr 2004 | B1 |
| 6735471 | Hill et al. | May 2004 | B2 |
| 6735475 | Whitehurst et al. | May 2004 | B1 |
| 6740321 | Donovan | May 2004 | B1 |
| 6743197 | Edwards | Jun 2004 | B1 |
| 6743413 | Schultz et al. | Jun 2004 | B1 |
| 6749604 | Eggers et al. | Jun 2004 | B1 |
| 6749606 | Keast et al. | Jun 2004 | B2 |
| 6752765 | Jensen et al. | Jun 2004 | B1 |
| 6755026 | Wallach | Jun 2004 | B2 |
| 6755849 | Gowda et al. | Jun 2004 | B1 |
| 6767347 | Sharkey et al. | Jul 2004 | B2 |
| 6767544 | Brooks et al. | Jul 2004 | B2 |
| 6770070 | Balbierz | Aug 2004 | B1 |
| 6772013 | Ingle et al. | Aug 2004 | B1 |
| 6773711 | Voet et al. | Aug 2004 | B2 |
| 6776991 | Naumann | Aug 2004 | B2 |
| 6777423 | Banholzer et al. | Aug 2004 | B2 |
| 6778854 | Puskas | Aug 2004 | B2 |
| 6780183 | Jimenez et al. | Aug 2004 | B2 |
| 6786889 | Musbach et al. | Sep 2004 | B1 |
| 6802843 | Truckai et al. | Oct 2004 | B2 |
| 6805131 | Kordis | Oct 2004 | B2 |
| 6819956 | DiLorenzo | Nov 2004 | B2 |
| 6826420 | Beatty et al. | Nov 2004 | B1 |
| 6826421 | Beatty et al. | Nov 2004 | B1 |
| 6827931 | Donovan | Dec 2004 | B1 |
| 6836688 | Ingle et al. | Dec 2004 | B2 |
| 6837888 | Ciarrocca et al. | Jan 2005 | B2 |
| 6838429 | Paslin | Jan 2005 | B2 |
| 6838434 | Voet | Jan 2005 | B2 |
| 6838471 | Tracey | Jan 2005 | B2 |
| 6840243 | Deem et al. | Jan 2005 | B2 |
| 6841156 | Aoki et al. | Jan 2005 | B2 |
| 6843998 | Steward et al. | Jan 2005 | B1 |
| 6846312 | Edwards et al. | Jan 2005 | B2 |
| 6847849 | Mamo et al. | Jan 2005 | B2 |
| 6849073 | Hoey et al. | Feb 2005 | B2 |
| 6852091 | Edwards et al. | Feb 2005 | B2 |
| 6852110 | Roy et al. | Feb 2005 | B2 |
| 6861058 | Aoki et al. | Mar 2005 | B2 |
| 6866662 | Fuimaono et al. | Mar 2005 | B2 |
| 6871092 | Piccone | Mar 2005 | B2 |
| 6872206 | Edwards et al. | Mar 2005 | B2 |
| 6872397 | Aoki et al. | Mar 2005 | B2 |
| 6878156 | Noda | Apr 2005 | B1 |
| 6881213 | Ryan et al. | Apr 2005 | B2 |
| 6885888 | Rezai | Apr 2005 | B2 |
| 6890347 | Machold et al. | May 2005 | B2 |
| 6893436 | Woodard et al. | May 2005 | B2 |
| 6893438 | Hall et al. | May 2005 | B2 |
| 6893439 | Fleischman | May 2005 | B2 |
| 6895267 | Panescu et al. | May 2005 | B2 |
| 6904303 | Phan et al. | Jun 2005 | B2 |
| 6908462 | Joye et al. | Jun 2005 | B2 |
| 6908928 | Banholzer et al. | Jun 2005 | B2 |
| 6913616 | Hamilton et al. | Jul 2005 | B2 |
| 6917834 | Koblish et al. | Jul 2005 | B2 |
| 6934583 | Weinberg et al. | Aug 2005 | B2 |
| 6937896 | Kroll | Aug 2005 | B1 |
| 6937903 | Schuler et al. | Aug 2005 | B2 |
| 6939309 | Beatty et al. | Sep 2005 | B1 |
| 6939345 | KenKnight et al. | Sep 2005 | B2 |
| 6939346 | Kannenberg et al. | Sep 2005 | B2 |
| 6947785 | Beatty et al. | Sep 2005 | B1 |
| 6954977 | Maguire et al. | Oct 2005 | B2 |
| 6957106 | Schuler et al. | Oct 2005 | B2 |
| 6961622 | Gilbert | Nov 2005 | B2 |
| 6970742 | Mann et al. | Nov 2005 | B2 |
| RE38912 | Walz et al. | Dec 2005 | E |
| 6971395 | Edwards et al. | Dec 2005 | B2 |
| 6974224 | Thomas-Benedict | Dec 2005 | B2 |
| 6974456 | Edwards et al. | Dec 2005 | B2 |
| 6974578 | Aoki et al. | Dec 2005 | B1 |
| 6978168 | Beatty et al. | Dec 2005 | B2 |
| 6978174 | Gelfand et al. | Dec 2005 | B2 |
| 6990370 | Beatty et al. | Jan 2006 | B1 |
| 6994706 | Chomenky et al. | Feb 2006 | B2 |
| 6997189 | Biggs et al. | Feb 2006 | B2 |
| 7004942 | Laird et al. | Feb 2006 | B2 |
| 7022088 | Keast et al. | Apr 2006 | B2 |
| 7022105 | Edwards | Apr 2006 | B1 |
| 7027869 | Danek et al. | Apr 2006 | B2 |
| 7043307 | Zelickson et al. | May 2006 | B1 |
| 7070800 | Bechtold-Peters et al. | Jul 2006 | B2 |
| 7072720 | Puskas | Jul 2006 | B2 |
| 7083614 | Fjield et al. | Aug 2006 | B2 |
| 7101368 | Lafontaine | Sep 2006 | B2 |
| 7101387 | Garabedian et al. | Sep 2006 | B2 |
| 7104987 | Biggs et al. | Sep 2006 | B2 |
| 7104990 | Jenkins et al. | Sep 2006 | B2 |
| 7112198 | Satake | Sep 2006 | B2 |
| 7118568 | Hassett et al. | Oct 2006 | B2 |
| 7122031 | Edwards et al. | Oct 2006 | B2 |
| 7122033 | Wood | Oct 2006 | B2 |
| 7125407 | Edwards et al. | Oct 2006 | B2 |
| 7131445 | Amoah | Nov 2006 | B2 |
| 7142910 | Puskas | Nov 2006 | B2 |
| 7150745 | Stem et al. | Dec 2006 | B2 |
| 7162303 | Levin et al. | Jan 2007 | B2 |
| 7165551 | Edwards et al. | Jan 2007 | B2 |
| 7167757 | Ingle et al. | Jan 2007 | B2 |
| 7175644 | Cooper et al. | Feb 2007 | B2 |
| 7179257 | West et al. | Feb 2007 | B2 |
| 7186251 | Malecki et al. | Mar 2007 | B2 |
| 7187964 | Khoury | Mar 2007 | B2 |
| 7187973 | Hauck | Mar 2007 | B2 |
| 7189208 | Beatty et al. | Mar 2007 | B1 |
| 7198635 | Danek et al. | Apr 2007 | B2 |
| 7200445 | Dalbec et al. | Apr 2007 | B1 |
| 7229469 | Witzel et al. | Jun 2007 | B1 |
| 7238357 | Barron | Jul 2007 | B2 |
| 7241295 | Maguire | Jul 2007 | B2 |
| 7255693 | Johnston et al. | Aug 2007 | B1 |
| RE39820 | Banholzer et al. | Sep 2007 | E |
| 7264002 | Danek et al. | Sep 2007 | B2 |
| 7266414 | Cornelius et al. | Sep 2007 | B2 |
| 7273055 | Danek et al. | Sep 2007 | B2 |
| 7289843 | Beatty et al. | Oct 2007 | B2 |
| 7291146 | Steinke et al. | Nov 2007 | B2 |
| 7292890 | Whitehurst et al. | Nov 2007 | B2 |
| 7309707 | Bender et al. | Dec 2007 | B2 |
| 7310552 | Puskas | Dec 2007 | B2 |
| RE40045 | Palmer | Feb 2008 | E |
| 7326207 | Edwards | Feb 2008 | B2 |
| 7344535 | Stem et al. | Mar 2008 | B2 |
| 7371231 | Rioux et al. | May 2008 | B2 |
| 7393330 | Keast et al. | Jul 2008 | B2 |
| 7393350 | Maurice | Jul 2008 | B2 |
| 7394976 | Entenman et al. | Jul 2008 | B2 |
| 7402172 | Chin et al. | Jul 2008 | B2 |
| 7422563 | Roschak et al. | Sep 2008 | B2 |
| 7422584 | Loomas et al. | Sep 2008 | B2 |
| 7425212 | Danek et al. | Sep 2008 | B1 |
| 7430449 | Aldrich et al. | Sep 2008 | B2 |
| 7462162 | Phan et al. | Dec 2008 | B2 |
| 7462179 | Edwards et al. | Dec 2008 | B2 |
| 7473273 | Campbell | Jan 2009 | B2 |
| 7477945 | Rezai et al. | Jan 2009 | B2 |
| 7483755 | Ingle et al. | Jan 2009 | B2 |
| 7493160 | Weber et al. | Feb 2009 | B2 |
| 7494661 | Sanders | Feb 2009 | B2 |
| 7507234 | Utley et al. | Mar 2009 | B2 |
| 7507238 | Edwards et al. | Mar 2009 | B2 |
| 7517320 | Wibowo et al. | Apr 2009 | B2 |
| 7530979 | Ganz et al. | May 2009 | B2 |
| 7532938 | Machado et al. | May 2009 | B2 |
| 7542802 | Danek et al. | Jun 2009 | B2 |
| 7553307 | Bleich et al. | Jun 2009 | B2 |
| 7556624 | Laufer et al. | Jul 2009 | B2 |
| 7559890 | Wallace et al. | Jul 2009 | B2 |
| 7572245 | Herweck et al. | Aug 2009 | B2 |
| 7585296 | Edwards et al. | Sep 2009 | B2 |
| 7588549 | Eccleston | Sep 2009 | B2 |
| 7594925 | Danek et al. | Sep 2009 | B2 |
| 7608275 | Deem et al. | Oct 2009 | B2 |
| 7613515 | Knudson et al. | Nov 2009 | B2 |
| 7617005 | Demarais et al. | Nov 2009 | B2 |
| 7620451 | Demarais et al. | Nov 2009 | B2 |
| 7628789 | Soltesz et al. | Dec 2009 | B2 |
| 7632268 | Edwards et al. | Dec 2009 | B2 |
| 7641632 | Noda et al. | Jan 2010 | B2 |
| 7641633 | Laufer et al. | Jan 2010 | B2 |
| 7648500 | Edwards et al. | Jan 2010 | B2 |
| 7653438 | Deem et al. | Jan 2010 | B2 |
| 7684865 | Aldrich et al. | Mar 2010 | B2 |
| 7689290 | Ingle et al. | Mar 2010 | B2 |
| 7691079 | Gobel | Apr 2010 | B2 |
| RE41334 | Beatty et al. | May 2010 | E |
| 7708712 | Phan et al. | May 2010 | B2 |
| 7708768 | Danek et al. | May 2010 | B2 |
| 7711430 | Errico et al. | May 2010 | B2 |
| 7717948 | Demarais et al. | May 2010 | B2 |
| 7722538 | Khoury | May 2010 | B2 |
| 7725188 | Errico et al. | May 2010 | B2 |
| 7734355 | Cohen et al. | Jun 2010 | B2 |
| 7734535 | Bums | Jun 2010 | B1 |
| 7740017 | Danek et al. | Jun 2010 | B2 |
| 7740631 | Bleich et al. | Jun 2010 | B2 |
| 7742795 | Stone et al. | Jun 2010 | B2 |
| 7747324 | Errico et al. | Jun 2010 | B2 |
| 7756583 | Demarais et al. | Jul 2010 | B2 |
| 7765010 | Chomenky et al. | Jul 2010 | B2 |
| 7770584 | Danek et al. | Aug 2010 | B2 |
| 7783358 | Aldrich et al. | Aug 2010 | B2 |
| 7815590 | Cooper | Oct 2010 | B2 |
| 7826881 | Beatty et al. | Nov 2010 | B1 |
| 7831288 | Beatty et al. | Nov 2010 | B1 |
| 7837676 | Sinelnikov et al. | Nov 2010 | B2 |
| 7837679 | Biggs et al. | Nov 2010 | B2 |
| 7841986 | He et al. | Nov 2010 | B2 |
| 7844338 | Knudson et al. | Nov 2010 | B2 |
| 7853331 | Kaplan et al. | Dec 2010 | B2 |
| 7854734 | Biggs et al. | Dec 2010 | B2 |
| 7854740 | Carney | Dec 2010 | B2 |
| 7869879 | Errico et al. | Jan 2011 | B2 |
| 7869880 | Errico et al. | Jan 2011 | B2 |
| 7873417 | Demarais et al. | Jan 2011 | B2 |
| 7877146 | Rezai et al. | Jan 2011 | B2 |
| 7904159 | Errico et al. | Mar 2011 | B2 |
| 7906124 | Laufer et al. | Mar 2011 | B2 |
| 7914448 | Bob et al. | Mar 2011 | B2 |
| 7921855 | Danek et al. | Apr 2011 | B2 |
| 7930012 | Beatty et al. | Apr 2011 | B2 |
| 7931647 | Wizeman et al. | Apr 2011 | B2 |
| 7937143 | Demarais et al. | May 2011 | B2 |
| 7938123 | Danek et al. | May 2011 | B2 |
| 7949407 | Kaplan et al. | May 2011 | B2 |
| 7967782 | Laufer et al. | Jun 2011 | B2 |
| 7985187 | Wibowo et al. | Jul 2011 | B2 |
| 7992572 | Danek et al. | Aug 2011 | B2 |
| 7993336 | Jackson et al. | Aug 2011 | B2 |
| 8002740 | Willink et al. | Aug 2011 | B2 |
| 8010197 | Errico et al. | Aug 2011 | B2 |
| 8012149 | Jackson et al. | Sep 2011 | B2 |
| 8041428 | Errico et al. | Oct 2011 | B2 |
| 8046085 | Knudson et al. | Oct 2011 | B2 |
| 8052668 | Sih | Nov 2011 | B2 |
| 8088127 | Mayse et al. | Jan 2012 | B2 |
| 8099167 | Errico et al. | Jan 2012 | B1 |
| 8105817 | Deem et al. | Jan 2012 | B2 |
| 8128595 | Walker et al. | Mar 2012 | B2 |
| 8128617 | Bencini et al. | Mar 2012 | B2 |
| 8131371 | Demarais et al. | Mar 2012 | B2 |
| 8133497 | Deem et al. | Mar 2012 | B2 |
| 8152803 | Edwards et al. | Apr 2012 | B2 |
| 8172827 | Deem et al. | May 2012 | B2 |
| 8204598 | Errico et al. | Jun 2012 | B2 |
| 8208998 | Beatty et al. | Jun 2012 | B2 |
| 8209034 | Simon et al. | Jun 2012 | B2 |
| 8216216 | Warnking et al. | Jul 2012 | B2 |
| 8226638 | Mayse et al. | Jul 2012 | B2 |
| 8229564 | Rezai | Jul 2012 | B2 |
| 8231621 | Hutchins et al. | Jul 2012 | B2 |
| 8233988 | Errico et al. | Jul 2012 | B2 |
| 8251992 | Utley et al. | Aug 2012 | B2 |
| 8267094 | Danek et al. | Sep 2012 | B2 |
| 8295902 | Salahieh et al. | Oct 2012 | B2 |
| 8303581 | Arts et al. | Nov 2012 | B2 |
| 8313484 | Edwards et al. | Nov 2012 | B2 |
| 8328798 | Witzel et al. | Dec 2012 | B2 |
| 8338164 | Deem et al. | Dec 2012 | B2 |
| 8347891 | Demarais et al. | Jan 2013 | B2 |
| 8357118 | Orr | Jan 2013 | B2 |
| 8364237 | Stone et al. | Jan 2013 | B2 |
| 8371303 | Schaner et al. | Feb 2013 | B2 |
| 8377055 | Jackson et al. | Feb 2013 | B2 |
| 8483831 | Hlavka et al. | Jul 2013 | B1 |
| 8489192 | Hlavka et al. | Jul 2013 | B1 |
| 8731672 | Hlavka et al. | May 2014 | B2 |
| 8740895 | Mayse et al. | Jun 2014 | B2 |
| 8777943 | Mayse et al. | Jul 2014 | B2 |
| 8808280 | Mayse et al. | Aug 2014 | B2 |
| 8821489 | Mayse et al. | Sep 2014 | B2 |
| 8911439 | Mayse et al. | Dec 2014 | B2 |
| 8932289 | Mayse et al. | Jan 2015 | B2 |
| 8961507 | Mayse et al. | Feb 2015 | B2 |
| 8961508 | Mayse et al. | Feb 2015 | B2 |
| 20010020151 | Reed et al. | Sep 2001 | A1 |
| 20010044596 | Jaafar | Nov 2001 | A1 |
| 20020002387 | Naganuma | Jan 2002 | A1 |
| 20020010495 | Freed et al. | Jan 2002 | A1 |
| 20020016344 | Tracey | Feb 2002 | A1 |
| 20020042564 | Cooper et al. | Apr 2002 | A1 |
| 20020042565 | Cooper et al. | Apr 2002 | A1 |
| 20020049370 | Laufer et al. | Apr 2002 | A1 |
| 20020072738 | Edwards et al. | Jun 2002 | A1 |
| 20020082197 | Aoki et al. | Jun 2002 | A1 |
| 20020087153 | Roschak et al. | Jul 2002 | A1 |
| 20020087208 | Koblish et al. | Jul 2002 | A1 |
| 20020091379 | Danek et al. | Jul 2002 | A1 |
| 20020107512 | Edwards | Aug 2002 | A1 |
| 20020107515 | Edwards et al. | Aug 2002 | A1 |
| 20020111386 | Sekins et al. | Aug 2002 | A1 |
| 20020111619 | Keast et al. | Aug 2002 | A1 |
| 20020111620 | Cooper et al. | Aug 2002 | A1 |
| 20020115991 | Edwards | Aug 2002 | A1 |
| 20020116030 | Rezai | Aug 2002 | A1 |
| 20020143302 | Hinchliffe et al. | Oct 2002 | A1 |
| 20020143326 | Foley et al. | Oct 2002 | A1 |
| 20020143373 | Courtnage et al. | Oct 2002 | A1 |
| 20020151888 | Edwards et al. | Oct 2002 | A1 |
| 20020183682 | Darvish et al. | Dec 2002 | A1 |
| 20020198512 | Seward | Dec 2002 | A1 |
| 20020198570 | Puskas | Dec 2002 | A1 |
| 20020198574 | Gumpert | Dec 2002 | A1 |
| 20030018344 | Kaji et al. | Jan 2003 | A1 |
| 20030023287 | Edwards et al. | Jan 2003 | A1 |
| 20030027752 | Steward et al. | Feb 2003 | A1 |
| 20030050591 | Patrick McHale | Mar 2003 | A1 |
| 20030050631 | Mody et al. | Mar 2003 | A1 |
| 20030065371 | Satake | Apr 2003 | A1 |
| 20030069570 | Witzel et al. | Apr 2003 | A1 |
| 20030070676 | Cooper et al. | Apr 2003 | A1 |
| 20030074039 | Puskas | Apr 2003 | A1 |
| 20030093069 | Panescu et al. | May 2003 | A1 |
| 20030093128 | Freed et al. | May 2003 | A1 |
| 20030125786 | Gliner et al. | Jul 2003 | A1 |
| 20030130657 | Tom et al. | Jul 2003 | A1 |
| 20030144572 | Oschman et al. | Jul 2003 | A1 |
| 20030153905 | Edwards et al. | Aug 2003 | A1 |
| 20030159700 | Laufer et al. | Aug 2003 | A1 |
| 20030181949 | Whale | Sep 2003 | A1 |
| 20030187430 | Vorisek | Oct 2003 | A1 |
| 20030195593 | Ingle et al. | Oct 2003 | A1 |
| 20030195604 | Ingle et al. | Oct 2003 | A1 |
| 20030202990 | Donovan et al. | Oct 2003 | A1 |
| 20030208103 | Sonnenschein et al. | Nov 2003 | A1 |
| 20030211121 | Donovan | Nov 2003 | A1 |
| 20030216791 | Schuler et al. | Nov 2003 | A1 |
| 20030216792 | Levin et al. | Nov 2003 | A1 |
| 20030216891 | Wegener | Nov 2003 | A1 |
| 20030225443 | Kiran et al. | Dec 2003 | A1 |
| 20030233099 | Danaek et al. | Dec 2003 | A1 |
| 20030236455 | Swanson et al. | Dec 2003 | A1 |
| 20040006268 | Gilboa et al. | Jan 2004 | A1 |
| 20040009180 | Donovan | Jan 2004 | A1 |
| 20040010289 | Biggs et al. | Jan 2004 | A1 |
| 20040010290 | Schroeppel et al. | Jan 2004 | A1 |
| 20040028676 | Klein et al. | Feb 2004 | A1 |
| 20040029849 | Schatzberg et al. | Feb 2004 | A1 |
| 20040030368 | Kemeny et al. | Feb 2004 | A1 |
| 20040031494 | Danek et al. | Feb 2004 | A1 |
| 20040044390 | Szeles | Mar 2004 | A1 |
| 20040059383 | Puskas | Mar 2004 | A1 |
| 20040073201 | Cooper et al. | Apr 2004 | A1 |
| 20040073206 | Foley et al. | Apr 2004 | A1 |
| 20040073278 | Pachys | Apr 2004 | A1 |
| 20040084049 | Baran | May 2004 | A1 |
| 20040086531 | Barron | May 2004 | A1 |
| 20040087936 | Stem et al. | May 2004 | A1 |
| 20040088030 | Jung, Jr. | May 2004 | A1 |
| 20040088036 | Gilbert | May 2004 | A1 |
| 20040091880 | Wiebusch et al. | May 2004 | A1 |
| 20040106954 | Whitehurst et al. | Jun 2004 | A1 |
| 20040116981 | Mazar | Jun 2004 | A1 |
| 20040122488 | Mazar et al. | Jun 2004 | A1 |
| 20040122489 | Mazar et al. | Jun 2004 | A1 |
| 20040127942 | Yomtov et al. | Jul 2004 | A1 |
| 20040127958 | Mazar et al. | Jul 2004 | A1 |
| 20040142005 | Brooks et al. | Jul 2004 | A1 |
| 20040147921 | Edwards et al. | Jul 2004 | A1 |
| 20040147969 | Mann et al. | Jul 2004 | A1 |
| 20040147988 | Stephens | Jul 2004 | A1 |
| 20040151741 | Borodic | Aug 2004 | A1 |
| 20040153056 | Muller et al. | Aug 2004 | A1 |
| 20040162584 | Hill et al. | Aug 2004 | A1 |
| 20040162597 | Hamilton et al. | Aug 2004 | A1 |
| 20040167509 | Taimisto | Aug 2004 | A1 |
| 20040167580 | Mann et al. | Aug 2004 | A1 |
| 20040172075 | Shafer et al. | Sep 2004 | A1 |
| 20040172080 | Stadler et al. | Sep 2004 | A1 |
| 20040172084 | Knudson et al. | Sep 2004 | A1 |
| 20040175399 | Schiffman | Sep 2004 | A1 |
| 20040176803 | Whelan et al. | Sep 2004 | A1 |
| 20040176805 | Whelan et al. | Sep 2004 | A1 |
| 20040182399 | Danek et al. | Sep 2004 | A1 |
| 20040186435 | Seward | Sep 2004 | A1 |
| 20040204747 | Kemeny et al. | Oct 2004 | A1 |
| 20040213813 | Ackerman | Oct 2004 | A1 |
| 20040213814 | Ackerman | Oct 2004 | A1 |
| 20040215235 | Jackson et al. | Oct 2004 | A1 |
| 20040215289 | Fukui | Oct 2004 | A1 |
| 20040215296 | Ganz et al. | Oct 2004 | A1 |
| 20040220556 | Cooper et al. | Nov 2004 | A1 |
| 20040220621 | Zhou et al. | Nov 2004 | A1 |
| 20040226556 | Deem et al. | Nov 2004 | A1 |
| 20040230251 | Schuler et al. | Nov 2004 | A1 |
| 20040230252 | Kullok et al. | Nov 2004 | A1 |
| 20040243118 | Ayers et al. | Dec 2004 | A1 |
| 20040243182 | Cohen et al. | Dec 2004 | A1 |
| 20040248188 | Sanders | Dec 2004 | A1 |
| 20040249401 | Rabiner et al. | Dec 2004 | A1 |
| 20040249416 | Yun et al. | Dec 2004 | A1 |
| 20040253274 | Voet | Dec 2004 | A1 |
| 20050004609 | Stahmann et al. | Jan 2005 | A1 |
| 20050004631 | Benedict | Jan 2005 | A1 |
| 20050010263 | Schauerte | Jan 2005 | A1 |
| 20050010270 | Laufer | Jan 2005 | A1 |
| 20050015117 | Gerber | Jan 2005 | A1 |
| 20050019346 | Boulis | Jan 2005 | A1 |
| 20050021092 | Yun et al. | Jan 2005 | A1 |
| 20050049615 | Cooper et al. | Mar 2005 | A1 |
| 20050056292 | Cooper | Mar 2005 | A1 |
| 20050059153 | George et al. | Mar 2005 | A1 |
| 20050060041 | Phan et al. | Mar 2005 | A1 |
| 20050060042 | Phan et al. | Mar 2005 | A1 |
| 20050060044 | Roschak et al. | Mar 2005 | A1 |
| 20050065553 | Ben Ezra et al. | Mar 2005 | A1 |
| 20050065562 | Rezai | Mar 2005 | A1 |
| 20050065567 | Lee et al. | Mar 2005 | A1 |
| 20050065573 | Rezai | Mar 2005 | A1 |
| 20050065574 | Rezai | Mar 2005 | A1 |
| 20050065575 | Dobak | Mar 2005 | A1 |
| 20050065584 | Schiff et al. | Mar 2005 | A1 |
| 20050074461 | Donovan | Apr 2005 | A1 |
| 20050076909 | Stahmann et al. | Apr 2005 | A1 |
| 20050080461 | Stahmann et al. | Apr 2005 | A1 |
| 20050085801 | Cooper et al. | Apr 2005 | A1 |
| 20050090722 | Perez | Apr 2005 | A1 |
| 20050096529 | Cooper et al. | May 2005 | A1 |
| 20050096644 | Hall et al. | May 2005 | A1 |
| 20050107783 | Tom et al. | May 2005 | A1 |
| 20050107829 | Edwards et al. | May 2005 | A1 |
| 20050107853 | Krespi et al. | May 2005 | A1 |
| 20050125044 | Tracey | Jun 2005 | A1 |
| 20050137518 | Biggs et al. | Jun 2005 | A1 |
| 20050137611 | Escudero et al. | Jun 2005 | A1 |
| 20050137715 | Phan et al. | Jun 2005 | A1 |
| 20050143788 | Yun et al. | Jun 2005 | A1 |
| 20050149146 | Boveja et al. | Jul 2005 | A1 |
| 20050152924 | Voet | Jul 2005 | A1 |
| 20050153885 | Yun et al. | Jul 2005 | A1 |
| 20050159736 | Danek et al. | Jul 2005 | A9 |
| 20050165456 | Mann et al. | Jul 2005 | A1 |
| 20050171396 | Pankratov et al. | Aug 2005 | A1 |
| 20050177144 | Phan et al. | Aug 2005 | A1 |
| 20050177192 | Rezai et al. | Aug 2005 | A1 |
| 20050182288 | Zabara | Aug 2005 | A1 |
| 20050182393 | Abboud et al. | Aug 2005 | A1 |
| 20050183732 | Edwards | Aug 2005 | A1 |
| 20050187579 | Danek et al. | Aug 2005 | A1 |
| 20050193279 | Daners | Sep 2005 | A1 |
| 20050203503 | Edwards et al. | Sep 2005 | A1 |
| 20050222628 | Krakousky | Oct 2005 | A1 |
| 20050222635 | Krakovsky | Oct 2005 | A1 |
| 20050222651 | Jung, Jr. | Oct 2005 | A1 |
| 20050228054 | Tatton | Oct 2005 | A1 |
| 20050228459 | Levin et al. | Oct 2005 | A1 |
| 20050228460 | Levin et al. | Oct 2005 | A1 |
| 20050234523 | Levin et al. | Oct 2005 | A1 |
| 20050238693 | Whyte | Oct 2005 | A1 |
| 20050240176 | Oral et al. | Oct 2005 | A1 |
| 20050240241 | Yun et al. | Oct 2005 | A1 |
| 20050245992 | Persen et al. | Nov 2005 | A1 |
| 20050251128 | Amoah | Nov 2005 | A1 |
| 20050251213 | Freeman | Nov 2005 | A1 |
| 20050255317 | Bavaro et al. | Nov 2005 | A1 |
| 20050256028 | Yun et al. | Nov 2005 | A1 |
| 20050261747 | Schuler et al. | Nov 2005 | A1 |
| 20050267536 | Freeman et al. | Dec 2005 | A1 |
| 20050277993 | Mower | Dec 2005 | A1 |
| 20050283197 | Daum et al. | Dec 2005 | A1 |
| 20060015151 | Aldrich | Jan 2006 | A1 |
| 20060058692 | Beatty et al. | Mar 2006 | A1 |
| 20060058693 | Beatty et al. | Mar 2006 | A1 |
| 20060058780 | Edwards et al. | Mar 2006 | A1 |
| 20060062808 | Laufer et al. | Mar 2006 | A1 |
| 20060079887 | Buysse et al. | Apr 2006 | A1 |
| 20060084884 | Beatty et al. | Apr 2006 | A1 |
| 20060084966 | Maguire et al. | Apr 2006 | A1 |
| 20060084970 | Beatty et al. | Apr 2006 | A1 |
| 20060084971 | Beatty et al. | Apr 2006 | A1 |
| 20060084972 | Beatty et al. | Apr 2006 | A1 |
| 20060089637 | Werneth et al. | Apr 2006 | A1 |
| 20060095032 | Jackson et al. | May 2006 | A1 |
| 20060100666 | Wilkinson et al. | May 2006 | A1 |
| 20060106361 | Muni et al. | May 2006 | A1 |
| 20060111755 | Stone et al. | May 2006 | A1 |
| 20060116749 | Willink et al. | Jun 2006 | A1 |
| 20060135953 | Kania et al. | Jun 2006 | A1 |
| 20060135984 | Kramer et al. | Jun 2006 | A1 |
| 20060135998 | Libbus et al. | Jun 2006 | A1 |
| 20060137698 | Danek et al. | Jun 2006 | A1 |
| 20060142801 | Demarais et al. | Jun 2006 | A1 |
| 20060167498 | DiLorenzo | Jul 2006 | A1 |
| 20060178703 | Huston et al. | Aug 2006 | A1 |
| 20060206150 | Demarais et al. | Sep 2006 | A1 |
| 20060212076 | Demarais et al. | Sep 2006 | A1 |
| 20060212078 | Demarais et al. | Sep 2006 | A1 |
| 20060222667 | Deem et al. | Oct 2006 | A1 |
| 20060225742 | Deem et al. | Oct 2006 | A1 |
| 20060235474 | Demarais | Oct 2006 | A1 |
| 20060241523 | Sinelnikov et al. | Oct 2006 | A1 |
| 20060247617 | Danek et al. | Nov 2006 | A1 |
| 20060247618 | Kaplan et al. | Nov 2006 | A1 |
| 20060247619 | Kaplan et al. | Nov 2006 | A1 |
| 20060247683 | Danek et al. | Nov 2006 | A1 |
| 20060247726 | Biggs et al. | Nov 2006 | A1 |
| 20060247727 | Biggs et al. | Nov 2006 | A1 |
| 20060247746 | Danek et al. | Nov 2006 | A1 |
| 20060254600 | Danek et al. | Nov 2006 | A1 |
| 20060259028 | Utley et al. | Nov 2006 | A1 |
| 20060259029 | Utley et al. | Nov 2006 | A1 |
| 20060259030 | Utley et al. | Nov 2006 | A1 |
| 20060265014 | Demarais et al. | Nov 2006 | A1 |
| 20060265015 | Demarais et al. | Nov 2006 | A1 |
| 20060271111 | Demarais et al. | Nov 2006 | A1 |
| 20060276807 | Keast et al. | Dec 2006 | A1 |
| 20060276852 | Demarais et al. | Dec 2006 | A1 |
| 20060278243 | Danek et al. | Dec 2006 | A1 |
| 20060278244 | Danek et al. | Dec 2006 | A1 |
| 20060280772 | Roschak et al. | Dec 2006 | A1 |
| 20060280773 | Roschak et al. | Dec 2006 | A1 |
| 20060282071 | Utley et al. | Dec 2006 | A1 |
| 20060287679 | Stone | Dec 2006 | A1 |
| 20070021803 | Deem et al. | Jan 2007 | A1 |
| 20070025919 | Deem et al. | Feb 2007 | A1 |
| 20070027496 | Parnis et al. | Feb 2007 | A1 |
| 20070032788 | Edwards et al. | Feb 2007 | A1 |
| 20070043342 | Kleinberger | Feb 2007 | A1 |
| 20070055328 | Mayse et al. | Mar 2007 | A1 |
| 20070060954 | Cameron et al. | Mar 2007 | A1 |
| 20070060990 | Satake | Mar 2007 | A1 |
| 20070062545 | Danek et al. | Mar 2007 | A1 |
| 20070066957 | Demarais et al. | Mar 2007 | A1 |
| 20070074719 | Danek et al. | Apr 2007 | A1 |
| 20070083194 | Kunis et al. | Apr 2007 | A1 |
| 20070083197 | Danek et al. | Apr 2007 | A1 |
| 20070083239 | Demarais et al. | Apr 2007 | A1 |
| 20070093802 | Danek et al. | Apr 2007 | A1 |
| 20070093809 | Edwards et al. | Apr 2007 | A1 |
| 20070100390 | Danaek et al. | May 2007 | A1 |
| 20070102011 | Danek et al. | May 2007 | A1 |
| 20070106292 | Kaplan et al. | May 2007 | A1 |
| 20070106296 | Laufer et al. | May 2007 | A1 |
| 20070106337 | Errico et al. | May 2007 | A1 |
| 20070106338 | Errico | May 2007 | A1 |
| 20070106339 | Errico et al. | May 2007 | A1 |
| 20070106348 | Laufer | May 2007 | A1 |
| 20070112349 | Danek et al. | May 2007 | A1 |
| 20070118184 | Danek et al. | May 2007 | A1 |
| 20070118190 | Danek et al. | May 2007 | A1 |
| 20070123922 | Cooper et al. | May 2007 | A1 |
| 20070123958 | Laufer | May 2007 | A1 |
| 20070123961 | Danek et al. | May 2007 | A1 |
| 20070129720 | Demarais et al. | Jun 2007 | A1 |
| 20070129760 | Demarais et al. | Jun 2007 | A1 |
| 20070129761 | Demarais et al. | Jun 2007 | A1 |
| 20070135875 | Demarais et al. | Jun 2007 | A1 |
| 20070173899 | Levin et al. | Jul 2007 | A1 |
| 20070191902 | Errico et al. | Aug 2007 | A1 |
| 20070197896 | Moll et al. | Aug 2007 | A1 |
| 20070203549 | Demarais et al. | Aug 2007 | A1 |
| 20070225768 | Dobak, III | Sep 2007 | A1 |
| 20070232896 | Gilboa et al. | Oct 2007 | A1 |
| 20070239256 | Weber et al. | Oct 2007 | A1 |
| 20070244479 | Beatty et al. | Oct 2007 | A1 |
| 20070250050 | Lafontaine | Oct 2007 | A1 |
| 20070255270 | Carney | Nov 2007 | A1 |
| 20070255304 | Roschak et al. | Nov 2007 | A1 |
| 20070265639 | Danek et al. | Nov 2007 | A1 |
| 20070265687 | Deem et al. | Nov 2007 | A1 |
| 20070267011 | Deem et al. | Nov 2007 | A1 |
| 20080004596 | Yun et al. | Jan 2008 | A1 |
| 20080021274 | Bayer et al. | Jan 2008 | A1 |
| 20080021369 | Deem et al. | Jan 2008 | A1 |
| 20080051839 | Libbus et al. | Feb 2008 | A1 |
| 20080086107 | Roschak | Apr 2008 | A1 |
| 20080097422 | Edwards et al. | Apr 2008 | A1 |
| 20080097424 | Wizeman et al. | Apr 2008 | A1 |
| 20080125772 | Stone et al. | May 2008 | A1 |
| 20080147137 | Cohen et al. | Jun 2008 | A1 |
| 20080154258 | Chang et al. | Jun 2008 | A1 |
| 20080161801 | Steinke et al. | Jul 2008 | A1 |
| 20080183248 | Rezai et al. | Jul 2008 | A1 |
| 20080188912 | Stone et al. | Aug 2008 | A1 |
| 20080188913 | Stone et al. | Aug 2008 | A1 |
| 20080194956 | Aldrich et al. | Aug 2008 | A1 |
| 20080208305 | Rezai et al. | Aug 2008 | A1 |
| 20080213331 | Gelfand et al. | Sep 2008 | A1 |
| 20080234564 | Beatty et al. | Sep 2008 | A1 |
| 20080243112 | DeNeve | Oct 2008 | A1 |
| 20080255449 | Warnking et al. | Oct 2008 | A1 |
| 20080255642 | Zarins et al. | Oct 2008 | A1 |
| 20080262489 | Steinke | Oct 2008 | A1 |
| 20080275445 | Kelly et al. | Nov 2008 | A1 |
| 20080302359 | Loomas et al. | Dec 2008 | A1 |
| 20080306570 | Rezai et al. | Dec 2008 | A1 |
| 20080312543 | Laufer et al. | Dec 2008 | A1 |
| 20080312725 | Penner | Dec 2008 | A1 |
| 20080319350 | Wallace et al. | Dec 2008 | A1 |
| 20090018473 | Aldrich et al. | Jan 2009 | A1 |
| 20090018538 | Webster et al. | Jan 2009 | A1 |
| 20090030477 | Jarrard | Jan 2009 | A1 |
| 20090036948 | Levin et al. | Feb 2009 | A1 |
| 20090043301 | Jarrard et al. | Feb 2009 | A1 |
| 20090043302 | Ford et al. | Feb 2009 | A1 |
| 20090048593 | Ganz et al. | Feb 2009 | A1 |
| 20090060953 | Sandars | Mar 2009 | A1 |
| 20090062873 | Wu et al. | Mar 2009 | A1 |
| 20090069797 | Danek et al. | Mar 2009 | A1 |
| 20090076409 | Wu et al. | Mar 2009 | A1 |
| 20090076491 | Roschak et al. | Mar 2009 | A1 |
| 20090112203 | Danek et al. | Apr 2009 | A1 |
| 20090124883 | Wibowo et al. | May 2009 | A1 |
| 20090131765 | Roschak et al. | May 2009 | A1 |
| 20090131928 | Edwards et al. | May 2009 | A1 |
| 20090131930 | Gelbart et al. | May 2009 | A1 |
| 20090143678 | Keast et al. | Jun 2009 | A1 |
| 20090143705 | Danek et al. | Jun 2009 | A1 |
| 20090143776 | Danek et al. | Jun 2009 | A1 |
| 20090143831 | Huston et al. | Jun 2009 | A1 |
| 20090155336 | Rezai | Jun 2009 | A1 |
| 20090177192 | Rioux et al. | Jul 2009 | A1 |
| 20090192505 | Askew et al. | Jul 2009 | A1 |
| 20090192508 | Laufer et al. | Jul 2009 | A1 |
| 20090204005 | Keast et al. | Aug 2009 | A1 |
| 20090204119 | Bleich et al. | Aug 2009 | A1 |
| 20090227885 | Lowery et al. | Sep 2009 | A1 |
| 20090227980 | Kangas et al. | Sep 2009 | A1 |
| 20090232850 | Manack et al. | Sep 2009 | A1 |
| 20090248011 | Hlavka et al. | Oct 2009 | A1 |
| 20090254079 | Edwards et al. | Oct 2009 | A1 |
| 20090254142 | Edwards et al. | Oct 2009 | A1 |
| 20090259274 | Simon et al. | Oct 2009 | A1 |
| 20090275840 | Roschak et al. | Nov 2009 | A1 |
| 20090275878 | Cambier et al. | Nov 2009 | A1 |
| 20090281593 | Errico et al. | Nov 2009 | A9 |
| 20090287087 | Gwerder et al. | Nov 2009 | A1 |
| 20090306644 | Mayse et al. | Dec 2009 | A1 |
| 20090318904 | Cooper et al. | Dec 2009 | A9 |
| 20090319002 | Simon | Dec 2009 | A1 |
| 20100003282 | Deem et al. | Jan 2010 | A1 |
| 20100004648 | Edwards et al. | Jan 2010 | A1 |
| 20100010564 | Simon | Jan 2010 | A1 |
| 20100016709 | Gilboa et al. | Jan 2010 | A1 |
| 20100042089 | Soltesz et al. | Feb 2010 | A1 |
| 20100049031 | Fruland et al. | Feb 2010 | A1 |
| 20100049186 | Ingle et al. | Feb 2010 | A1 |
| 20100049188 | Nelson et al. | Feb 2010 | A1 |
| 20100057178 | Simon | Mar 2010 | A1 |
| 20100063495 | Edwards et al. | Mar 2010 | A1 |
| 20100070004 | Hlavka et al. | Mar 2010 | A1 |
| 20100076518 | Hlavka et al. | Mar 2010 | A1 |
| 20100087783 | Weber et al. | Apr 2010 | A1 |
| 20100087809 | Edwards et al. | Apr 2010 | A1 |
| 20100094231 | Bleich et al. | Apr 2010 | A1 |
| 20100114087 | Edwards et al. | May 2010 | A1 |
| 20100116279 | Cooper | May 2010 | A9 |
| 20100125239 | Perry et al. | May 2010 | A1 |
| 20100130892 | Warnking | May 2010 | A1 |
| 20100137860 | Demarais et al. | Jun 2010 | A1 |
| 20100145427 | Gliner et al. | Jun 2010 | A1 |
| 20100152835 | Orr | Jun 2010 | A1 |
| 20100160906 | Jarrard | Jun 2010 | A1 |
| 20100160996 | Simon et al. | Jun 2010 | A1 |
| 20100174340 | Simon | Jul 2010 | A1 |
| 20100179424 | Warnking et al. | Jul 2010 | A1 |
| 20100185190 | Danek et al. | Jul 2010 | A1 |
| 20100191089 | Stebler et al. | Jul 2010 | A1 |
| 20100204689 | Danek et al. | Aug 2010 | A1 |
| 20100222851 | Deem et al. | Sep 2010 | A1 |
| 20100228318 | Errico et al. | Sep 2010 | A1 |
| 20100241188 | Errico et al. | Sep 2010 | A1 |
| 20100249873 | Errico | Sep 2010 | A1 |
| 20100256629 | Wylie et al. | Oct 2010 | A1 |
| 20100256630 | Hamilton et al. | Oct 2010 | A1 |
| 20100268222 | Danek et al. | Oct 2010 | A1 |
| 20100298905 | Simon | Nov 2010 | A1 |
| 20100305463 | Macklem et al. | Dec 2010 | A1 |
| 20100318020 | Atanasoska et al. | Dec 2010 | A1 |
| 20100331776 | Salahieh et al. | Dec 2010 | A1 |
| 20110004148 | Ishii | Jan 2011 | A1 |
| 20110015548 | Aldrich et al. | Jan 2011 | A1 |
| 20110028898 | Clark, III et al. | Feb 2011 | A1 |
| 20110046432 | Simon et al. | Feb 2011 | A1 |
| 20110060380 | Gelfand et al. | Mar 2011 | A1 |
| 20110079230 | Danek et al. | Apr 2011 | A1 |
| 20110093032 | Boggs, II et al. | Apr 2011 | A1 |
| 20110098762 | Rezai | Apr 2011 | A1 |
| 20110112400 | Emery et al. | May 2011 | A1 |
| 20110112521 | DeLonzor et al. | May 2011 | A1 |
| 20110118725 | Mayse et al. | May 2011 | A1 |
| 20110125203 | Simon et al. | May 2011 | A1 |
| 20110125213 | Simon et al. | May 2011 | A1 |
| 20110130708 | Perry et al. | Jun 2011 | A1 |
| 20110137284 | Arora et al. | Jun 2011 | A1 |
| 20110144630 | Loeb | Jun 2011 | A1 |
| 20110146673 | Keast et al. | Jun 2011 | A1 |
| 20110146674 | Roschak | Jun 2011 | A1 |
| 20110152855 | Mayse et al. | Jun 2011 | A1 |
| 20110152967 | Simon et al. | Jun 2011 | A1 |
| 20110152974 | Rezai et al. | Jun 2011 | A1 |
| 20110166499 | Demarais et al. | Jul 2011 | A1 |
| 20110166565 | Wizeman et al. | Jul 2011 | A1 |
| 20110172655 | Biggs et al. | Jul 2011 | A1 |
| 20110172658 | Gelbart et al. | Jul 2011 | A1 |
| 20110178569 | Pamis et al. | Jul 2011 | A1 |
| 20110184330 | Laufer et al. | Jul 2011 | A1 |
| 20110190569 | Simon et al. | Aug 2011 | A1 |
| 20110195973 | Johnson | Aug 2011 | A1 |
| 20110196288 | Kaplan et al. | Aug 2011 | A1 |
| 20110202098 | Demarais et al. | Aug 2011 | A1 |
| 20110224768 | Edwards | Sep 2011 | A1 |
| 20110230701 | Simon et al. | Sep 2011 | A1 |
| 20110230938 | Simon et al. | Sep 2011 | A1 |
| 20110245756 | Arora et al. | Oct 2011 | A1 |
| 20110251592 | Biggs et al. | Oct 2011 | A1 |
| 20110257622 | Saiahieh et al. | Oct 2011 | A1 |
| 20110257647 | Mayse et al. | Oct 2011 | A1 |
| 20110263960 | Mitchell | Oct 2011 | A1 |
| 20110264086 | Ingle | Oct 2011 | A1 |
| 20110270249 | Utley et al. | Nov 2011 | A1 |
| 20110276107 | Simon et al. | Nov 2011 | A1 |
| 20110276112 | Simon et al. | Nov 2011 | A1 |
| 20110282229 | Danek et al. | Nov 2011 | A1 |
| 20110282418 | Saunders et al. | Nov 2011 | A1 |
| 20110301587 | Deem et al. | Dec 2011 | A1 |
| 20110301664 | Rezai | Dec 2011 | A1 |
| 20110301679 | Rezai et al. | Dec 2011 | A1 |
| 20110306851 | Wang | Dec 2011 | A1 |
| 20110306904 | Jacobson et al. | Dec 2011 | A1 |
| 20110306997 | Roschak et al. | Dec 2011 | A9 |
| 20110319958 | Simon et al. | Dec 2011 | A1 |
| 20120004656 | Jackson et al. | Jan 2012 | A1 |
| 20120015019 | Pacetti et al. | Jan 2012 | A1 |
| 20120016256 | Mabary et al. | Jan 2012 | A1 |
| 20120016358 | Mayse et al. | Jan 2012 | A1 |
| 20120016363 | Mayse et al. | Jan 2012 | A1 |
| 20120016364 | Mayse et al. | Jan 2012 | A1 |
| 20120029261 | Deem et al. | Feb 2012 | A1 |
| 20120029500 | Jenson | Feb 2012 | A1 |
| 20120029512 | Willard et al. | Feb 2012 | A1 |
| 20120029591 | Simon et al. | Feb 2012 | A1 |
| 20120029601 | Simon et al. | Feb 2012 | A1 |
| 20120041412 | Roth et al. | Feb 2012 | A1 |
| 20120041509 | Knudson et al. | Feb 2012 | A1 |
| 20120071870 | Saiahieh et al. | Mar 2012 | A1 |
| 20120078096 | Kroiik et al. | Mar 2012 | A1 |
| 20120083734 | Ayres et al. | Apr 2012 | A1 |
| 20120089078 | Deem et al. | Apr 2012 | A1 |
| 20120089138 | Edwards et al. | Apr 2012 | A1 |
| 20120101326 | Simon et al. | Apr 2012 | A1 |
| 20120101413 | Beetei et al. | Apr 2012 | A1 |
| 20120109278 | Sih | May 2012 | A1 |
| 20120143132 | Orlowski | Jun 2012 | A1 |
| 20120143177 | Avitall | Jun 2012 | A1 |
| 20120143179 | Avitall | Jun 2012 | A1 |
| 20120143181 | Demarais et al. | Jun 2012 | A1 |
| 20120157986 | Stone et al. | Jun 2012 | A1 |
| 20120157987 | Steinke et al. | Jun 2012 | A1 |
| 20120157988 | Stone et al. | Jun 2012 | A1 |
| 20120157989 | Stone et al. | Jun 2012 | A1 |
| 20120158101 | Stone et al. | Jun 2012 | A1 |
| 20120165803 | Bencini et al. | Jun 2012 | A1 |
| 20120184801 | Simon et al. | Jul 2012 | A1 |
| 20120185020 | Simon et al. | Jul 2012 | A1 |
| 20120191081 | Markowitz | Jul 2012 | A1 |
| 20120191082 | Markowitz | Jul 2012 | A1 |
| 20120197100 | Razavi et al. | Aug 2012 | A1 |
| 20120197246 | Mauch | Aug 2012 | A1 |
| 20120197251 | Edwards et al. | Aug 2012 | A1 |
| 20120203067 | Higgins et al. | Aug 2012 | A1 |
| 20120203216 | Mayse et al. | Aug 2012 | A1 |
| 20120203222 | Mayse et al. | Aug 2012 | A1 |
| 20120209118 | Warnking | Aug 2012 | A1 |
| 20120209259 | Danek et al. | Aug 2012 | A1 |
| 20120209261 | Mayse et al. | Aug 2012 | A1 |
| 20120209296 | Mayse et al. | Aug 2012 | A1 |
| 20120221087 | Pamis et al. | Aug 2012 | A1 |
| 20120232436 | Warnking | Sep 2012 | A1 |
| 20120245415 | Emura et al. | Sep 2012 | A1 |
| 20120253442 | Gliner et al. | Oct 2012 | A1 |
| 20120259263 | Celermajer et al. | Oct 2012 | A1 |
| 20120259269 | Meyer | Oct 2012 | A1 |
| 20120259326 | Brannan et al. | Oct 2012 | A1 |
| 20120265280 | Errico et al. | Oct 2012 | A1 |
| 20120289952 | Utley et al. | Nov 2012 | A1 |
| 20120290035 | Levine et al. | Nov 2012 | A1 |
| 20120294424 | Chin et al. | Nov 2012 | A1 |
| 20120296329 | Ng | Nov 2012 | A1 |
| 20120302909 | Mayse et al. | Nov 2012 | A1 |
| 20120310233 | Dimmer et al. | Dec 2012 | A1 |
| 20120316552 | Mayse et al. | Dec 2012 | A1 |
| 20120316559 | Mayse et al. | Dec 2012 | A1 |
| 20120330298 | Ganz et al. | Dec 2012 | A1 |
| 20130012844 | Demarais et al. | Jan 2013 | A1 |
| 20130012866 | Deem et al. | Jan 2013 | A1 |
| 20130012867 | Demarais et al. | Jan 2013 | A1 |
| 20130035576 | O'Grady et al. | Feb 2013 | A1 |
| 20130123751 | Deem et al. | May 2013 | A1 |
| 20130289555 | Mayse et al. | Oct 2013 | A1 |
| 20130289556 | Mayse et al. | Oct 2013 | A1 |
| 20130296647 | Mayse et al. | Nov 2013 | A1 |
| 20130303948 | Deem et al. | Nov 2013 | A1 |
| 20130310822 | Mayse et al. | Nov 2013 | A1 |
| 20130345700 | Hlavka et al. | Dec 2013 | A1 |
| 20140186341 | Mayse | Jul 2014 | A1 |
| 20140236148 | Hlavka et al. | Aug 2014 | A1 |
| 20140257271 | Mayse et al. | Sep 2014 | A1 |
| 20140276792 | Kaveckis et al. | Sep 2014 | A1 |
| 20150051597 | Mayse et al. | Feb 2015 | A1 |
| Number | Date | Country |
|---|---|---|
| 2419228 | Aug 2004 | CA |
| 101115448 | Jan 2008 | CN |
| 101115448 | May 2010 | CN |
| 19529634 | Feb 1997 | DE |
| 19952505 | May 2001 | DE |
| 189329 | Jun 1987 | EP |
| 286145 | Oct 1988 | EP |
| 280225 | Mar 1989 | EP |
| 282225 | Jun 1992 | EP |
| 0 643 982 | Mar 1995 | EP |
| 908713 | Apr 1999 | EP |
| 1 143 864 | Oct 2001 | EP |
| 1 271 384 | Jan 2003 | EP |
| 1 281 366 | Feb 2003 | EP |
| 908150 | May 2003 | EP |
| 1 326 549 | Jul 2003 | EP |
| 768091 | Jul 2003 | EP |
| 1326548 | Jul 2003 | EP |
| 1 400 204 | Mar 2004 | EP |
| 1297795 | Aug 2005 | EP |
| 1 588 662 | Oct 2005 | EP |
| 2659240 | Jul 1997 | FR |
| 2233293 | Jan 1991 | GB |
| 2233293 | Feb 1994 | GB |
| 59167707 | Sep 1984 | JP |
| 7289557 | Nov 1995 | JP |
| 9047518 | Feb 1997 | JP |
| 9243837 | Sep 1997 | JP |
| 10026709 | Jan 1998 | JP |
| 2053814 | Feb 1996 | RU |
| 2091054 | Sep 1997 | RU |
| 545358 | Feb 1977 | SU |
| 8911311 | Nov 1989 | WO |
| 9301862 | Feb 1993 | WO |
| 9316632 | Sep 1993 | WO |
| 9407446 | Apr 1994 | WO |
| 9501075 | Jan 1995 | WO |
| WO-9502370 | Jan 1995 | WO |
| WO-9510322 | Apr 1995 | WO |
| WO-9604860 | Feb 1996 | WO |
| WO-9610961 | Apr 1996 | WO |
| 9725917 | Jul 1997 | WO |
| WO-9732532 | Sep 1997 | WO |
| WO-9733715 | Sep 1997 | WO |
| WO-9737715 | Oct 1997 | WO |
| WO-9740751 | Nov 1997 | WO |
| 9818391 | May 1998 | WO |
| WO 9818391 | May 1998 | WO |
| WO-9844854 | Oct 1998 | WO |
| WO-9852480 | Nov 1998 | WO |
| WO-9856234 | Dec 1998 | WO |
| WO-9856324 | Dec 1998 | WO |
| WO-9903413 | Jan 1999 | WO |
| WO-9858681 | Mar 1999 | WO |
| WO-9913779 | Mar 1999 | WO |
| WO-9932040 | Jul 1999 | WO |
| 9942047 | Aug 1999 | WO |
| WO-9964109 | Dec 1999 | WO |
| 0010598 | Mar 2000 | WO |
| WO 0010598 | Mar 2000 | WO |
| WO-0051510 | Sep 2000 | WO |
| 0062699 | Oct 2000 | WO |
| 0066017 | Nov 2000 | WO |
| 0100114 | Jan 2001 | WO |
| WO-0103642 | Jan 2001 | WO |
| 0170114 | Sep 2001 | WO |
| 0189526 | Nov 2001 | WO |
| WO-0205720 | Jan 2002 | WO |
| WO-0205868 | Jan 2002 | WO |
| WO-0232333 | Apr 2002 | WO |
| WO-0232334 | Apr 2002 | WO |
| 03073358 | Sep 2003 | WO |
| 03088820 | Oct 2003 | WO |
| 2004078252 | Sep 2004 | WO |
| 2004082736 | Sep 2004 | WO |
| 2004101028 | Nov 2004 | WO |
| 2005006963 | Jan 2005 | WO |
| 2005006964 | Jan 2005 | WO |
| 2006053308 | May 2006 | WO |
| 2006053309 | May 2006 | WO |
| 2006116198 | Nov 2006 | WO |
| 2007058780 | May 2007 | WO |
| 2007061982 | May 2007 | WO |
| 2007092062 | Aug 2007 | WO |
| 2007094828 | Aug 2007 | WO |
| 2007143665 | Dec 2007 | WO |
| 2008005953 | Jan 2008 | WO |
| 2008024220 | Feb 2008 | WO |
| 2008051706 | May 2008 | WO |
| 2008063935 | May 2008 | WO |
| 2009009236 | Jan 2009 | WO |
| 2009015278 | Jan 2009 | WO |
| WO-2009082433 | Jul 2009 | WO |
| 2009126383 | Oct 2009 | WO |
| WO-2009137819 | Nov 2009 | WO |
| 2010110785 | Sep 2010 | WO |
| WO 2011056684 | May 2011 | WO |
| WO 2011060200 | May 2011 | WO |
| WO 2011060201 | May 2011 | WO |
| WO-2011060200 | May 2011 | WO |
| WO 2013052501 | Apr 2013 | WO |
| Entry |
|---|
| Drugs.com “Second generation cephalosporins” accessed from drugs.com on Jan. 5, 2015. |
| Gershon et al. 2011 “Comparison of inhaled long-acting B-agonist and anticholinergic effectiveness in older patients with chronic obstructive pulmonary disease” Ann Intern Med 154:583-592. |
| Application and File History of U.S. Appl. No. 10/437,882; Inventors: Deem et al., filed May 13, 2003. |
| Application and File History of U.S. Appl. No. 11/446,043; Inventors: Deem et al., filed Jun. 1, 2006. |
| Application and File History of U.S. Appl. No. 11/445,644; Inventors: Deem et al., filed Jun. 1, 2006; Issued as U.S. Pat. No. 8,172,827 on May 8, 2012. |
| Application and File History of U.S. Appl. No. 13/669,305; Inventors: Deem et al., filed Nov. 5, 2012. |
| Office Action Action and Search Report from related Chinese Application 201110410659.0, dated Dec. 5, 2013, 8 pgs. |
| Final Office Action from related Japanese Application 2011-284359, dated Mar. 22, 2013, 1 pg. |
| Office Action from related European Application 04752282.6, dated May 8, 2014, 7 pgs. |
| Office Action from related Chinese Application 201110410659.0, dated Jul. 8, 2014, 5 pgs. |
| Cazzola, et al. “Acute effect of pretreatment with single conventional dose of salmeterol on dose-response curve to oxtropium bromide in chronic obstructive pulmonary disease”, Thorax, 54, 1999, pp. 1083-1086. |
| Matera, et al. “A combination with clinical recommended dosages of salmeterol and ipratropium is not more effective than salmeterol alone in patients with chronic obstructive pulmonary disease”, Respiratory Medicine, 90, 1996, pp. 497-499. |
| Sichletidis, et al. “Bronchodilatory responses to formoterol, ipratropium, and their combination in patients with stable COPD”, Int J Clin Pract., 53 (3), Apr.-May 1999, 1 page Abstract. |
| Abbott, “Present Concepts Relative to Autonomic Nerve Surgery in the Treatment of Pulmonary Disease,” American Journal ofSurRery 90:479-489, 1955. |
| Accad, M., “Single-Step Renal Denervation With the OneShot™ Ablation System,” presentation at the Leipzig Interventional Course 2012 in Leipzig, Germany, Jan. 26, 2012, 11 pages. |
| Ahnert-Hilger et al., “Introduction of Macromolecules into Bovine Adrenal-Medullary Chromaffin Cells and Rat Pheochromocytoma Cells (PC12) by Permeabilization with Streptolysin O: Inhibitory Effect of Tetanus Toxin on Catecholamine Secretion,” J Neurochem 52(6):1751-1758, Jun. 1989. |
| Amendment After Allowance filed Sep. 17, 2012, in co-pending U.S. Appl. No. 12/372,607, filed Feb. 17, 2009, Edwin J. Hlavka, et al. |
| An, S. S. et al., Airway smooth muscle dynamics; a common pathway of airway obstruction in asthma, European Respiratory Journal, 2007, vol. 29, No. 5, pp. 834-860. |
| Awadh, N., et al. “Airway Wall Thickness in Patients With Near Fatal Asthma and Control Groups: Assessment With High Resolution Computed Tomographic Scanning,” Thorax 53:248-253, 1998. |
| Babichev et al., “Clinico-morphological comparisons in patients with bronchial asthma aftet denervation of the lungs,” Sov Med. 12:13-16, 1985. |
| Babichev et al., “Long-term results of surgical treatment of bronchial asthma based on adaptive response,” Khirurgiia (Mask) 4:5-11, 1993. |
| Babichev et al., “Partial deneration of the lungs in bronchial asthma,” Khirurgiia (Mask) 4:31-35, 1985. |
| Barlaw, “Surgical Treatment of Asthma,” Postgrad Med. Journal25:193-196, 1949. |
| Bel, E, H., Hot Stuff: Bronchial Thermoplasty for Asthma, American Journal of Respiratory and Critical Care Medicine, 2006, vol. 173, pp. 941-942. |
| Bertog, S., “Covidien-Maya: OneShot™,” presentation at the 2012 Congenital & Structural Interventions Congress in Frankfurt, Germany, Jun. 28, 2012, 25 pages. |
| Bester et al., “Recovery of C-Fiber-Induced Extravasation Following Peripheral Nerve Injury in the Rat,” Experimental Neurology 154:628-636, 1998. |
| Bigalke et al., “Clostridial Neurotoxins,” Handbook of Experimental Pharmacology (Aktories, K., and Just, I., eds) 145:407-443, 2000. |
| Bittner et al., “Isolated Light Chains of Botulinum Neurotoxins Inhibit Exocytosis,” The Journal of Biological Chemistry 264(18):10354-10360, 1989. |
| Blindt et al., “Development of a New Biodegradable Intravascular Polymer Stent with Simultaneous Incorporation ofBioactive Substances,” The International Journal of Artificial Organs 22(12):843-853, 1999. |
| Bradley et al., “Effect of vagotomy on the breathing pattern and exercise ability in emphysematous patients,” Clinical Science 62:311-319, 1982. |
| Breekveldt-Postma et al., “Enhanced persistence with tiotropium compared with other respiratory drugs in COPD,” Respiratory Medicine 101:1398-1405,2007. |
| Brody et al., “Mucociliary clearance after lung denervation and bronchial transection,” J Applied Physiology 32(2):160-164, 1972. |
| Brown, R. H. et al., Effect of bronchial thermoplasty on airway distensibility, European Respiratory Journal, vol. 26, No. 2, pp. 277-282, Aug. 2005. |
| Brown, R. H. et al., In vivo evaluation of the effectiveness of bronchial thermoplasty with computed tomography. Journal of Applied Physiology, 2005, vol. 98, pp. 1603-1606. |
| Buzzi, “Diphtheria Toxin Treatment of Human Advanced Cancer,” Cancer Research 42:2054-2058, 1982. |
| Canning et al., “Reflex Mechanisms in Gastroesophageal Reflux Disease and Asthma,” The American Journal ofMedicine 115(3A):45S-48S, 2003. |
| Canning et al., “Reflex Mechanisms in Gastroesophageal Reflux Disease and Asthma,” Am J Med. 115(Suppl3A):45S-48S, 2003. (Abstract only.). |
| Canning, “Reflex regulation of airway smooth muscle tone,” J Appl. Physiol. (1OJ):971-985,2006. |
| Castro, M., et al., “Effectiveness and Safety of Bronchial Thermoplasty in the Treatment of Severe Asthma: A Multicenter, Randomized, Double-Blind, Sham-Controlled Clinical Trial,” American Journal of Respiratory and Critical Care Medicine 181: 116-124, 2010. |
| Chaddock et al. “Expression and Purification of Catalytically Active, Non-Toxic Endopeptidase Derivatives of Clostridium botulinum Toxin Type A,” Protein Expression and Purification 25(2):219-228, Jul. 2002. |
| Chang, “Cell poration and cell fusion using an oscillating electric field,” Biophys. J 56:641 652, 1989. |
| Chernyshova et al., “The Effect of Low-Energy Laser Radiation in the Infrared Spectrum on Bronchial Patency in Children With Bronchial Asthma,” Vopr Kurortol, Fizioter Lech Fiz Kult 2:11 14, 1995. |
| Chhajed, P., Will There be a Role for Bronchoscopic Radiofrequency Ablation?, 2005, J Bronchol, vol. 12, No. 3, p. 184. |
| Chumakov et al., “Morphologic Studies of Bronchial Biopsies in Chronic Bronchitis Before and After Treatment,” Arkh. Patol. 57(6):21-25, 1995. (+English abstract and translation, 8 pages.). |
| Co-Pending U.S. Appl. No. 12/372,607, filed Feb. 17, 2009, Edwin J. Hlavka, et al. |
| Co-Pending U.S. Appl. No. 13/523,223, filed Jun. 14, 2012, Edwin J. Hlavka, et al. |
| Co-pending U.S. Appl. No. 09/095,323. |
| Co-pending U.S. Appl. No. 09/244,173. |
| Cox, G. et al., Asthma Control During the Year After Bronchial Thermoplasty, The New England Journal of Medicine, Mar. 29, 2007, vol. 356, No. 13, pp. 1327-1337. |
| Cox, G., et al, . Early Clinical Experience With Bronchial Thermoplasty for the Treatment of Asthma, 2002, p. 1068. |
| Cox, G., et al., Bronchial Thermoplasty for Asthma, American Journal of Respiratory and Critical Care Medicine, 2006, vol. 173, pp. 965-969. |
| Cox, G., et al., Bronchial Thermoplasty: Long-Term Follow-up and Patient Satisfaction, 2004, p. 1. |
| Cox, G., et al., Clinical Experience with Bronchial Thermoplasty for the Treatment of Asthma, 2003, Chest 124, p. 106S. |
| Cox, G., et al., Development of a Novel Bronchoscope Therapy for Asthma, Journal of Allergy and Clinical Immunology, 2003, p. 1. |
| Cox, G., et al., Impact of bronchial thermoplasty on asthma status: interim results from the AIR trial, 2006, European Respiratory Society Annual. Meeting, Munich, Germany, p. 1. |
| Cox, G., et al., Radiofrequency ablation of airway smooth muscle for sustained treatment of asthma: preliminary investigations, European Respiratory Journal, 2004, 24, pp. 659-663. |
| Cox. G. et al., Bronchial Thermoplasty: One-Year Update, American Thoracic Society Annual Meeting, 2004, p. 1. |
| Crimi et al., “Protective effects of inhaled ipratropium bromide on bronchoconstriction induced by adenosine and methacholine in asthma,” Eur Respir J 5:560-565, 1992. |
| Danek, C. J., et al., Asthma Intervention Research (AIR) Trial Evaluating Bronchial Thermoplasty™; Early Results, 2002, American Thoracic Society Annual Meeting, p. 1. |
| Danek, C. J., et al., Bronchial thermoplasty reduces canine airway responsiveness to local methacholine challenge, 2002, American Thoracic Society Annual Meeting, p. 1. |
| Danek, C. J., et al., Reduction in airway hyperesponsiveness to methacholine by the application ofRF energy in dogs, J Appl Physiol, 2004, vol. 97, pp. 1946-1933. |
| De Paiva et al., “Light chain of botulinum neurotoxin is active in mammalian motor nerve terminals when delivered via liposomes,” FEES Lett. 17:277(1-2): 171-174, Dec. 1990. |
| Dierkesmann et al., Indication and Results of Endobronchial Laser Therapy, Lung, 1990, 168, 1095-1102. |
| Dimitrov-Szokodi et al., “Lung Denervation in the Therapy ofIntractable Bronchial Asthma,” J. Thoracic Surg. 33(2):166-184, Feb. 1957. |
| Donohue et al., “A 6-Month, Placebo-Controlled Study Comparing Lung Function and Health Status Changes in COPD Patients Treated With Tiotropium or Salmeterol,” Chest 122:47-55, 2002. |
| Evis Exera Bronchovideoscope Brochure, Olympus BF-XT160, Olympus, Jun. 15, 2007, 2 pages. |
| Feshenko et al., “Clinico-morphological comparisons in the laser therapy of chronic bronchitis patients,” Lik Sprava. (10-12):75-79, 1993. (+English abstract, 1 Page.). |
| Friedman et al., “Healthcare Costs with Tiotropium Plus Usual Care versus Usual Care Alone Following 1 Year of Treatment in Patients with Chronic Obstructive Pulmonary Disorder (COPD),” Pharmacoeconomics 22(11):741-749, 2004. |
| Gaude, G.S., “Pulmonary Manifestations of Gastroesophageal Reflux Disease,” Annals of Thoracic Medicine 4(3):115-123, Jul.-Sep. 2009. |
| Gelb et al., “Laser in treatment of lung cancer,” Chest 86(5):662-666, 1984. |
| George et al., “Factors Associated With Medication Nonadherence in Patients With COPD,” Chest 128:3198-3204,2005. |
| Gerasin et al., “Endobronchial electrosurgery,” Chest 93:270-274, 1988. |
| Gibson et al., “Gastroesophageal Reflux Treatment for Asthma in Adults and Children,” Cochrane Database Syst. Rev. 2:CD001496, 2003. (Abstract only.). |
| Glanville et al., “Bronchial responsiveness after human heart-lung transplantation,” Chest 97(6):1360-1366, 1990. |
| Glanville et al., “Bronchial responsiveness to exercise after human cardiopulmonary transplantation,” Chest 96(2):81-286, 1989. |
| Global Strategy for Asthma Management and Prevention, 2002, 192 Pages Total. |
| Gosens et al., “Muscarinic receptor signaling in the pathophysiology of asthma and COPD,” Respiratory Research 7(73):1-15, 2006. |
| Groeben et al. “High Thoracic Epidural Anesthesia Does Not Alter Airway Resistance and Attenuates the Response to an Inhalational Provocation Test in Patients with Bronchial Hyperreactivity,” Anesthesiology 81(4):868-874, 1994. |
| Guarini et al., “Efferent Vagal Fibre Stimulation Blunts Nuclear Factor-kB Activation and Protects Against Hypovolemic Hemmorrhagic Shock,” Circulation 107:1189-1194, 2003. |
| Guzman et al., “Bioeffects Caused by Changes in Acoustic Cavitation Bubble Density and Cell Concentration: A Unified Explanation Based on Cell-to-Bubble Ratio and Blast Radius,” Ultrasound in Med. & Biol. 29(8):1211-1222, 2003. |
| Hainsworth et al., “Afferent lung denervation by brief inhalation of steam,” Journal of Applied Physiolo;zy (34)5: 708-714, 1972. |
| Harding, “Recent Clinical Investigations Examining the Association of Asthma and Gastroesophageal Reflux,” Am J Med. 115(Suppl3A):39S-44S, 2003. (Abstract only.). |
| Hiraga, “Experimental surgical therapy of bronchial asthma. The effect of denervation in dogs,” Nihon Kyobu Shikkan Gakkai Zasshi 19(1):46-56, 1981. |
| Hoffmann et al , “Inhibition of Histamine-Induced Bronchoconstriction in Guinea Pig and Swine by Pulsed Electrical Vagus Nerve Stimulation,” Neuromodulation: Technology at the Neural Inte face:1-9, 2009. |
| Hooper et al., “Endobronchial electrocautery,” Chest 87(6):12-714, 1985. |
| Ivanyuta OM, et al., “Effect of Low-Power Laser Irradiation of Bronchia Mucosa on the State of Systemic and Local Immunity in Patients with Chronic Bronchitis,” Problemy Tuberkuleza 6:26-29, 1991. |
| James C. Hogg, The Pathology of Asthma, APMIS, Oct. 1997, 105(10), 735-745. |
| James, et al., “The Mechanics of Airway Narrowing in Asthma,” Am. Rev. Respir. Dis., 1989, 139 242-246. |
| Jammes et al., “Assessment of the Pulmonary Origin of Bronchoconstrictor Vagal Tone,” J Physiol. 291: 305-316, 1979. |
| Janssen L. J., “Asthma therapy: how far have we come, why did we fail and where should we go next?,” Eur Respir J, 2009, 33, pp. 11-20. |
| Jiang et al., “Effects of Antireflux Treatment on Bronchial Hyper-responsiveness and Lung Function in Asthmatic Patients with Gastroesophageal Reflux Disease,” World J Gastroenterol. 9:1123-1125, 2003. (Abstract only.). |
| Karashurov et al., “Electrostimulation in the therapy of bronchial asthma,” Klin Med (Mask) 79(11):38-41, 2001. |
| Karashurov et al., “Radiofrequency electrostimulation of carotid sinus nerves for the treatment ofbronchial asthma,” KhirurRiia (Mask) 12:2-6, 1999. |
| Khmel'kova et al., “Does laser irridation affect bronchial obstruction?,” Probl Tuberk 3:41-42, 1995. (Abstract only.). |
| Khoshoo et al., “Role of Gastroesophageal Reflux in Older Children with Persistent Asthma,” Chest 123:1008-1013,2003. (Abstract only.). |
| Kiljander, “The Role ofProton Pump Inhibitors in the Management of Gastroesophageal Reflux Disease-Related Asthma and Chronic Cough,” Am J Med. 115(Suppl3A):65S-71S, 2003. (Abstract only.). |
| Kistner et al., “Reductive Cleavage of Tetanus Toxin and Botulinum Neurotoxin A by the Thioredoxin System from Brain,” Naunyn-Schmiedebergs Arch Pharmacal 345(2):227-234, Feb. 1992. |
| Kitamura S., “Color Atlas of Clinical Application ofFiberoptic Bronchoscopy,” 1990, Year Book Medical Publishers, 17. |
| Kletskin et al., “Value of assessing the autonomic nervous system in bronchial asthma in selecting the surgical treatment method,” KhirurRiia (Mask) 7:91-95, 1987. |
| Kliachkin et al., “Bronchoscopy in the treatment of bronchial asthma of infectious allergic origin,” Ter Arkh 54(4):76-79, 1982. |
| Korochkin et al., “Use of a Helium-Neon Laser in Combined Treatment of Bronchial Asthma,” New Developments in Diaf{nostics and Treatment, 1990, 9 pgs. |
| Korpela et al., “Comparison of Tissue Reactions in the Tracheal Mucosa Surrounding a Bioabsorbable and Silicone Airway Stents,” Annals of Thoracic Surgery 66:1772-1776, 1998. |
| Kozaki et al., “New surgical treatment of bronchial asthma—denervation of the hilus pulmonis (2),” Nippon Kyobu Geka Gakkai Zasshi 22(5):465-466, 1974. |
| Kraft M., “The distal airways: are they Important in asthma?,” European Respiratory, 1999, 1403-1417. |
| Kreitman, “Taming ricin toxin,” Nature Biotechnology 21:372-374,2003. |
| Kuntz, “The Autonomic Nervous System in Relation to the Thoracic Viscera,” Chest 10:1-18, 1944. |
| Laufer, “Method and Apparatus for Treating Smooth Muscles in the Walls of Body Conduits,” U.S. Appl. No. 09/095,323, filed Jun. 10, 1998,25 pages. |
| La Violetts, et al. Asthma Intervention Research (AIR) Trial: Early Safety Assessment of Bronchial Thermoplasty, 2004, p. 1. |
| Leff et al., Bronchial Thermoplasty Alters Airway Smooth Muscle and Reduces Responsiveness in Dogs; A Possible Procedure for the Treatment of Asthma, American Thoracic Society Annual Meeting, 2002, p. 1. |
| Lennerz et al., “Electrophysiological characterization of vagal afferents relevant to mucosal nociception in the rat upper oesophagus,” J Physiol. 582(1):229-242, 2007. |
| Levin, “The Treatment ofBronchial Asthma by Dorsal Sympathectomy,” Annals of Surgery 102(2):161-170, 1935. |
| Lim, E.E. et al., Botulinum Toxin: A Novel Therapeutic Option for Bronchial Asthma?, Medical Hypotheses, 2006, vol. 66, pp. 915-919. |
| Liou et al., “Causative and Contributive Factors to Asthmas Severity and Patterns of Medication Use in Patients Seeking Specialized Asthma Care,” Chest 124:1781-1788,2003. (Abstract only.). |
| Lokke et al., “Developing COPD: a 25 year follow up study of the general population,” Thorax 61:935-939, 2006. |
| Lombard, et al, Histologic Effects ofBronchial Thermoplasty of Canine and Human Airways, American Thoracic Society Annual Meeting, 2002, p. 1. |
| Macklem P.T., Mechanical Factors Determining Maximum Bronchoconstriction, European Respiratory Journal, Jun. 1989, 6, 516s-519s. |
| Maesen et al., “Tiotropium bromide, a new long-acting antimuscarinic bronchodilator: a pharmacodynamic study in patients with chronic obstructive pulmonary disease (COPD),” Eur. Respi. J. 8:1506-1513, 1995. |
| Magnussen et al., “Effect ofInhaled Ipratropium Bromide on the Airway Response to Methacholine, Histamine, and Exercise in Patients with Mild Bronchial Asthma,” Respiration 59:42-47, 1992. |
| Maltais et al., “Improvements in Symptom-Limited Exercise Performance Over 8 h With Once-Daily Tiotropium in Patients With COPD,” Chest 128:1168-1178, 2005. |
| Martin, N., et al., “Bronchial Thermoplasty for the Treatment of Asthma,” Current Allergy and Asthma Reports 9(1):88-95, Jan. 2009. |
| Mathew et al., “Gastro-oesophageal reflux and bronchial asthma: current status and future directions,” PostRrad Med. J 80:701-705,2004. |
| Mayse, M. et al., Clinical Pearls for Bronchial Thermoplasty, J Bronchol, Apr. 2007, vol. 14, No. 2, pp. 115-123. |
| McEvoy, C.E., et al., “Changing the Landscape: Bronchial Thermoplasty Offers a Novel Approach to Asthma Treatment,” Advance for Managers of Respiratory Care, pp. 22,24-25, Oct. 2007. |
| McKay et al., “Autocrine regulation of asthmatic airway inflammation: role of airway smooth muscle,” Respir Res 3(11):1-13, 2002. |
| Mehta et al., “Effect of endobronchial radiation therapy on malignant bronchial obstruction,” Chest 97(3):662-665, 1990. |
| Meshalkin et al., “Partial denervation of the pulmonary hilus as one of the methods of surgical treatment of bronchial asthma,” Grudn Khir 1:109-111, 1975. |
| Michaud, G., et al., “Positioned for Success: Interest in Diagnostic and Therapeutic Bronchoscopy is Growing,” Advance for Managers of Respiratory Care, pp. 40, 42-43, Jul./Aug. 2008. |
| Miller, J.D. et al., Bronchial Thermoplasty is Well Tolerated by Non-Asthmatic Patients Requiring Lobectomy, 2002, American Thoracic Society Annual Meeting, p. 1. |
| Miller. J.D. et al., A Prospective Feasibility Study of Bronchial Thermoplasty in the Human Airway. 2005. vol. 127, No. 6 pp. 1999-2006. |
| Montaudon, M., et al., “Assessment of bronchial wall thickness and lumen diameter in human adults using multi-detector computed tomography: comparison with theoretical models,” J. Anat. 211:579-588, 2007. |
| Moore, Keith L., Clinically Oriented Anatomy, 2nd ed., Williams & Wilkins, Baltimore, 1985, pp. 85 and 87. (Abstract only.). |
| Netter F.H., Respiratory System: A Compilation of Paintings Depicting Anatomy and Embryology, Physiology, Pathology, Pathophysiology, and Clinical Features and Treatment of Diseases, In the CIBA Collection of Medical Illustrations M.B. Divertie, ed., Summit New Jersey, 1979, vol. 7, 119-135. |
| Netter, Frank H., The Ciba Collection of Medical Illustrations: vol. 7, Respiratory System, CIBA-GEIGY Corporation, West Caldwell, 1979, p. 23, section 1. (Abstract only.\. |
| Non-Final Office Action for U.S. Appl. No. 11/398,353; Mailed on Aug. 31, 2009; 7 pages. |
| Non-Final Office Action for U.S. Appl. No. 11/398,353; Mailed on Apr. 27, 2010; 8 pages. |
| Notice of final Rejection, Japanese Patent Application No. 2000-553172, dated Sep. 2, 2008, 5 pages. |
| O'Connor et al., “Prolonged Effect ofTiotropium Bromide on Methacholine-induced Bronchoconstriction in Asthma,” Am. J. Respir. Crit. Care Med. 154:876-880, 1996. |
| O'Sullivan, M.P., et al., “Apoptosis in the Airways: Another Balancing Act in the Epithelial Program,” American Journal of Respiratory Cell and Molecular Biology 29:3-7, 2003. |
| Ochs, Matthias et al., Fisherman, Alfred P., et al. (eds), Functional Design of the Human Lungfor Gas Exchange, 4th ed., McGraw Hill Medical, New York, 2008, Chap. 2, “Fisherman's Pulmonary Diseases and Disorders.” (Abstract only.). |
| Ovcharenko et al., “Endobronchial use oflow-frequency ultrasound and ultraviolet laser radiation in the complex treatment of patients with suppurative bronchial diseases,” Probl Tuberk 3:40-42, 1997. (Abstract only.). |
| Overholt, “Glomectomy for Asthma,” Dis Chest 40:605-610, 1961. |
| Pavord, I.D., et al., “Safety and Efficacy of Bronchial Thermoplasty in Symptomatic, Severe Asthma,” American Journal of Respiratory and Critical Care Medicine 176:1185-1191, 2007. |
| PCT International search report for application No. PCT/US00/05412 mailed on Jun. 20, 2000, 2 pages. |
| PCT International search report for application No. PCT/US00/18197 mailed on Oct. 3, 2000, 1 page. |
| PCT International search report for application No. PCT/US00/28745 mailed on Mar. 28, 2001, 6 pages. |
| PCT International search report for application No. PCT/USO1/32321 mailed on Jan. 18, 2002, 2 pages. |
| PCT International search report for application No. PCT/US98/03759 mailed on Jul. 30, 1998, 1 page. |
| PCT International search report for application No. PCT/US98/26227 mailed on Mar. 25, 1999, 1 page. |
| PCT International search report for application No. PCT/US99/00232 mailed on Mar. 4, 1999, 1 page. |
| PCT International search report for application No. PCT/US99/12986 mailed on Sep. 29, 1999, 1 page. |
| Peter K. Jeffery, “Remodeling in Asthma and Chronic Obstructive Lung Disease,” American Journal ofRespiratory and Critical Care Medicine, 2001, 164 (10), 13516. |
| Peters et al., “Tiotropium Bromide Step-Up Therapy for Adults with Uncontrolled Asthma,” New En land Journal of Medicine 363(18):1715-1726, Oct. 28, 2010. |
| Petrou, et al., “Bronchoscopic Diathermy Resection and Stent Insertion: a Cost Effective Treatment for Tracheobronchial Obstruction,” Thorax 48:1156-1159, 1993. |
| Polosukhin, “Dynamics of the ultrastructural changes in blood and lymphatic capillaries of bronchi in inflammation and following endobronchial laser therapy,” Virchows Arch. 431:283-290, 1997. |
| Polosukhin, “Regeneration of Bronchial Epithelium on Chronic Inflammatory Changes Under Laser Treatment,” Path. Res. Pract. 192:909-918, 1996. |
| Polosukhin, “Ultrastructural study of the destructive and repair processes in pulmonary inflammation and following endobronchial laser therapy,” Virchows Arch. 435:13-19, 1999. |
| Polosukhin, “Ultrastructure of the Blood and Lymphatic Capillaries of the Respiratory Tissue During Inflammation and Endobronchial Laser Therapy,” Ultrastructural Pathology 24:183-189, 2000. |
| Preliminary Amendment and Response to Restriction Requirement filed Oct. 22, 2012, in co-pending U.S. Appl. No. 13/523,223, filed Jun. 14, 2012, Martin L. Mayse, et al. |
| Provotorov et al.; The Clinical Efficacy of Treating Patients with Nonspecific Lung Disease by Using Low-energy Laser Irradiation and Intrapulmonary Drug Administration, ISSN: 0040-3660., Terapevticheskii Arkhiv (USSR), 1991, 63 (12), 18-23. |
| Provotorov VM, et al., “Clinical Efficacy of Treatment of Patients with Non-Specific Pulmonary Diseases by Using Low-Power Laser Irradiation and Performing Intrapulmonary Drug Administration,” Terapevichesky Arkhiv 62:18-23, 1991. |
| Raj, “Editorial,” Pain Practice 4(1S): S1-S3, 2004. |
| Ramirez et al., “Sympathetomy in Bronchial Asthma,” J A.M. A. 84 (26):2002-2003, 1925. |
| Rienhoff et al., “Treatment ofIntractable Bronchial Asthma by Bilateral Resection of the Posterior Pulmonary Plexus,” Arch Surf.; 37(3):456-469, 1938. |
| Rocha-Singh, K.J., “Renal Artery Denervation: A Brave New Frontier,” Endovascular Today, Feb. 2012, pp. 45-53. |
| Rubin, et al., Bronchial Thermoplasty improves Asthma Status of Moderate to Severe Persistent Asthmatics Over and Above Current Standard-of-Care, 2006, American College of Chest Physicians, 2 pages. |
| Savchenko et al., “Adaptation of regulatory physiological systems in surgical treatment of patients with bronchial asthma,” Klin Med (Mask) 74(7):38-39, 1996. |
| Sengupta, “Part 1 Oral cavity, pharynx and esophagus—Esophageal sensory physiology,” GI Motility online:17 pages, 2006. |
| Seow C. Y., et al. “Signal Transduction in Smooth Muscle Historical perspective on airway smooth muscle: the saga of a frustrated cell,” J Appl Physiol, 2001, 91, 938-952. |
| Sepulveda et al., “Treatment of Asthmatic Bronchoconstriction by Percutaneous Low Voltage Vagal Nerve Stimulation: Case Report,” Internet Journal of Asthma, Allergy, and Immunology 7(2):3 pages, 2009. |
| Shaari et al., “Rhinorrhea is Decreased in Dogs After Nasal Application of Botulinum Toxin,” Otolaryngol Head Neck Surg 112(14):566-571, 1992. |
| Sheski FD, et al., “Cryotherapy, Electrocautery, and Brachytherapy,” Clinics in Chest Medicine 20(1):123-138, Mar. 1999. |
| Shesterina. M. V. et al., Effect of laser therapy on immunity in patients with bronchial asthma and pulmonary tuberculosis, 1993, pp. 23-26. |
| Sil'vestrov et al., “The Clinico-Pathogenetic Validation and Efficacy of the Use ofLow-Energy Laser Irradiation and Glucocorticoids in the Treatment of Bronchial Asthma Patients,” Ter Arkh 63(11), 87-92, 1991. |
| Simon R. Johnson et al., Synthetic Functions of Airway Smooth Muscle in Asthma, Trends Pharmacal. Sci., Aug. 1997, 18(8), 288-292. |
| Simonsson et al., “Role of Autonomic Nervous System and the Cough Reflex in the Increased Responsiveness of Airways in Patients with Obstructive Airway Disease,” The Journal ofClinical Investigation 46(11): 1812-1818, 1967. |
| Simpson et al., “Isolation and Characterization of the Botulinum Neurotoxins,” Methods Enzymoll65:76-85, 1988. |
| Smakov, “Denervation of the lung in the treatment ofbronchial asthma,” Khirurgiia (Mask)9:117-120, 1982. |
| Smakov, “Pathogenetic substantiation of lung denervation in bronchial asthma and it's indications,” KhirurRiia (Mask) 2:67-69, 1999. |
| Smakov, “Prognostication of the effect of therapeutic bronchoscopy in patients with bronchial asthma according to the state oflocal immunity,” Klin Med (Mask) 73(5):76-77, 1995. |
| Solway, J. et al., Airway Smooth Muscle as a Target for Asthma Therapy, The New England Journal of Medicine, Mar. 29, 2007, 356(13), pp. 1367-1369. |
| Sontag et al., “Asthmatics with Gastroesophageal Reflux: Long-term Results of a Randomized Trial of Medical and Surgical Antireflux Therapies,” Am J Gastroenterol. 98:987-999, 2003. (Abstract only.). |
| Stein, “Possible Mechanisms of Influence of Esophageal Acid on Airway Hyperresponsiveness,” Am J Med. 115(Suppl3A):55S-59S, 2003. (Abstract only.). |
| Stephanie Ashore, “Airway Smooth Muscle in Asthma—Not Just More of the Same.” N Enol J Med, 2004,351 (6), 531-532. |
| Sterk, P. J., Heterogeneity of Airway Hyperresponsiveness: Time for Unconventional, but Traditional Studies, 2004, The American Pshychoiogical Society, pp. 2017-2018. |
| Sundaram et al., “An Experimental and Theoretical Analysis ofUltrasound-Induced Permeabilization of Cell Membranes,” Biophysical Journal84:3087-3101, 2003. |
| Takino et al., “Surgical Removal of the Carotid Body and its Relation to the Carotid Chemoreceptor and Baroreceptor Reflex in Asthmatics,” Dis Chest 47:129-138, 1965. |
| Tashkin et al., “Long-term Treatment Benefits With Tiotropium in COPD Patients With and Without Short-term Bronchodilator Responses,” Chest 123: 1441-1449, 2003. |
| Toma, T. P., Brave New World for Interventional Bronchoscopy, 2005, Thorax, vol. 60, pp. 180-181. |
| Trow, T., Clinical Year in Review I, proceedings of the American Thoracic Society, 2006, vol. 3, pp. 553-556. |
| Tschumperlin, D.J., et al., “Chronic Effects of Mechanical Force on Airways,” Annual Review of Physiolozy 68: 563-83, 2006. |
| Tschumperlin, D.J., et al., “Mechanical Stimuli to Airway Remodeling,” American Journal of Respiratory and Critical Care Medicine 164:S90-S94, 2001. |
| Tsugeno et al., “A Proton-Pump Inhibitor, Rabeprazole, Improves Ventilatory Function in Patients with Asthma Associated with Gastroesophageal Reflux,” Scand J Gastroenterol. 38:456-461, 2003. (Abstract only.). |
| Tsuji et al., “Biodegradable Stents as a Platform to Drug Loading,” International Journal of Cardiovascular Interventions 5:13-16, 2003. |
| Unal et al., “Effect of Botulinum Toxin Type A on Nasal Symptoms in Patients with Allergic Rhinitis: A Double-blind, Placebo-controlled Clinical Trial,” Acta Oto-Laryngologica 123(9):1060-0163, Dec. 2003. |
| UNSW Embryo—Respiratory System [online]. Embryology, 2007, [retrieved on Dec. 10, 2007]. Retrieved from the internet: (URL: http://embryology.med.unsw.edu.au/Refer/respire/select.htm). |
| Urologix, Inc., “Cooled ThermoTherapy™,” 2012, retrieved on Mar. 3, 2005 from URL=http://www.urologix.com/cllinicians/cooled-thermotherapy.php, 2 pages. |
| Urologix, Inc., “CTC Advance™ Instructions for Use,” Targis® System Manual, 2010, 8 pages. |
| Van Boxem TJM, et al., “Tissue Effects ofBronchoscopic Electrocautery,” Chest 117(3):887-891, Mar. 1999. |
| van der Velden et al., “Autonomic Innervation of Human Airways: Structure, Function, and Pathophysiology in Asthma,” Neuroimmunomodulation 6:145-159, 1999. |
| Vasilotta, P. I. et al., “I-R Laser: A New Therapy in Rhino-Sino-Nasal Bronchial Syndrome with Asthmatic Component,” American Society for Laser medicine and Surgery abstracts, facsimile copy dated Feb. 8, 2007, p. 74. |
| Verhein et al., “Neural Control of Airway Inflammation,” Current Allergy and Asthma Reports 9:484-490, 2009. |
| Vincken et al., “Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium,” Eur. Respir. J. 19: 209-216, 2002. |
| Vorotnev et al., “Treatment of Patients with Chronic Obstructive Bronchitis Using Low Energy Laser at a General Rehabilitation Center,” Therapeutic Archive 3:17-19, 1997. (+English translation, 4 pages.). |
| Wagner et al., “Methacholine causes reflex bronchoconstriction,” J. Appl. Physiol. 86:294-297, 1999. |
| Wahidi et al., “State of the Art: Interventional Pulmonology,” Chest 131:261-274, 2007. |
| Wayne Mitzner, “Airway Smooth Muscle The appendix of the Lung,” American Journal of Respiratory and Critical Care Medicine, 2004, 169, 787-790. |
| Wayne Mitzner, “Bronchial Thermoplasty in Asthma,” Allergology International, 2006, 55, 225-234. |
| Weaver, “Electroporation: A General Phenomenon for Manipulating Cells and Tissues,” Journal ofCellular Biochemistry 51(4):426-435, Apr. 1993. |
| Wechsler, M.E., “Bronchial Thermoplasty for Asthma: A Critical Review of a New Therapy,” Allerzy and Asthma Proceedings 29(4):1-6, Jul.-Aug. 2008. |
| Wiggs B.R. et al., On the Mechanism of Mucosal Folding in Normal and Asthmatic Airways, J. Appl. Physiol., Dec. 1997, 83(6), 1814-1821. |
| Wilson, K.C., et al., “Flexible Bronchoscopy: Indications and Contraindications,” UpToDate, Nov. 12, 2010 <www.uptodate.com> [retrieved Sep. 30, 2012], 15 pages. |
| Wilson, S. R. et al., Global assessment after bronchial thermoplasty: the patient's perspective, Journal of Outcomes Research, 2006, vol. 10, pp. 37-46. |
| Wirtz et al., “Bilateral Lung Transplantation for Severe Persistent and Difficult Asthma,” The Journal of Heart and Lung Transplantation 24(10):1700-1703, 2005. |
| Wizeman, et al., A Computer Model of Thermal Treatment of Airways by Radiofrequency (RF) Energy Delivery, 2007, American Thoracic Society Annual Meeting, p. 1. |
| SA Gomm et al., “Dose-response comparison of ipratropium bromide from a metered-dose inhaler and by jet nebulisation”, Thorax, 1983; 38:297-301 (1983) 5 pages. |
| Number | Date | Country | |
|---|---|---|---|
| 20140186341 A1 | Jul 2014 | US |
| Number | Date | Country | |
|---|---|---|---|
| 61746460 | Dec 2012 | US |
